Ionizable cationic lipids for lipid nanoparticles

By designing ionizable lipids with specific structures, their biodegradability and clearance are improved, and the shortcomings of ionizable lipids in the prior art in multiple drug administration applications are solved, and efficient delivery in target tissues and stability.

CN118922401APending Publication Date: 2024-11-08GENEVANT SCI GMBH
View PDF 88 Cites 0 Cited by

Patent Information

Application Number
CN202380026325.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-01-31
Filing Date
2023-01-31
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The low clearance of existing ionizable cationic lipids in target tissues affects their applicability in multiple dosage applications, especially for short dose intervals and chronic indications, and lacks improved biodegradability.

Method used

A novel ionizable lipid with chemical structure of specific compounds of formula (I), including specific groups, is developed for the preparation of lipid nanoparticles to improve their biodegradability and clearance while maintaining nucleic acid delivery. active.

Benefits of technology

It improves the biodegradability and clearance of lipid nanoparticles, is suitable for multiple administrations and chronic treatments, and enhances its delivery efficiency and stability in target tissues.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005033517800000021
    Figure BDA0005033517800000021
  • Figure BDA0005033517800000181
    Figure BDA0005033517800000181
  • Figure BDA0005033517800000781
    Figure BDA0005033517800000781
Patent Text Reader

Abstract

Certain embodiments of the present invention provide ionizable lipids with optimized scavenging characteristics. Certain embodiments of the invention also provide nucleic acid-lipid particles comprising ionizable lipids, methods of making the lipid particles, and methods of delivering and / or administering the lipid particles.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] priority

[0002] This application claims priority to U.S. Provisional Patent Application No. 63 / 305,181, filed on January 31, 2021. The entire contents of this U.S. Provisional Patent Application are hereby incorporated herein by reference. Background Art

[0003] Ionizable cationic lipids are usually the main lipid components in lipid nanoparticles (LNPs). They are designed to be charge neutral at standard physiological pH (about 7), but acquire a positive charge at lower (acidic) pH. This helps to encapsulate nucleic acid payloads during LNP formation and helps intracellular delivery because the endosomal fusion step requires a positive charge on the ionizable lipids.

[0004] Ionizable lipids such as MC3 (used in the FDA-approved siRNA-LNP product Onpattro) and 3D-P-DMA have shown excellent activity and tolerability in various applications. However, they are not rapidly metabolized, and they take weeks to clear from target tissues. This makes them less attractive for applications that require multiple dosing, especially for short dosing intervals and / or chronic indications.

[0005] Currently, there is a need for ionizable lipids that exhibit improved clearance while maintaining good activity in their ability to deliver nucleic acids. There is also a need for ionizable lipids that have beneficial or improved biodegradability. Summary of the invention

[0006] The present invention provides ionizable lipids with improved biodegradability and / or clearance.

[0007] In one embodiment, the present invention provides an ionizable lipid, wherein the ionizable lipid is a compound of formula (I):

[0008]

[0009] or a salt thereof, wherein:

[0010] X is -CH 2 -, -O-, -O(C=O)- or -C(=O)-

[0011] Y is -CH 2 -、-O-、-SO 2 - or -C(=O)-;

[0012] R 1 It is C 2 -C 25 Hydrocarbon;

[0013] R 2It is C 1 -C 3 alkyl; and R 3 It is C 1 -C 3 Alkyl; or R 2 and R 3 Together with the nitrogen to which they are attached they form an aziridino, azetidinino or pyrrolidino ring;

[0014] m is 0, 1, 2, 3, 4, 5, or 6;

[0015] n is 0-15;

[0016] o is 0-15;

[0017] L 1 does not exist, is -(C=O)-O-, -(C=O)N(H)N(R 4 )-、-(C=O)N(H)-N=C(R 4 )-、-(C=O)N(H)N(H)C(R 4 )(R 5 )-、-(C=O)-O-CH 2 -R z or -O(C=O)-R w -;

[0018] L 2 does not exist, is -(C=O)-O-, -(C=O)N(H)N(R 4’ )-、-(C=O)N(H)-N=C(R 4’ )-、-(C=O)N(H)N(H)C(R 4’ )(R 5’ )-、-(C=O)-O-CH 2 -R z’ or -O(C=O)-R x -

[0019] a is H or F;

[0020] b is H or F;

[0021] c is H or F; and d is H or F; or c and d together with the carbon to which they are attached form -C(=O)-

[0022] R 4 Is H or C 2 -C 25 Hydrocarbon;

[0023] R 5 Is H or C 2 -C 25 Hydrocarbon;

[0024] R 4’ Is H or C 2 -C 25 Hydrocarbon;

[0025] R 5’ Is H or C 2 -C 25 Hydrocarbon;

[0026] R 6 It is C 2 -C 25 Hydrocarbon;

[0027] R 7 It is C 2 -C 25 Hydrocarbon;

[0028] R w Does not exist, is -C(F)H- or -C(F) 2 -;

[0029] R x Does not exist, is -C(F)H- or -C(F) 2 -;

[0030] R z is 1, 2 or 3 independently selected from C 2 -C 10 a phenyl group substituted with a hydrocarbyl group; and

[0031] R z’ is 1, 2 or 3 independently selected from C 2 -C 10 A phenyl group substituted with a hydrocarbyl group.

[0032] The present invention also provides a composition comprising 1) an ionizable lipid of the present invention, and 2) an active agent or a therapeutic agent.

[0033] The present invention also provides a lipid nanoparticle, wherein the lipid nanoparticle comprises the ionizable lipid of the present invention.

[0034] The present invention also provides a lipid nanoparticle, the lipid nanoparticle comprising: (a) one or more active agents or therapeutic agents; (b) an ionizable lipid of the present invention; (c) a non-cationic lipid;

[0035] and (d) conjugated lipids. Typically, one or more agents are encapsulated within the lipid nanoparticles.

[0036] The present invention also provides a pharmaceutical composition comprising: 1) an ionizable lipid of the present invention, and 2) one or more active agents or therapeutic agents.

[0037] The present invention also provides a pharmaceutical composition, which comprises the lipid nanoparticles of the present invention and a pharmaceutically acceptable carrier.

[0038] The present invention also provides a method for delivering an active agent or therapeutic agent (eg, a nucleic acid) to an animal, the method comprising administering to the animal a nanoparticle of the present invention.

[0039] The present invention also provides a method for introducing a nucleic acid into a cell, the method comprising contacting the cell in vivo, ex vivo or in vitro with the nucleic acid-lipid particle described herein.

[0040] The present invention also provides a method for treating a disease or disorder in an animal, the method comprising administering to the animal a therapeutically effective amount of the nucleic acid-lipid particle described herein.

[0041] The present invention also provides methods and intermediates disclosed herein that can be used to prepare the compounds, formulations or nanoparticles of the present invention. DETAILED DESCRIPTION

[0042] definition

[0043] As used herein, the following terms have the meanings ascribed to them unless otherwise indicated.

[0044] As used herein, the term "hydrocarbyl" describes an organic compound or radical consisting of about 4 to about 500 atoms selected from carbon and hydrogen. Certain specific hydrocarbyl moieties have a specified number of carbon atoms, e.g., C 2 -C 25Hydrocarbyl is a hydrocarbon with 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25 carbon atoms and up to 52 hydrogen atoms, depending on the level of unsaturation. Hydrocarbyl moieties include but are not limited to branched or unbranched alkyl, branched or unbranched alkenyl, branched or unbranched alkynyl, cycloalkyl and aryl moieties. In one embodiment, the hydrocarbyl is composed of approximately 4 to approximately 400 atoms selected from carbon and hydrogen. In one embodiment, the hydrocarbyl is composed of approximately 4 to approximately 300 atoms selected from carbon and hydrogen. In one embodiment, the hydrocarbyl is composed of approximately 4 to approximately 200 atoms selected from carbon and hydrogen. In one embodiment, the hydrocarbyl is composed of approximately 4 to approximately 100 atoms selected from carbon and hydrogen. In one embodiment, the hydrocarbyl is composed of approximately 4 to approximately 62 atoms selected from carbon and hydrogen. In one embodiment, the hydrocarbyl consists of about 20 to about 500 atoms selected from carbon and hydrogen. In one embodiment, the hydrocarbyl consists of about 20 to about 400 atoms selected from carbon and hydrogen. In one embodiment, the hydrocarbyl consists of about 20 to about 300 atoms selected from carbon and hydrogen. In one embodiment, the hydrocarbyl consists of about 20 to about 200 atoms selected from carbon and hydrogen. In one embodiment, the hydrocarbyl consists of about 20 to about 100 atoms selected from carbon and hydrogen. In one embodiment, the hydrocarbyl consists of about 20 to about 62 atoms selected from carbon and hydrogen. In one embodiment, the hydrocarbyl consists of about 40 to about 500 atoms selected from carbon and hydrogen. In one embodiment, the hydrocarbyl consists of about 40 to about 400 atoms selected from carbon and hydrogen. In one embodiment, the hydrocarbyl consists of about 40 to about 300 atoms selected from carbon and hydrogen. In one embodiment, the hydrocarbyl consists of about 40 to about 200 atoms selected from carbon and hydrogen. In one embodiment, the hydrocarbyl consists of about 40 to about 100 atoms selected from carbon and hydrogen. In one embodiment, the hydrocarbyl group consists of about 40 to about 62 atoms selected from carbon and hydrogen. In one embodiment, the hydrocarbyl group consists of at least about 20, at least about 40, at least about 60, or at least about 80 atoms selected from carbon and hydrogen. In one embodiment, the hydrocarbyl group consists of less than about 500, less than about 400, less than about 300, less than about 200, or less than about 100 atoms selected from carbon and hydrogen.

[0045] Unless otherwise indicated, the term "alkyl" by itself or as part of another substituent refers to a radical having the specified number of carbon atoms (i.e., C 1-8 represents a straight or branched hydrocarbon group of one to eight carbon atoms. Examples include (C 1 -C 8 ) alkyl, (C 2 -C 8 ) alkyl, C 1 -C 6 ) alkyl, (C2 -C 6 ) alkyl and (C 3 -C 6 Examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, isobutyl, sec-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, and higher homologs and isomers.

[0046] The term "alkenyl" refers to an unsaturated alkyl group having one or more (e.g., 1, 2, 3, or 4) double bonds. Examples of such unsaturated alkyl groups include vinyl, 2-propenyl, crotyl, 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(1,4-pentadienyl), and higher homologs and isomers.

[0047] The term "alkynyl" refers to an unsaturated alkyl group having one or more (e.g., 1, 2, 3, or 4) triple bonds. Examples of such unsaturated alkyl groups include ethynyl, 1-propynyl, and 3-propynyl, 3-butynyl, and higher homologs and isomers.

[0048] The term "alkoxy" refers to an alkyl group attached to the remainder of the molecule through an oxygen atom (the "oxy").

[0049] The term "alkylthio" refers to an alkyl group attached to the rest of the molecule through a sulfur group.

[0050] The term "cycloalkyl" refers to a saturated or partially unsaturated (non-aromatic) all-carbon ring (i.e., (C 3 -C 8 ) carbocycle). The term also includes polycondensed, saturated all-carbocyclic ring systems (e.g., ring systems containing 2, 3, or 4 carbocyclic rings). Accordingly, carbocycle includes polycyclic carbocycles, such as bicyclic carbocycles (e.g., bicyclic carbocycles having about 3 to 15 carbon atoms, about 6 to 15 carbon atoms, or 6 to 12 carbon atoms, such as bicyclo [3.1.0] hexane and bicyclo [2.1.1] hexane), and polycyclic carbocycles (e.g., tricyclic and tetracyclic carbocycles having up to about 20 carbon atoms). When valence requirements permit, the rings of polycondensed ring systems may be connected to each other by fusion, spiro, and bridging bonds. For example, polycyclic carbocycles can be connected to each other through a single carbon atom to form a spirocyclic connection (e.g., spiropentane, spiro[4,5]decane, etc.), connected to each other through two adjacent carbon atoms to form a fused connection (e.g., carbocycles such as decahydronaphthalene, norsabinane, norcarane), or connected to each other through two non-adjacent carbon atoms to form a bridged connection (e.g., norbornane, bicyclo[2.2.2]octane, etc.). Non-limiting examples of cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo[2.2.1]heptane, pinane, and adamantane.

[0051] As used herein, the term "aryl" refers to a single all-carbon aromatic ring or a polycondensed all-carbon ring system, wherein at least one ring is aromatic. For example, in certain embodiments, the aryl has 6 to 20 carbon atoms, 6 to 14 carbon atoms, 6 to 12 carbon atoms or 6 to 10 carbon atoms. Aryl includes phenyl. Aryl also includes a polycondensed carbocyclic ring system (for example, a ring system comprising 2, 3 or 4 rings) with about 9 to 20 carbon atoms, wherein at least one ring is aromatic, and wherein other rings may be aromatic or not aromatic (i.e. cycloalkyl). When valence needs allow, the rings of the polycondensed ring system can be connected to each other by fusion, spiral and bridge bonds. It should be understood that the connection point of the polycondensed ring system as defined above can be any position of the ring system, including the aromatic or carbocyclic portion of the ring. Non-limiting examples of aryl include but are not limited to phenyl, indenyl, indanyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, anthracenyl, etc.

[0052] The term "interfering RNA" or "RNAi" or "interfering RNA sequence" refers to a single-stranded RNA (e.g., mature miRNA) or double-stranded RNA (i.e., duplex RNA, such as siRNA, aiRNA or precursor miRNA) that can reduce or inhibit the expression of a target gene or sequence (e.g., by mediating degradation or inhibiting the translation of an mRNA complementary to the interfering RNA sequence) when the interfering RNA is in the same cell as the target gene or sequence. Interfering RNA therefore refers to a single-stranded RNA complementary to a target mRNA sequence or a double-stranded RNA formed by two complementary strands or by a single self-complementary strand. Interfering RNA may be substantially identical or completely identical to a target gene or sequence, or may contain a mismatch region (i.e., a mismatch motif). The sequence of an interfering RNA may correspond to a full-length target gene or a subsequence thereof.

[0053] Interfering RNAs include "small interfering RNAs" or "siRNAs", e.g., interfering RNAs of about 15-60, 15-50, or 15-40 (duplex) nucleotides in length, more typically about 15-30, 15-25, or 19-25 (duplex) nucleotides in length, and preferably about 20-24, 21-22, or 21-23 (duplex) nucleotides in length (e.g., the length of each complementary sequence of a double-stranded siRNA The length of the double-stranded siRNA is about 15-60, 15-50, 15-40, 15-30, 15-25 or 19-25 base pairs, preferably about 20-24, 21-22 or 21-23 nucleotides in length, and the length of the double-stranded siRNA is about 15-60, 15-50, 15-40, 15-30, 15-25 or 19-25 base pairs, preferably about 18-22, 19-20 or 19-21 base pairs in length). The siRNA duplex can include a 3' overhang of about 1 to about 4 nucleotides or about 2 to about 3 nucleotides and a 5' phosphate terminus. Examples of siRNA include, but are not limited to: a double-stranded polynucleotide molecule assembled from two separate strand molecules, wherein one strand is a sense strand and the other is a complementary antisense strand; a double-stranded polynucleotide molecule assembled from single-stranded molecules, wherein the sense region and the antisense region are connected by a nucleic acid-based or non-nucleic acid-based linker; a double-stranded polynucleotide molecule having a hairpin secondary structure with self-complementary sense and antisense regions; and a circular single-stranded polynucleotide molecule having two or more loop structures and a stem structure with self-complementary sense and antisense regions, wherein the circular polynucleotide can be processed in vivo or in vitro to produce an active double-stranded siRNA molecule.

[0054] Preferably, the siRNA is chemically synthesized. siRNA can also be produced by cleaving longer dsRNAs (eg, dsRNAs greater than about 25 nucleotides in length) with E. coli RNase III or Dicer. These enzymes process dsRNA into biologically active siRNA (see, e.g., Yang et al., Proc. Natl. Acad. Sci. USA, 99:9942-9947 (2002); Calegari et al., Proc. Natl. Acad. Sci. USA, 99:14236 (2002); Byrom et al., Ambion Tech Notes, 10(1):4-6 (2003); Kawasaki et al., Nucleic Acids Res., 31:981-987 (2003); Knight et al., Science, 293:2269-2271 (2001); and Robertson et al., J. Biol. Chem., 243:82 (1968)). Preferably, the dsRNA is at least 50 nucleotides to about 100, 200, 300, 400 or 500 nucleotides in length. The length of dsRNA can be up to 1000, 1500, 2000, 5000 nucleotides or longer. dsRNA can encode the entire gene transcript or a portion of the gene transcript. In some examples, siRNA can be encoded by a plasmid (e.g., transcribed as a sequence that automatically folds into a duplex with a hairpin loop).

[0055] As used herein, the term "mismatch motif" or "mismatch region" refers to a portion of an interfering RNA (e.g., siRNA, aiRNA, miRNA) sequence that does not have 100% complementarity to its target sequence. An interfering RNA may have at least one, two, three, four, five, six or more mismatch regions. Mismatch regions may be contiguous or may be separated by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more nucleotides. A mismatch motif or region may comprise a single nucleotide or may comprise two, three, four, five or more nucleotides.

[0056] An "effective amount" or "therapeutically effective amount" of an active or therapeutic agent such as a nucleic acid (e.g., interfering RNA or mRNA) is an amount sufficient to produce a desired effect, such as inhibiting the expression of a target sequence compared to the normal expression level detected in the absence of interfering RNA; or inhibiting the mRNA-directed expression of a certain amount of a protein, causing a desired biological effect in an organism expressing the protein. Inhibition of expression of a target gene or target sequence is achieved when the value obtained using interfering RNA relative to a control is about 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5% or 0%. In other embodiments, the expressed protein is an active form of a protein normally expressed in a cell type in vivo, and the therapeutically effective amount of the mRNA is an amount of the encoded protein that produces an amount of at least 50% (e.g., at least 60% or at least 70% or at least 80% or at least 90%) of the amount of the protein normally expressed in a cell type of a healthy individual. Suitable assays for measuring the expression of a target gene or target sequence include, for example, examining protein or RNA levels using techniques known to those skilled in the art (e.g., dot blots, Northern blots, in situ hybridization, ELISA, immunoprecipitation, enzyme function) and phenotypic assays known to those skilled in the art.

[0057] The immune response "decrease", "decreasing", "reduce" or "reducing" caused by an interfering RNA is intended to mean a detectable decrease in the immune response of a given interfering RNA (e.g., a modified interfering RNA). The amount of decrease in the immune response caused by the modified interfering RNA can be determined relative to the level of the immune response in the presence of unmodified interfering RNA. The detectable decrease can be about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100% or more lower than the immune response detected in the presence of unmodified interfering RNA. Reduction of immune responses to interfering RNA is typically measured by reduced cytokine production (e.g., IFNγ, IFNα, TNFα, IL-6, or IL-12) by responding cells in vitro or in the serum of a mammalian subject following administration of the interfering RNA.

[0058] An immune response "decrease," "decreasing," "reduce," or "reducing" caused by an mRNA is intended to mean a detectable decrease in the immune response to a given mRNA (e.g., a modified mRNA). The amount of decrease in the immune response caused by the modified mRNA can be determined relative to the level of the immune response in the presence of unmodified mRNA. The detectable decrease can be about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100% or more lower than the immune response detected in the presence of unmodified mRNA. Reduction of the immune response to an mRNA is typically measured by reduced cytokine production (e.g., IFNγ, IFNα, TNFα, IL-6, or IL-12) by responding cells in vitro or in the serum of a mammalian subject following administration of the mRNA.

[0059] As used herein, the term "response cell" refers to a cell, preferably a mammalian cell, that produces a detectable immune response when contacted with an immunostimulatory interfering RNA such as an unmodified siRNA. Exemplary responding cells include, for example, dendritic cells, macrophages, peripheral blood mononuclear cells (PBMC), splenocytes, etc. Detectable immune responses include, for example, the production of cytokines or growth factors such as TNF-α, IFN-α, IFN-β, IFN-γ, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-10, IL-12, IL-13, TGF, and combinations thereof.

[0060] "Substantial identity" refers to sequences that hybridize to a reference sequence under stringent conditions, or to sequences that have a specified percent identity over a specified region of a reference sequence.

[0061] The phrase "stringent hybridization conditions" refers to conditions under which a nucleic acid will hybridize to its target sequence but not to other sequences, typically in a complex mixture of nucleic acids. Stringent conditions are sequence-dependent and will be different in different environments. Longer sequences hybridize specifically at higher temperatures. For a comprehensive guide to nucleic acid hybridization, see Tijssen, Techniques in Biochemistry and Molecular Biology—Hybridization with Nucleic Probes, "Overview of principles of hybridization and the strategy of nucleic acid assays" (1993). Typically, stringent conditions are selected to be higher than the thermal melting point (T ) of a specific sequence at a defined ionic strength pH. m ) is about 5℃-10℃ lower. T m The probe complementary to the target is 50% hybridized to the target sequence at equilibrium at the temperature (because the target sequence is present in excess, so at T m Stringent conditions are defined as a temperature (under defined ionic strength, pH, and nucleic acid concentration) at which 50% of the probes are occupied at equilibrium. Stringent conditions may also be achieved by adding destabilizing agents such as formamide. For selective or specific hybridization, a positive signal is at least twice the background, preferably 10 times the background hybridization.

[0062] Exemplary stringent hybridization conditions may be as follows: 50% formamide, 5×SSC and 1% SDS, incubated at 42° C., or 5×SSC, 1% SDS, incubated at 65° C., with washing in 0.2×SSC and 0.1% SDS at 65° C. For PCR, the temperature for low stringency amplification is typically about 36° C., although the annealing temperature may vary between about 32° C. and 48° C. depending on primer length. For high stringency PCR amplification, the typical temperature is about 62° C., although the high stringency annealing temperature may range from about 50° C. to about 65° C. depending on primer length and specificity. Cycling conditions typically used for high stringency and low stringency amplification include a denaturation phase of 90° C.-95° C. for 30 seconds-2 minutes, an annealing phase for 30 seconds-2 minutes, and an extension phase of about 72° C. for 1-2 minutes. Protocols and guidance for low stringency and high stringency amplification reactions are provided, for example, in Innis et al., PCR Protocols, A Guide to Methods and Applications, Academic Press, Inc. NY (1990).

[0063] If the polypeptides they encode are substantially the same, nucleic acids that do not hybridize to each other under stringent conditions are still substantially the same. For example, when a copy of a nucleic acid is generated using the maximum codon degeneracy allowed by the genetic code, this occurs. In such cases, nucleic acids are hybridized typically under medium stringent hybridization conditions. Exemplary "medium stringent hybridization conditions" include hybridization at 37°C, in a buffer solution of 40% formamide, 1M NaCl, 1% SDS, and washing at 45°C in 1 × SSC. Positive hybridization is at least twice the background. Those skilled in the art will readily recognize that alternative hybridization and washing conditions can be used to provide conditions of similar stringency. Additional guidance for determining hybridization parameters is provided in many references, such as Current Protocols in Molecular Biology, compiled by Ausubel et al.

[0064] The term "substantially identical" or "substantial identity" in the context of two or more nucleic acids refers to two or more sequences or subsequences that are identical or have a specified percentage of identical nucleotides (i.e., at least about 60%, preferably at least about 65%, 70%, 75%, 80%, 85%, 90% or 95% identity over a specified region) when compared and aligned for maximum correspondence over a comparison window or specified region using one of the following sequence comparison algorithms or measured by manual alignment and visual inspection. This definition also refers similarly to the complement of a sequence when the context indicates. Preferably, substantial identity is present over a region of at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55 or 60 nucleotides in length.

[0065] For sequence comparison, usually a sequence serves as a reference sequence, and the test sequence is compared with it. When using a sequence comparison algorithm, the test sequence and the reference sequence are input into a computer, and if necessary, subsequence coordinates are specified, and sequence algorithm program parameters are specified. Default program parameters can be used or alternative parameters can be specified. The sequence comparison algorithm then calculates the sequence identity percentage of the test sequence relative to the reference sequence based on the program parameters.

[0066] As used herein, a "comparison window" includes any segment involving a plurality of consecutive positions selected from the group consisting of about 5 to about 60, typically about 10 to about 45, more typically about 15 to about 30, wherein a sequence can be compared to a reference sequence of the same number of consecutive positions after the two sequences are optimally aligned. Methods of aligning sequences for comparison are well known in the art. Optimal alignment of sequences for comparison can be performed by methods such as the local homology algorithm of Smith and Waterman, Adv. Appl. Math., 2:482 (1981); the homology alignment algorithm of Needleman and Wunsch, J. Mol. Biol., 48:443 (1970); the similarity search method of Pearson and Lipman, Proc. Natl. Acad. Sci. USA, 85:2444 (1988); computer implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.); or manual alignment and visual inspection (see, e.g., Current Protocols in Molecular Biology, Ausubel et al., eds. (1995 Supplement)).

[0067] Preferred examples of algorithms suitable for determining sequence identity percentages and sequence similarity are BLAST and BLAST 2.0 algorithms, which are described in Altschul et al., Nuc. Acids Res., 25:3389-3402 (1977) and Altschul et al., J. Mol. Biol., 215:403-410 (1990), respectively. BLAST and BLAST 2.0 with parameters described herein are used to determine the sequence identity percentages of nucleic acids of the present invention. Software for performing BLAST analysis can be publicly available through the National Center for Biotechnology Information (http: / / www.ncbi.nlm.nih.gov / ).

[0068] The BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin and Altschul, Proc. Natl. Acad. Sci. USA, 90:5873-5787 (1993)). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)) method, which provides an indication of the probability that a match between two nucleotide sequences occurs by chance. For example, a test nucleic acid sequence is considered similar to a reference sequence if the smallest sum probability is less than about 0.2, more preferably less than about 0.01, and most preferably less than about 0.001 in a comparison of the test nucleic acid sequence to the reference nucleic acid sequence.

[0069] As used herein, the term "nucleic acid" refers to a polymer containing at least two deoxyribonucleotides or ribonucleotides in single-stranded or double-stranded form and includes DNA and RNA. DNA can be in the following forms: for example, antisense molecules, plasmid DNA, pre-condensed DNA, PCR products, carriers (P1, PAC, BAC, YAC, artificial chromosomes), expression cassettes, chimeric sequences, chromosomal DNA, or derivatives and combinations of these groups. RNA can be in the following forms: siRNA, asymmetric interfering RNA (aiRNA), microRNA (miRNA), mRNA, tRNA, rRNA, tRNA, viral RNA (vRNA), self-amplification RNA, and combinations thereof. Nucleic acids include nucleic acids containing known nucleotide analogs or modified backbone residues or linkages, which are synthetic, naturally occurring, and non-naturally occurring, and have binding properties similar to reference nucleic acids. Examples of such analogs include, but are not limited to, phosphorothioates, phosphoramidates, methyl phosphonates, chiral methyl phosphonates, 2'-O-methyl ribonucleotides, and peptide-nucleic acids (PNA). Unless specifically limited, the term encompasses nucleic acids containing known analogs of natural nucleotides with binding properties similar to reference nucleic acids. Unless otherwise specified, a specific nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions), alleles, orthologs, SNPs, and complementary sequences, as well as sequences explicitly specified. Specifically, degenerate codon substitutions can be achieved by generating sequences in which the third position of one or more selected (or all) codons is replaced by mixed bases and / or deoxyinosine residues (Batzer et al., Nucleic Acid Res., 19: 5081 (1991); Ohtsuka et al., J. Biol. Chem., 260: 2605-2608 (1985); Rossolini et al., Mol. Cell. Probes, 8: 91-98 (1994)). "Nucleotide" contains sugar deoxyribose (DNA) or ribose (RNA), bases, and phosphate groups. Nucleotides are linked together by phosphate groups. "Bases" include purines and pyrimidines, which further include the natural compounds adenine, thymine, guanine, cytosine, uracil, inosine and natural analogs; as well as synthetic derivatives of purines and pyrimidines, which include but are not limited to modifications that place new reactive groups such as but not limited to amines, alcohols, thiols, carboxylates and alkyl halides.

[0070] The term "gene" refers to a nucleic acid (eg, DNA or RNA) sequence that contains a partial-length or full-length coding sequence required for producing a polypeptide or precursor polypeptide.

[0071] As used herein, "gene product" refers to the product of a gene, such as an RNA transcript or a polypeptide.

[0072] The term "lipid" refers to a group of organic compounds including, but not limited to, esters of fatty acids, and is characterized by being insoluble in water but soluble in many organic solvents. They are generally divided into at least three categories: (1) "simple lipids," which include fats and oils as well as waxes; (2) "complex lipids," which include phospholipids and glycolipids; and (3) "derivative lipids" such as steroids.

[0073] As used herein, the term "LNP" refers to lipid-nucleic acid particles or nucleic acid-lipid particles (e.g., stable nucleic acid-lipid particles). LNP refers to particles made of lipids (e.g., ionizable lipids of the present invention, non-cationic lipids, and conjugated lipids that prevent particle aggregation) and nucleic acids, wherein nucleic acids (e.g., siRNA, aiRNA, miRNA, ssDNA, dsDNA, ssRNA, short hairpin RNA (shRNA), dsRNA, mRNA, self-amplification RNA or plasmids, including plasmids transcribed from them interfering RNA or mRNA) are encapsulated in lipids. In one embodiment, nucleic acids are at least 50% encapsulated in lipids; in one embodiment, nucleic acids are at least 75% encapsulated in lipids; in one embodiment, nucleic acids are at least 90% encapsulated in lipids; and in one embodiment, nucleic acids are completely encapsulated in lipids. LNPs typically contain cationic lipids, non-cationic lipids, and lipid conjugates (e.g., PEG-lipid conjugates). LNPs are extremely useful for systemic applications because they can exhibit extended circulation lifetimes following intravenous (iv) injection, they can accumulate at remote sites (e.g., sites physically separate from the site of administration), and they can mediate expression of transfected genes or silencing of target gene expression at these remote sites.

[0074] The lipid particles of the present invention (e.g., LNP) generally have an average diameter of about 40nm to about 150nm. In one embodiment, the lipid particles of the present invention have an average diameter of about 40nm to about 80nm. In one embodiment, the lipid particles of the present invention have an average diameter of about 40nm to about 70nm. In one embodiment, the lipid particles of the present invention have an average diameter of about 40nm to about 60nm. In one embodiment, the lipid particles of the present invention have an average diameter of about 50nm to about 60nm. In one embodiment, the lipid particles of the present invention have an average diameter of about 50nm to about 150nm. In one embodiment, the lipid particles of the present invention have an average diameter of about 60nm to about 130nm. In one embodiment, the lipid particles of the present invention have an average diameter of about 70nm to about 110nm. In one embodiment, the lipid particles of the present invention have an average diameter of about 70 to about 90nm. The lipid particles of the present invention are substantially nontoxic. In addition, when present in the lipid particles of the present invention, nucleic acids are resistant to degradation using nucleases in aqueous solution. Nucleic acid-lipid particles and methods for making them are disclosed, for example, in U.S. Patent Publication Nos. 20040142025 and 20070042031, the disclosures of which are incorporated herein by reference in their entireties for all purposes.

[0075] As used herein, "lipid encapsulated" can refer to a lipid granule that provides an active agent or therapeutic agent such as a nucleic acid (e.g., interfering RNA or mRNA) under complete encapsulation, partial encapsulation, or both. In a preferred embodiment, the nucleic acid is fully encapsulated in the lipid granule (e.g., to form SPLP, pSPLP, LNP or other nucleic acid-lipid granules).

[0076] The term "lipid conjugate" refers to the lipid conjugated by the polymer that suppresses lipid particle aggregation.Such lipid conjugates include but are not limited to polyamide oligomers (for example, ATTA-lipid conjugates), polysarcosine-lipid conjugates, polyoxazoline (POZ)-lipid conjugates, PEG-lipid conjugates, such as PEG coupled with dialkyloxypropyl, PEG coupled with diacylglycerol, PEG coupled with cholesterol, PEG coupled with phosphatidylethanolamine, PEG conjugated with ceramide (see, for example, U.S. Patent number 5,885,613, which is incorporated herein by reference in its entirety for all purposes), cationic PEG lipids and mixtures thereof.PEG can be directly conjugated to lipid or can be connected to lipid via a linker moiety.Any linker moiety suitable for PEG being coupled to lipid can be used, including, for example, a linker moiety containing non-esters and an ester-containing linker moiety.In a preferred embodiment, a linker moiety containing non-esters is used.

[0077] The term "amphiphilic lipid" refers in part to any suitable material wherein the hydrophobic portion of the lipid material is oriented into the hydrophobic phase and the hydrophilic portion is oriented toward the aqueous phase. The hydrophilic character is derived from the presence of polar or charged groups, such as carbohydrates, phosphates, carboxylic acids, sulfates, amino groups, sulfhydryl groups, nitro groups, hydroxyl groups and other similar groups. Hydrophobicity can be imparted by including non-polar groups, including but not limited to long-chain saturated and unsaturated aliphatic hydrocarbon groups and such groups substituted by one or more aromatic, alicyclic or heterocyclic groups. Examples of amphiphilic compounds include but are not limited to phospholipids, amino lipids and sphingolipids.

[0078] The representative example of phospholipid includes but not limited to phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidic acid, palmitoyloleoylphosphatidylcholine, lysophosphatidylcholine, lysophosphatidylethanolamine, dipalmitoylphosphatidylcholine, dioleoylphosphatidylcholine, distearoylphosphatidylcholine and dilinoleoylphosphatidylcholine. Other compounds lacking phosphorus such as sphingolipids, glycosphingolipid family, diacylglycerol and beta-acyloxy acid are also in the group called amphipathic lipid. In addition, the amphipathic lipid described above can be mixed with other lipids comprising triglyceride and sterol.

[0079] The term "neutral lipid" refers to any of a number of lipid species that exist in an uncharged or neutral zwitterionic form at a selected pH. At physiological pH, such lipids include, for example, diacylphosphatidylcholine, diacylphosphatidylethanolamine, ceramide, sphingomyelin, cephalin, cholesterol, cerebrosides, and diacylglycerols.

[0080] The term "non-cationic lipid" refers to any amphipathic lipid as well as any other neutral lipid or anionic lipid.

[0081] The term "anionic lipid" refers to any lipid that is negatively charged at physiological pH. These lipids include, but are not limited to, phosphatidylglycerol, cardiolipin, diacylphosphatidylserine, diacylphosphatidic acid, N-dodecanoylphosphatidylethanolamine, N-succinylphosphatidylethanolamine, N-glutarylphosphatidylethanolamine, lysylphosphatidylglycerol, palmitoyloleylphosphatidylglycerol (POPG), and other anionic modifying groups attached to neutral lipids.

[0082] The term "cationic lipid" refers to a lipid that can be positively charged. These lipids include lipids with one or more positively charged amine groups. Certain cationic lipids are ionizable (and are referred to as "ionizable lipids") and can exist in a charge-neutral or positively charged state depending on the surrounding pH.

[0083] In one embodiment, the cationic lipid is a compound of formula (I) as described herein, which in certain embodiments has a clearance such that <10% of the parent ionizable lipid remains seven (7) days after administration (e.g., in the assay described in Example 33).

[0084] The term "hydrophobic lipid" refers to a compound having a non-polar group, including but not limited to long-chain saturated and unsaturated aliphatic hydrocarbon groups and such groups optionally substituted with one or more aromatic, alicyclic or heterocyclic groups. Suitable examples include but are not limited to diacylglycerols, dialkylglycerols, N—N-dialkylamino, 1,2-diacyloxy-3-aminopropane and 1,2-dialkyl-3-aminopropane.

[0085] The term "fusogenic" refers to the ability of lipid particles such as LNPs to fuse with the membrane of a cell. The membrane may be a plasma membrane or a membrane surrounding a cell organelle such as an endosome, a cell nucleus, etc.

[0086] As used herein, the term "aqueous solution" refers to a composition that comprises wholly or partially water.

[0087] As used herein, the term "organic lipid solution" refers to a composition comprising in whole or in part an organic solvent with lipids.

[0088] As used herein, "distal site" refers to a physically separate site that is not limited to adjacent capillary beds, but includes sites widely distributed throughout an organism.

[0089] "Serum stable" in relation to nucleic acid-lipid particles such as LNPs means that the particles do not significantly degrade after exposure to serum or nuclease assays that would significantly degrade free DNA or RNA. Suitable assays include, for example, standard serum assays, DNase assays, or RNase assays.

[0090] As used herein, "systemic delivery" refers to the delivery of lipid particles that cause active agents or therapeutic agents (such as interfering RNA or mRNA) to be widely biodistributed in the organism. Some technologies used can cause the systemic delivery of certain agents, but will not cause the systemic delivery of other agents. Systemic delivery means that the useful amount, preferably the agent of the therapeutic amount, is exposed to most parts of the body. In order to obtain extensive biodistribution, blood life is usually required so that the agent will not be rapidly degraded or removed (such as by first-pass organs (liver, lungs, etc.) or by fast nonspecific cell binding) before arriving at the disease site away from the application site. The systemic delivery of lipid particles can be achieved by any means known in the art, including, for example, intravenous, subcutaneous and intraperitoneal. In a preferred embodiment, the systemic delivery of lipid particles is achieved by intravenous delivery.

[0091] As used herein, "local delivery" refers to delivering an active agent or therapeutic agent, such as interfering RNA or mRNA, directly to a target site in an organism. For example, the agent can be delivered locally by direct injection into a disease site such as a tumor or other target site such as a site of inflammation or a target organ such as the liver, heart, pancreas, kidney, etc.

[0092] The term "mammal" refers to any species of mammals, such as humans, mice, rats, dogs, cats, hamsters, guinea pigs, rabbits, livestock, and the like.

[0093] The term "cancer" refers to any member of a class of diseases characterized by uncontrolled growth of abnormal cells. The term includes all known cancers and neoplastic conditions, whether characterized as malignant, benign, soft tissue or solid and all stages and grades of cancer, including pre-metastatic cancer and post-metastatic cancer. Examples of different types of cancer include, but are not limited to, lung cancer, colon cancer, rectal cancer, anal cancer, bile duct cancer, small intestine cancer, stomach (gastric) cancer, esophageal cancer; gallbladder cancer, liver cancer, pancreatic cancer, appendix cancer, breast cancer, ovarian cancer; cervical cancer, prostate cancer, kidney cancer (e.g., renal cell carcinoma), cancer of the central nervous system, glioblastoma, skin cancer, lymphoma, choriocarcinoma, head and neck cancer, osteogenic sarcoma and blood cancer. Non-limiting examples of specific types of liver cancer include hepatocellular carcinoma (HCC), secondary liver cancer (e.g., caused by the metastasis of some other non-liver cancer cell types) and hepatoblastoma. As used herein, "tumor" comprises one or more cancer cells.

[0094] The term "anion precursor group" includes groups that are capable of forming ions at physiological pH. For example, the term includes the group -CO 2 H, -OP(=O)(OH) 2 、-OS(=O) 2 (OH), -OS(=O)(OH) and -B(OH) 2 In one embodiment, the anion precursor is -CO 2 H.

[0095] In certain embodiments, PEG-C-DMA has the following structure:

[0096]

[0097] Wherein n is selected so that the resulting polymer chain has a molecular weight of about 500 to about 10,000. In one embodiment, n is selected so that the resulting polymer chain has a molecular weight of about 500 to about 7500. In one embodiment, n is selected so that the resulting polymer chain has a molecular weight of about 500 to about 6000. In one embodiment, n is selected so that the resulting polymer chain has a molecular weight of about 500 to about 5000. In one embodiment, n is selected so that the resulting polymer chain has a molecular weight of about 500 to about 3000. In one embodiment, n is selected so that the resulting polymer chain has a molecular weight of about 1000 to about 7500. In one embodiment, n is selected so that the resulting polymer chain has a molecular weight of about 1000 to about 6000. In one embodiment, n is selected so that the resulting polymer chain has a molecular weight of about 1000 to about 5000. In one embodiment, n is selected so that the resulting polymer chain has a molecular weight of about 1000 to about 3000. In another embodiment, n is selected so that the resulting polymer chain has a molecular weight of about 2000. PEG-C-DMA can be prepared as described in Heyes et al., Synthesis and Characterization of Novel Poly(Ethylene Glycol)-lipid Conjugates Suitable for use in Drug Delivery,” Journal of Controlled Release, 2006 and U.S. Pat. No. 8,936,942.

[0098] Description of the implementation plan

[0099] The present invention provides novel, serum-stable lipid particles comprising one or more active or therapeutic agents, methods of making the lipid particles, and methods of delivering and / or administering the lipid particles (e.g., for treating a disease or disorder).

[0100] In one aspect, the invention provides lipid particles comprising: (a) one or more active or therapeutic agents; (b) one or more ionizable lipids of the invention accounting for about 30 mol % to about 85 mol % of the total lipids present in the particle; (c) one or more non-cationic lipids accounting for about 13 mol % to about 49.5 mol % of the total lipids present in the particle; and (d) one or more conjugated lipids that inhibit particle aggregation accounting for about 0.1 mol % to about 10 mol % of the total lipids present in the particle.

[0101] In one aspect, the invention provides lipid particles comprising: (a) one or more active or therapeutic agents; (b) one or more ionizable lipids of the invention accounting for about 50 mol % to about 85 mol % of the total lipids present in the particle; (c) one or more non-cationic lipids accounting for about 13 mol % to about 49.5 mol % of the total lipids present in the particle; and (d) one or more conjugated lipids that inhibit particle aggregation accounting for about 0.5 mol % to about 2 mol % of the total lipids present in the particle.

[0102] In certain embodiments, the active agent or therapeutic agent is completely encapsulated in the lipid portion of the lipid particle, so that the active agent or therapeutic agent in the lipid particle is resistant to enzymatic degradation such as caused by nucleases or proteases in aqueous solution. In certain other embodiments, the lipid particle is substantially nontoxic to mammals such as humans.

[0103] In some embodiments, the activating agent or therapeutic agent comprises a nucleic acid. In some instances, the nucleic acid comprises an interfering RNA molecule, such as siRNA, aiRNA, miRNA or a mixture thereof. In some other instances, the nucleic acid comprises a single-stranded or double-stranded DNA, RNA or a DNA / RNA hybrid, such as an antisense oligonucleotide, a ribozyme, a plasmid, an immunostimulatory oligonucleotide or a mixture thereof. In some cases, the nucleic acid comprises an mRNA molecule.

[0104] In other embodiments, the active agent or therapeutic agent comprises a peptide or polypeptide. In some cases, the peptide or polypeptide comprises an antibody, such as, for example, a polyclonal antibody, a monoclonal antibody, an antibody fragment; a humanized antibody, a recombinant antibody, a recombinant human antibody, a Primatized TM In certain other examples, the peptide or polypeptide comprises a cytokine, a growth factor, an apoptosis factor, a differentiation-inducing factor, a cell surface receptor, a ligand, a hormone, a small molecule (eg, a small organic molecule or compound), or a mixture thereof.

[0105] In one embodiment, activating agent or therapeutic agent comprises siRNA.In one embodiment, siRNA molecule comprises the double-stranded region of about 15 to about 60 nucleotides (for example, length is about 15-60, 15-50, 15-40, 15-30, 15-25 or 19-25 nucleotides, or length is 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides).SiRNA molecule of the present invention can silence the expression of target sequence in vitro and / or in vivo.

[0106] In some embodiments, the siRNA molecule comprises at least one modified nucleotide. In certain preferred embodiments, the siRNA molecule comprises one, two, three, four, five, six, seven, eight, nine, ten or more modified nucleotides in the double-stranded region. In certain examples, the siRNA comprises about 1% to about 100% (e.g., about 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100%) modified nucleotides in the double-stranded region. In preferred embodiments, less than about 25% (e.g., less than about 25%, 20%, 15%, 10%, or 5%) or about 1% to about 25% (e.g., about 1%-25%, 5%-25%, 10%-25%, 15%-25%, 20%-25%, or 10%-20%) of the nucleotides in the double-stranded region comprise modified nucleotides.

[0107] In other embodiments, the siRNA molecule comprises modified nucleotides, including but not limited to 2'-O-methyl (2'OMe) nucleotides, 2'-deoxy-2'-fluoro (2'F) nucleotides, 2'-deoxy nucleotides, 2'-O-(2-methoxyethyl) (MOE) nucleotides, locked nucleic acid (LNA) nucleotides, and mixtures thereof. In preferred embodiments, the siRNA comprises 2'OMe nucleotides (e.g., 2'OMe purine and / or pyrimidine nucleotides), such as, for example, 2'OMe-guanosine nucleotides, 2'OMe-uridine nucleotides, 2'OMe-adenosine nucleotides, 2'OMe-cytosine nucleotides, and mixtures thereof. In some cases, the siRNA does not comprise 2'OMe-cytosine nucleotides. In other embodiments, the siRNA comprises a hairpin loop structure.

[0108] The siRNA may comprise modified nucleotides in one strand (i.e., sense or antisense) or both strands of the double-stranded region of the siRNA molecule. Preferably, uridine and / or guanosine nucleotides are modified at selective positions in the double-stranded region of the siRNA duplex. With regard to uridine nucleotide modification, at least one, two, three, four, five, six or more uridine nucleotides in the sense and / or antisense strands may be modified uridine nucleotides, such as 2'OMe-uridine nucleotides. In some embodiments, each uridine nucleotide in the sense and / or antisense strands is a 2'OMe-uridine nucleotide. With regard to guanosine nucleotide modification, at least one, two, three, four, five, six or more guanosine nucleotides in the sense and / or antisense strands may be modified guanosine nucleotides, such as 2'OMe-guanosine nucleotides. In some embodiments, each guanosine nucleotide in the sense and / or antisense strands is a 2'OMe-guanosine nucleotide.

[0109] In certain embodiments, at least one, two, three, four, five, six, seven or more 5'-GU-3' motifs in the siRNA sequence can be modified, for example, by introducing mismatches to eliminate the 5'-GU-3' motif and / or by introducing modified nucleotides such as 2'OMe nucleotides. The 5'-GU-3' motif can be in the sense strand, the antisense strand, or both strands of the siRNA sequence. The 5'-GU-3' motifs can be adjacent to each other or alternatively, they can be separated by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more nucleotides.

[0110] In some preferred embodiments, the immunostimulatory properties of the modified siRNA molecules are less than the immunostimulatory properties of the corresponding unmodified siRNA sequences. In such embodiments, the modified siRNA molecules with reduced immunostimulatory properties advantageously retain the RNAi activity against the target sequence. In another embodiment, the immunostimulatory properties of the modified siRNA molecules and their ability to silence target gene expression can be balanced or optimized by introducing minimal and selective 2'OMe modifications in the siRNA sequence, such as in the double-stranded region of the siRNA duplex. In certain instances, the immunostimulatory activity of the modified siRNA is at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% less than the immunostimulatory activity of the corresponding unmodified siRNA. It will be readily apparent to those skilled in the art that the immunostimulatory properties of the modified siRNA molecules and the corresponding unmodified siRNA molecules can be determined by measuring INF-α and / or IL-6 levels, for example, from about two hours to about twelve hours after systemic administration in a mammal or transfection of mammalian responder cells using an appropriate lipid-based delivery system (such as the LNP delivery system disclosed herein).

[0111] In certain embodiments, the modified siRNA molecule has a C less than or equal to ten times that of the corresponding unmodified siRNA. 50 (i.e., half maximal inhibitory concentration) (i.e., the modified siRNA has an IC less than or equal to that of the corresponding unmodified siRNA 50 Ten times the IC 50 In other embodiments, the modified siRNA has an IC less than or equal to three times that of the corresponding unmodified siRNA sequence. 50 In other embodiments, the modified siRNA has an IC less than or equal to two times that of the corresponding unmodified siRNA. 50It will be readily apparent to one skilled in the art that a dose-response curve can be generated and the IC values ​​of the modified siRNA and the corresponding unmodified siRNA 50 Values ​​can be readily determined using methods known to those skilled in the art.

[0112] In another embodiment, the modified siRNA molecule is capable of silencing the expression of at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the target sequence relative to the corresponding unmodified siRNA sequence.

[0113] In some embodiments, the siRNA molecule, for example, does not comprise a phosphate backbone modification in the sense and / or antisense strand of the double-stranded region. In other embodiments, the siRNA, for example, comprises one, two, three, four or more phosphate backbone modifications in the sense and / or antisense strand of the double-stranded region. In preferred embodiments, the siRNA does not comprise a phosphate backbone modification.

[0114] In other embodiments, the siRNA does not contain 2'-deoxynucleotides, e.g., in the sense and / or antisense strands of the double-stranded region. In other embodiments, the siRNA contains one, two, three, four or more 2'-deoxynucleotides, e.g., in the sense and / or antisense strands of the double-stranded region. In preferred embodiments, the siRNA does not contain 2'-deoxynucleotides.

[0115] In some instances, the nucleotides at the 3'-end of the double-stranded region in the sense and / or antisense strand are not modified nucleotides. In some other instances, the nucleotides near the 3'-end of the double-stranded region in the sense and / or antisense strand (e.g., within one, two, three or four nucleotides of the 3'-end) are not modified nucleotides.

[0116] The siRNA molecules described herein may have 3' overhangs of one, two, three, four or more nucleotides on one or both sides of the double-stranded region, or may lack overhangs (i.e., have flat ends) on one or both sides of the double-stranded region. Preferably, siRNA has 3' overhangs of two nucleotides on each side of the double-stranded region. In some instances, the 3' overhangs on the antisense strand have complementarity with the target sequence, and the 3' overhangs on the sense strand have complementarity with the complementary strand of the target sequence. Alternatively, the 3' overhangs do not have complementarity with the target sequence or its complementary strand. In some embodiments, the 3' overhangs include one, two, three, four or more nucleotides, such as 2'-deoxy (2'H) nucleotides. In certain preferred embodiments, the 3' overhangs include deoxythymidine (dT) and / or uridine nucleotides. In other embodiments, one or more nucleotides in the 3' overhangs on one or both sides of the double-stranded region include modified nucleotides. Non-limiting examples of modified nucleotides are described above and include 2'OMe nucleotides, 2'-deoxy-2'F nucleotides, 2'-deoxy nucleotides, 2'-O-2-MOE nucleotides, LNA nucleotides, and mixtures thereof. In preferred embodiments, one, two, three, four or more nucleotides present in the 3' overhang on the sense and / or antisense strand of the siRNA comprise 2'OMe nucleotides (e.g., 2'OMe purine and / or pyrimidine nucleotides), such as, for example, 2'OMe-guanosine nucleotides, 2'OMe-uridine nucleotides, 2'OMe-adenosine nucleotides, 2'OMe-cytosine nucleotides, and mixtures thereof.

[0117] The siRNA may comprise at least one or a mixture (e.g., at least two, three, four, five, six, seven, eight, nine, ten or more) of unmodified and / or modified siRNA sequences that silence the expression of the target gene. The mixture of siRNA may comprise sequences for the same region or domain (e.g., "hotspot") and / or for different regions or domains of one or more target genes. In some instances, one or more (e.g., at least two, three, four, five, six, seven, eight, nine, ten or more) modified siRNAs that silence the expression of the target gene are present in the mixture. In some other instances, one or more (e.g., at least two, three, four, five, six, seven, eight, nine, ten or more) unmodified siRNA sequences that silence the expression of the target gene are present in the mixture.

[0118] In some embodiments, the antisense strand of the siRNA molecule comprises or consists of a sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% complementary to the target sequence or a portion thereof. In other embodiments, the antisense strand of the siRNA molecule comprises or consists of a sequence that is 100% complementary to the target sequence or a portion thereof. In other embodiments, the antisense strand of the siRNA molecule comprises or consists of a sequence that specifically hybridizes to the target sequence or a portion thereof.

[0119] In other embodiments, the sense strand of the siRNA molecule comprises or consists of a sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the target sequence or a portion thereof. In additional embodiments, the sense strand of the siRNA molecule comprises or consists of a sequence that is 100% identical to the target sequence or a portion thereof.

[0120] In some embodiments, the ionizable lipids of the invention may comprise about 30 mol % to about 90 mol %, about 30 mol % to about 85 mol %, about 30 mol % to about 80 mol %, about 30 mol % to about 75 mol %, about 30 mol % to about 70 mol %, about 30 mol % to about 65 mol %, or about 30 mol % to about 60 mol % of the total lipids present in the particle.

[0121] In some embodiments, the ionizable lipids of the invention may comprise about 40 mol % to about 90 mol %, about 40 mol % to about 85 mol %, about 40 mol % to about 80 mol %, about 40 mol % to about 75 mol %, about 40 mol % to about 70 mol %, about 40 mol % to about 65 mol %, or about 40 mol % to about 60 mol % of the total lipids present in the particle.

[0122] In other embodiments, the ionizable lipids of the invention may comprise about 55 mol % to about 90 mol %, about 55 mol % to about 85 mol %, about 55 mol % to about 80 mol %, about 55 mol % to about 75 mol %, about 55 mol % to about 70 mol %, or about 55 mol % to about 65 mol % of the total lipids present in the particle.

[0123] In other embodiments, the ionizable lipids of the invention may comprise about 60 mol % to about 90 mol %, about 60 mol % to about 85 mol %, about 60 mol % to about 80 mol %, about 60 mol % to about 75 mol %, or about 60 mol % to about 70 mol % of the total lipids present in the particle.

[0124] In other embodiments, the ionizable lipids of the invention may comprise about 65 mol % to about 90 mol %, about 65 mol % to about 85 mol %, about 65 mol % to about 80 mol %, or about 65 mol % to about 75 mol % of the total lipids present in the particle.

[0125] In other embodiments, the ionizable lipids of the invention may comprise about 70 mol % to about 90 mol %, about 70 mol % to about 85 mol %, about 70 mol % to about 80 mol %, about 75 mol % to about 90 mol %, about 75 mol % to about 85 mol %, or about 80 mol % to about 90 mol % of the total lipids present in the particle.

[0126] In other embodiments, the ionizable lipids of the invention may comprise (at least) about 30 mol%, 35 mol%, 40 mol%, 45 mol%, 50 mol%, 51 mol%, 52 mol%, 53 mol%, 54 mol%, 55 mol%, 56 mol%, 57 mol%, 58 mol%, 59 mol%, 60 mol%, 61 mol%, 62 mol%, 63 mol%, 64 mol%, 65 mol%, 66 mol%, 67 mol%, 68 mol%, 69 mol%, 70 mol%, 71 mol%, 72 mol%, 73 mol%, 74 mol%, 75 mol%, 76 mol%, 77 mol%, 78 mol%, 79 mol%, 80 mol%, 81 mol%, 82 mol%, 83 mol%, 84 mol%, 85 mol%, 86 mol%, 87 mol%, 88 mol%, 89 mol%, 90 mol%, 91 mol%, 92 mol%, 93 mol%, 94 mol%, 95 mol%, 96 mol%, 97 mol%, 98 mol%, 99 mol%, 100 mol%, 101 mol%, 102 mol%, 103 mol%, 104 mol%, 105 mol%, 106 mol%, 107 mol%, 108 mol%, 109 mol%, 110 %, 67mol%, 68mol%, 69mol%, 70mol%, 71mol%, 72mol%, 73mol%, 74mol%, 75mol%, 76mol%, 77mol%, 78mol%, 79mol%, 80mol%, 81mol%, 82mol%, 83mol%, 84mol%, 85mol%, 86mol%, 87mol%, 88mol%, 89mol% or 90mol% (or any fraction or range therein).

[0127] In lipid particles of the present invention, non-cationic lipids may include, for example, one or more anionic lipids and / or neutral lipids. In preferred embodiments, non-cationic lipids include one of the following neutral lipid components: (1) cholesterol or a derivative thereof; (2) phospholipids; or (3) a mixture of phospholipids and cholesterol or a derivative thereof.

[0128] Examples of cholesterol derivatives include, but are not limited to, cholesterol, cholestanone, cholestenone, coprostanol, cholesteryl-2'-hydroxyethyl ether, cholesteryl-4'-hydroxybutyl ether, and mixtures thereof. The synthesis of cholesteryl-2'-hydroxyethyl ether is described herein.

[0129] The phospholipid can be a neutral lipid, including but not limited to dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylethanolamine (DOPE), palmitoyloleoyl-phosphatidylcholine (POPC), palmitoyloleoyl-phosphatidylethanolyl (POPE), palmitoyloleoyl-phosphatidylglycerol (POPG), dipalmitoyl-phosphatidylethanolamine (DPPE), dimyristoyl-phosphatidylethanolamine (DMPE), distearoyl-phosphatidylethanolamine (DSPE), monomethyl-phosphatidylethanolamine, dimethyl-phosphatidylethanolamine, ditrans-oleoyl-phosphatidylethanolamine (DEPE), stearoyloleoyl-phosphatidylethanolamine (SOPE), egg phosphatidylcholine (EPC) and mixtures thereof. In certain preferred embodiments, the phospholipid is DPPC, DSPC or mixtures thereof.

[0130] In some embodiments, the non-cationic lipid (e.g., one or more phospholipids and / or cholesterol) can account for about 10 mol% to about 70 mol%, about 15 mol% to about 70 mol%, about 20 mol% to about 70 mol%, about 25 mol% to about 70 mol%, about 30 mol% to about 70 mol%, about 10 mol% to about 55 mol%, about 15 mol% to about 55 mol%, about 20 mol% to about 55 mol%, about 25 mol% to about 55 mol%, about 30 mol% to about 55 mol%, about 13 mol% to about 50 mol%, about 15 mol% to about 50 mol%, or about 20 mol% to about 50 mol% of the total lipid present in the particle. When the non-cationic lipid is a mixture of phospholipids and cholesterol or a cholesterol derivative, the mixture can account for up to about 40 mol%, 50 mol% or 60 mol% of the total lipid present in the particle.

[0131] In other embodiments, the non-cationic lipids (e.g., one or more phospholipids and / or cholesterol) may comprise from about 10 mol % to about 49.5 mol %, from about 13 mol % to about 49.5 mol %, from about 15 mol % to about 49.5 mol %, from about 20 mol % to about 49.5 mol %, from about 25 mol % to about 49.5 mol %, from about 30 mol % to about 49.5 mol %, from about 35 mol % to about 49.5 mol %, or from about 40 mol % to about 49.5 mol %, of the total lipids present in the particle.

[0132] In other embodiments, the non-cationic lipids (e.g., one or more phospholipids and / or cholesterol) may comprise from about 10 mol % to about 45 mol %, from about 13 mol % to about 45 mol %, from about 15 mol % to about 45 mol %, from about 20 mol % to about 45 mol %, from about 25 mol % to about 45 mol %, from about 30 mol % to about 45 mol %, or from about 35 mol % to about 45 mol % of the total lipids present in the particle.

[0133] In other embodiments, the non-cationic lipids (e.g., one or more phospholipids and / or cholesterol) may comprise about 10 mol % to about 40 mol %, about 13 mol % to about 40 mol %, about 15 mol % to about 40 mol %, about 20 mol % to about 40 mol %, about 25 mol % to about 40 mol %, or about 30 mol % to about 40 mol % of the total lipids present in the particle.

[0134] In other embodiments, the non-cationic lipids (e.g., one or more phospholipids and / or cholesterol) may comprise from about 10 mol % to about 35 mol %, from about 13 mol % to about 35 mol %, from about 15 mol % to about 35 mol %, from about 20 mol % to about 35 mol %, or from about 25 mol % to about 35 mol % of the total lipids present in the particle.

[0135] In other embodiments, the non-cationic lipids (e.g., one or more phospholipids and / or cholesterol) may comprise from about 10 mol % to about 30 mol %, from about 13 mol % to about 30 mol %, from about 15 mol % to about 30 mol %, from about 20 mol % to about 30 mol %, from about 10 mol % to about 25 mol %, from about 13 mol % to about 25 mol %, or from about 15 mol % to about 25 mol % of the total lipids present in the particle.

[0136] In other embodiments, the non-cationic lipids (e.g., one or more phospholipids and / or cholesterol) may comprise (at least) about 10 mol%, 11 mol%, 12 mol%, 13 mol%, 14 mol%, 15 mol%, 16 mol%, 17 mol%, 18 mol%, 19 mol%, 20 mol%, 21 mol%, 22 mol%, 23 mol%, 24 mol%, 25 mol%, 26 mol%, 27 mol%, 28 mol%, 29 mol%, 30 mol%, 31 mol%, 32 mol%, 33 mol%, 34 mol%, 35 mol%, 36 mol%, 37 mol%, 38 mol%, 39 mol%, 40 mol%, 41 mol%, 42 mol%, 43 mol%, 44 mol%, 45 mol%, 46 mol%, 47 mol%, 48 mol%, 49 mol%, 50 mol%, 51 mol%, 52 mol%, 53 mol%, 54 mol%, 55 mol%, 56 mol%, 57 mol%, 58 mol%, 59 mol%, 60 mol%, 61 mol%, 62 mol%, 63 mol%, 64 mol%, 65 mol%, 66 mol%, 67 mol%, 68 mol%, 69 mol%, 70 mol%, 71 mol%, 72 mol%, 73 mol%, 74 mol%, 75 %, 33mol%, 34mol%, 35mol%, 36mol%, 37mol%, 38mol%, 39mol%, 40mol%, 41mol%, 42mol%, 43mol%, 44mol%, 45mol%, 46mol%, 47mol%, 48mol%, 49mol%, 50mol%, 51mol%, 52mol%, 53mol%, 54mol%, 55mol%, 56mol%, 57mol%, 58mol%, 59mol% or 60mol% (or any fraction or range therein).

[0137] In certain preferred embodiments, non-cationic lipid comprises cholesterol or its derivatives accounting for about 31.5mol% to about 42.5mol% of the total lipid present in the particle. As non-limiting example, lipid particles without phospholipids of the present invention can comprise cholesterol or its derivatives accounting for about 37mol% of the total lipid present in the particle. In other preferred embodiments, the phospholipid-free lipid particles of the invention may comprise cholesterol or a derivative thereof, comprising about 30 mol% to about 45 mol%, about 30 mol% to about 40 mol%, about 30 mol% to about 35 mol%, about 35 mol% to about 45 mol%, about 40 mol% to about 45 mol%, about 32 mol% to about 45 mol%, about 32 mol% to about 42 mol%, about 32 mol% to about 40 mol%, about 34 mol% to about 45 mol%, about 34 mol% to about 42 mol%, about 34 mol% to about 40 mol%, or about 30 mol%, 31 mol%, 32 mol%, 33 mol%, 34 mol%, 35 mol%, 36 mol%, 37 mol%, 38 mol%, 39 mol%, 40 mol%, 41 mol%, 42 mol%, 43 mol%, 44 mol% or 45 mol% (or any fraction or range therein) of the total lipid present in the particle.

[0138] In certain other preferred embodiments, the non-cationic lipid comprises a mixture of (i) phospholipids accounting for about 4mol% to about 10mol% of the total lipid present in the particle; and (ii) cholesterol or a derivative thereof accounting for about 30mol% to about 40mol% of the total lipid present in the particle. As a non-limiting example, a lipid particle comprising a mixture of phospholipids and cholesterol may comprise about 7mol% of DPPC and about 34mol% of cholesterol of the total lipid present in the particle. In other embodiments, the non-cationic lipid comprises a mixture of: (i) about 3 mol% to about 15 mol%, about 4 mol% to about 15 mol%, about 4 mol% to about 12 mol%, about 4 mol% to about 10 mol%, about 4 mol% to about 8 mol%, about 5 mol% to about 12 mol%, about 5 mol% to about 9 mol%, about 6 mol% to about 12 mol%, about 6 mol% to about 10 mol%, or about 3 mol%, 4 mol%, 5 mol%, 6 mol%, 7 mol%, 8 mol%, 9 mol%, 10 mol%, 11 mol%, 12 mol%, 13 mol%, 14 mol% or 15 mol% (or any fraction or range therein) of the total lipid present in the particle; and (ii) about 25 mol% to about 45 mol%, about 30 mol% to about 45 mol%, about 25 mol% to about 50 ... %, 34 mol%, 35 mol%, 36 mol%, 37 mol%, 38 mol%, 39 mol%, 40 mol%, 41 mol%, 42 mol%, 43 mol%, 44 mol% or 45 mol% (or any fraction or range therein) of cholesterol or a derivative thereof.

[0139] In other preferred embodiments, the non-cationic lipid comprises a mixture of: (i) about 10mol% to about 30mol% of the tl present in the particle of phospholipids; and (ii) about 10mol% to about 30mol% of the tl present in the particle of cholesterol or a derivative thereof. As a non-limiting example, a lipid particle comprising a mixture of phospholipids and cholesterol can comprise about 20mol% of DPPC and about 20mol% of the tl present in the particle. In other embodiments, the non-cationic lipid comprises a mixture of: (i) about 10 mol% to about 30 mol%, about 10 mol% to about 25 mol%, about 10 mol% to about 20 mol%, about 15 mol% to about 30 mol%, about 20 mol% to about 30 mol%, about 15 mol% to about 25 mol%, about 12 mol% to about 28 mol%, about 14 mol% to about 26 mol%, or about 10 mol%, 11 mol%, 12 mol%, 13 mol%, 14 mol%, 15 mol%, 16 mol%, 17 mol%, 18 mol%, 19 mol%, 20 mol%, 21 mol%, 22 mol%, 23 mol%, 24 mol%, 25 mol%, 26 mol%, 27 mol%, 28 mol%, 29 mol%, or 30 mol% (or any fraction or fractions thereof) of the total lipid present in the particle. and (ii) about 10 mol % to about 30 mol %, about 10 mol % to about 25 mol %, about 10 mol % to about 20 mol %, about 15 mol % to about 30 mol %, about 20 mol % to about 30 mol %, about 15 mol % to about 25 mol %, about 12 mol % to about 28 mol %, about 14 mol % to about 26 mol %, or about 10 mol %, 11 mol %, 12 mol %, 13 mol %, 14 mol %, 15 mol %, 16 mol %, 17 mol %, 18 mol %, 19 mol %, 20 mol %, 21 mol %, 22 mol %, 23 mol %, 24 mol %, 25 mol %, 26 mol %, 27 mol %, 28 mol %, 29 mol % or 30 mol % (or any fraction or range therein) of cholesterol or a derivative thereof, based on the total lipid present in the particle.

[0140] Conjugated lipids

[0141] In the lipid particles of the present invention (e.g., comprising, for example, interfering RNA, such as LNPs of siRNA or mRNA), the conjugated lipid may include, for example, one or more of the following: polyethylene glycol (PEG)-lipid conjugates, polyamide (ATTA)-lipid conjugates, or mixtures thereof. In a preferred embodiment, the nucleic acid-lipid particles include PEG-lipid conjugates or ATTA-lipid conjugates. The conjugated lipid may include PEG-lipids, including, for example, PEG-diacylglycerols (DAG), PEG dialkyloxypropyls (DAA), PEG-phospholipids, PEG-ceramides (Cer), or mixtures thereof. The PEG-DAA conjugates may be PEG-dilauryloxypropyl (C12), PEG-dimyristyloxypropyl (C14), PEG-dipalmityloxypropyl (C16), PEG-distearyloxypropyl (C18), or mixtures thereof.

[0142] Additional PEG-lipid conjugates suitable for use in the present invention include, but are not limited to, mPEG2000-1,2-di-O-alkyl-sn3-carbamoylglycerol (PEG-C-DOMG). The synthesis of PEG-C-DOMG is described in PCT Application No. PCT / US08 / 88676, filed December 31, 2008, the disclosure of which is incorporated herein by reference in its entirety for all purposes. Additional PEG-lipid conjugates suitable for use in the present invention include, but are not limited to, 1-[8′-(1,2-dimyristoyl-3-propoxy)-formamido-3′,6′-dioxaoctyl]carbamoyl-w-methyl-poly(ethylene glycol) (2KPEG-DMG). The synthesis of 2KPEG-DMG is described in U.S. Patent No. 7,404,969, the disclosure of which is incorporated herein by reference in its entirety for all purposes.

[0143] The PEG portion of the PEG-lipid conjugates described herein may comprise an average molecular weight in the range of about 550 daltons to about 10,000 daltons. In certain instances, the PEG portion has an average molecular weight of about 750 daltons to about 5,000 daltons (e.g., about 1,000 daltons to about 5,000 daltons, about 1,500 daltons to about 3,000 daltons, about 750 daltons to about 3,000 daltons, about 750 daltons to about 2,000 daltons, etc.). In preferred embodiments, the PEG portion has an average molecular weight of about 2,000 daltons or about 750 daltons.

[0144] In certain examples, the conjugated lipid (eg, PEG-lipid conjugate) may comprise from about 0.1% to about 10% (or any fraction or range therein) of the total lipid present in the particle. In certain examples, the conjugated lipid (e.g., PEG-lipid conjugate) may comprise about 0.1 mol% to about 2 mol%, about 0.5 mol% to about 2 mol%, about 1 mol% to about 2 mol%, about 0.6 mol% to about 1.9 mol%, about 0.7 mol% to about 1.8 mol%, about 0.8 mol% to about 1.7 mol%, about 1 mol% to about 1.8 mol%, about 1.2 mol% to about 1.8 mol%, about 1.2 mol% to about 1.7 mol%, about 1.3 mol% to about 1.6 mol%, about 1.4 mol% to about 1.5 mol%, or about 1 mol%, 1.1 mol%, 1.2 mol%, 1.3 mol%, 1.4 mol%, 1.5 mol%, 1.6 mol%, 1.7 mol%, 1.8 mol%, 1.9 mol%, or 2 mol% (or any fraction or range therein) of the total lipid present in the particle.

[0145] In lipid granules of the present invention, active agent or therapeutic agent can be completely encapsulated in the lipid portion of the granule, so as to protect active agent or therapeutic agent from enzymatic degradation.In preferred embodiments, the LNP comprising nucleic acid such as interfering RNA (such as siRNA) or mRNA is completely encapsulated in the lipid portion of granule, so as to protect nucleic acid from nuclease degradation.In some instances, at 37 ℃, granule is exposed to nuclease at least about 20,30,45 or 60 minutes later, the nucleic acid in LNP is not degraded substantially.In some other instances, at 37 ℃, granule is hatched in serum at least about 30,45 or 60 minutes or at least about 2,3,4,5,6,7,8,9,10,12,14,16,18,20,22,24,26,28,30,32,34 or 36 hours later, the nucleic acid in LNP is not degraded substantially.In other embodiments, active agent or therapeutic agent (such as nucleic acid, such as siRNA) is compounded with the lipid portion of granule. One of the benefits of the formulations of the present invention is that the lipid particle compositions are substantially non-toxic to mammals such as humans.

[0146] The term "fully encapsulated" means that the active agent or therapeutic agent in the lipid particles is not significantly degraded after exposure to serum or a nuclease or protease assay that would significantly degrade free DNA, RNA or protein. In a fully encapsulated system, preferably less than about 25% of the active agent or therapeutic agent in the particles is degraded in a treatment that would normally degrade 100% of the free active agent or therapeutic agent, more preferably less than about 10% and most preferably less than about 5% of the active agent or therapeutic agent in the particles is degraded. In the context of nucleic acid therapeutics, complete encapsulation can be achieved by Determine by measurement. is an ultrasensitive fluorescent nucleic acid stain for quantification of oligonucleotides and single-stranded DNA or RNA in solution (available from Invitrogen Corporation; Carlsbad, Calif.) "Completely encapsulated" also indicates that the lipid particles are serum stable, that is, they do not rapidly break down into their component parts when administered in vivo.

[0147] In another aspect, the invention provides lipid granules (for example, LNP) compositions comprising multi-lipid granules.In preferred embodiments, active agent or therapeutic agent (for example, nucleic acid) are completely encapsulated in the lipid portion of lipid granules (for example LNP), so that about 30% to about 100%, about 40% to about 100%, about 50% to about 100%, about 60% to about 100%, about 70% to about 100%, about 80% to about 100%, about 90% to about 100%, about 30% to about 95%, about 40% to about 95%, about 50% to about 95%, about 60% to about 95%, about 70% to about 95%, about 80% to about 100%, about 85% to about 95%, about 90% to about 95%, about 30% to about 90%, about 40% to about 90%, about 50% to about 90%, about 60% to about 90%, about 70% to about 90%, about 80% to about 90%, or at least about 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% (or any fraction or range therein) of the lipid particles (e.g., LNPs) have an active or therapeutic agent encapsulated therein.

[0148] Typically, lipid particles of the invention (e.g., LNP) have a lipid:active agent (e.g., lipid:nucleic acid) ratio (mass / mass ratio) of about 1 to about 100. In some instances, the lipid:active agent (e.g., lipid:nucleic acid) ratio (mass / mass ratio) is in the range of about 1 to about 50, about 2 to about 25, about 3 to about 20, about 4 to about 15, or about 5 to about 10. In preferred embodiments, lipid particles of the invention have a lipid:active agent (e.g., lipid:nucleic acid) ratio (mass / mass ratio) of about 5 to about 15, e.g., about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 (or any fraction or range thereof).

[0149] Typically, lipid particles (eg, LNPs) of the invention have an average diameter of about 40 nm to about 150 nm. In preferred embodiments, the lipid particles of the invention (e.g., LNPs) have an average diameter of about 40 nm to about 130 nm, about 40 nm to about 120 nm, about 40 nm to about 100 nm, about 50 nm to about 120 nm, about 50 nm to about 100 nm, about 40 nm to about 80 nm, about 40 nm to about 60 nm, about 50 nm to about 60 nm, about 60 nm to about 120 nm, about 60 nm to about 110 nm, about 60 nm to about 100 nm, about 60 nm to about 90 nm, about 60 nm to about 80 nm, about 70 nm to about 120 nm, about 70 nm to about 110 nm, about 70 nm to about 100 nm, about 70 nm to about 90 nm, about 70 nm to about 80 nm, or less than about 150 nm, 120 nm, 110 nm, 100 nm, 90 nm, or 80 nm (or any fraction or range therein).

[0150] In a specific embodiment of the invention, LNP comprises: (a) one or more unmodified and / or modified nucleic acid molecules (e.g., interfering RNAs that silence target gene expression, such as siRNA, aiRNA, miRNA; or mRNA that causes target protein expression); (b) about 56.5 mol% to about 66.5 mol% of the ionizable lipids of the invention of the total lipids present in the particle; (c) about 31.5 mol% to about 42.5 mol% of the non-cationic lipids of the total lipids present in the particle; and (d) about 1 mol% to about 2 mol% of the total lipids present in the particle that inhibit particle aggregation. This specific embodiment of LNP is generally referred to herein as a "1:62" formulation.

[0151] In another specific embodiment of the present invention, LNP comprises: (a) one or more unmodified and / or modified nucleic acid molecules (e.g., interfering RNAs that silence target gene expression, such as siRNA, aiRNA, miRNA; or mRNA that causes target protein expression); (b) ionizable lipids of the present invention accounting for about 52 mol% to about 62 mol% of the total lipids present in the particle; (c) non-cationic lipids accounting for about 36 mol% to about 47 mol% of the total lipids present in the particle; and (d) conjugated lipids that inhibit particle aggregation accounting for about 1 mol% to about 2 mol% of the total lipids present in the particle. This specific embodiment of LNP is generally referred to herein as a "1:57" formulation.

[0152] The present invention also provides a pharmaceutical composition comprising the lipid particles (eg, LNP) described herein and a pharmaceutically acceptable carrier.

[0153] On the other hand, the invention provides a method for introducing one or more active agents or therapeutic agents (such as nucleic acids) into cells, the method comprising contacting the cell with lipid particles (such as, LNP) as described herein. In one embodiment, the cell is in a mammal and the mammal is a person. In another embodiment, the invention provides a method for delivering one or more active agents or therapeutic agents (such as nucleic acids) in vivo, the method comprising administering lipid particles (such as, LNP) as described herein to a mammalian subject. In a preferred embodiment, the mode of administration includes but is not limited to oral, intranasal, intravenous, intraperitoneal, intramuscular, intraarticular, intralesional, intratracheal, subcutaneous and intradermal. Preferably, the mammalian subject is a person.

[0154] In one embodiment, about 8,12,24,36 or 48 hours after injection, at least about 5%, 10%, 15%, 20% or 25% of the total injection dose of lipid particles (for example, LNP) is present in blood plasma.In other embodiments, about 8,12,24,36 or 48 hours after injection, more than about 20%, 30%, 40% and up to about 60%, 70% or 80% of the total injection dose of lipid particles (for example, LNP) is present in blood plasma.In some instances, about 1 hour after administration, more than about 10% of multiple particles are present in mammalian blood plasma.In some other instances, at least about 1 hour after administration of particles can detect the presence of lipid particles (for example, LNP).In certain embodiments, after administration (for example, lung, liver, tumor or inflammation site) about 8,12,24,36,48,60,72 or 96 hours, active agent or therapeutic agent can be detected in the cell, such as interfering RNA (for example siRNA) or mRNA. In other embodiments, about 8,12,24,36,48,60,72 or 96 hours after administration, active agent or therapeutic agent can be detected, such as interfering RNA (for example, siRNA) to the down-regulation of target sequence expression.In other embodiments, active agent or therapeutic agent such as interfering RNA (for example, siRNA) preferentially occurs in the cells of tumor cells or inflammatory sites to the down-regulation of target sequence expression.In other embodiments, about 12,24,48,72 or 96 hours or about 6,8,10,12,14,16,18,19,20,22,24,26 or 28 days after administration, active agent or therapeutic agent such as interfering RNA (for example, siRNA) in the cell at the proximal or distal part of the application site or in the lung, liver or tumor cell can be detected.In other embodiments, about 8,12,24,36,48,60,72 or 96 hours after administration, active agent or therapeutic agent can be detected, such as mRNA or self-amplification RNA to the up-regulation of target sequence expression. In other embodiments, the up-regulation of activating agent or therapeutic agent such as mRNA or self-amplification RNA to target sequence expression preferentially occurs in the cell of tumor cell or inflammation site.In other embodiments, about 12,24,48,72 or 96 hours or about 6,8,10,12,14,16,18,19,20,22,24,26 or 28 days after administration can detect the presence or effect of activating agent or therapeutic agent such as mRNA or self-amplification RNA in the cell at the near-end or distal site of the application site or in lung, liver or tumor cell.In other embodiments, lipid granules (e.g., LNP) of the present invention are parenterally or intraperitoneally administered.

[0155] In some embodiments, lipid granules of the present invention (e.g., LNP) are particularly useful in the method for therapeutic delivery of one or more nucleic acids comprising an interfering RNA sequence (e.g., siRNA). Specifically, the purpose of the present invention is to provide for treating a disease or illness in a mammal (e.g., rodent such as mouse or primate such as people, chimpanzee or monkey) by down-regulating or silencing the transcription and / or translation of one or more target nucleic acid sequences or genes in vitro and in vivo methods. As a non-limiting example, the method of the present invention is useful for delivering interfering RNA (e.g., siRNA) in vivo to the liver and / or tumor of a mammalian subject. In certain embodiments, disease or illness are related to expression and / or overexpression of a gene, and expression or overexpression of a gene are reduced by interfering RNA (e.g., siRNA). In certain other embodiments, the lipid granules (e.g., LNP) of a therapeutically effective amount can be administered to a mammal. In some instances, interfering RNA (e.g., siRNA) is formulated into LNP, and the granules are applied to the patient who needs this treatment. In other examples, cells are removed from the patient, interfering RNA (eg, siRNA) is delivered in vitro (eg, using the LNPs described herein), and the cells are reinfused into the patient.

[0156] In another aspect, the invention provides lipid particles (eg, LNPs) comprising asymmetric interfering RNA (aiRNA) molecules that silence target gene expression, and methods of using such particles to silence target gene expression.

[0157] In one embodiment, the aiRNA molecule comprises a double-stranded (duplex) region of about 10 to about 25 (base paired) nucleotides in length, wherein the aiRNA molecule comprises an antisense strand comprising 5' and 3' overhangs, and wherein the aiRNA molecule is capable of silencing target gene expression.

[0158] In some examples, the aiRNA molecule comprises a double-stranded (duplex) region of about 12-20, 12-19, 12-18, 13-17, or 14-17 (base pairing) nucleotides in length, more typically 12, 13, 14, 15, 16, 17, 18, 19, or 20 (base pairing) nucleotides in length. In certain other examples, the 5' and 3' overhangs on the antisense strand comprise sequences complementary to the target RNA sequence, and may optionally further comprise non-target sequences. In some embodiments, the 5' and 3' overhangs on the antisense strand each comprise 1, 2, 3, 4, 5, 6, 7, or more nucleotides or consist of 1, 2, 3, 4, 5, 6, 7, or more nucleotides.

[0159] In other embodiments, the aiRNA molecule comprises modified nucleotides selected from the group consisting of 2'OMe nucleotides, 2'F nucleotides, 2'-deoxynucleotides, 2'-O-MOE nucleotides, LNA nucleotides, and mixtures thereof. In a preferred embodiment, the aiRNA molecule comprises 2'OMe nucleotides. As a non-limiting example, the 2'OMe nucleotides may be selected from the group consisting of 2'OMe-guanosine nucleotides, 2'OMe-uridine nucleotides, and mixtures thereof.

[0160] In a related aspect, the invention provides lipid particles (eg, LNPs) comprising microRNA (miRNA) molecules that silence target gene expression, and methods of using such compositions to silence target gene expression.

[0161] In one embodiment, the miRNA molecule comprises a length of about 15 to about 60 nucleotides, wherein the miRNA molecule is capable of silencing target gene expression.

[0162] In certain examples, the miRNA molecule comprises a length of about 15-50, 15-40 or 15-30 nucleotides, more typically a length of about 15-25 or 19-25 nucleotides, and preferably a length of about 20-24, 21-22 or 21-23 nucleotides. In a preferred embodiment, the miRNA molecule is a mature miRNA molecule that targets a target RNA sequence.

[0163] In some embodiments, the miRNA molecule comprises a modified nucleotide selected from the group consisting of: 2'OMe nucleotides, 2'F nucleotides, 2'-deoxynucleotides, 2'-O-MOE nucleotides, LNA nucleotides, and mixtures thereof. In a preferred embodiment, the miRNA molecule comprises 2'OMe nucleotides. As a non-limiting example, the 2'OMe nucleotides may be selected from the group consisting of: 2'OMe-guanosine nucleotides, 2'OMe-uridine nucleotides, and mixtures thereof.

[0164] In some embodiments, lipid granules of the present invention (e.g., LNP) can be used for the method for therapeutic delivery of one or more mRNA molecules. Specifically, an object of the present invention is to provide for treating the disease or illness of mammals (e.g., rodents such as mice or primates such as people, chimpanzees or monkeys) by expressing one or more target proteins in vitro and in vivo methods. As a non-limiting example, the method of the present invention can be used for delivery of one or more mRNA molecules to mammalian subjects in vivo. In certain other embodiments, the lipid granules (e.g., LNP) of therapeutically effective amount can be applied to mammals. In some instances, one or more mRNA molecules are formulated into LNP, and the particles are applied to the patient who needs this treatment. In other examples, cells are removed from the patient, one or more mRNA molecules are delivered in vitro (e.g., using LNP as described herein), and cells are re-injected into the patient.

[0165] Thus, the lipid particles (e.g., LNPs) of the present invention are advantageous and suitable for administering active or therapeutic agents, such as nucleic acids (e.g., interfering RNA, such as siRNA, aiRNA and / or miRNA; or mRNA; guide RNA; self-amplifying RNA; circular RNA; DNA, including plasmid DNA and capped DNA) to a subject (e.g., a mammal, such as a human) because they are stable in circulation, have a size required for pharmacodynamic behavior, thereby enabling access to extravascular sites, and are able to reach target cell populations.

[0166] Active Agent

[0167] Active agents (e.g., therapeutic agents) include any molecule or compound that is capable of exerting a desired effect on a cell, tissue, organ, or subject. Such effects can be, for example, biological, physiological, and / or cosmetic. Active agents can be any type of molecule or compound, including, but not limited to, nucleic acids, peptides, polypeptides, small molecules, and mixtures thereof. Non-limiting examples of nucleic acids include interfering RNA molecules (e.g., siRNA, aiRNA, miRNA), antisense oligonucleotides, mRNA, self-amplifying RNA, plasmids, ribozymes, immunostimulatory oligonucleotides, and mixtures thereof. Examples of peptides or polypeptides include, but are not limited to, antibodies (e.g., polyclonal antibodies, monoclonal antibodies, antibody fragments; humanized antibodies, recombinant antibodies, recombinant human antibodies, Primatized TM Antibodies), cytokines, growth factors, apoptosis factors, differentiation inducing factors, cell surface receptors and their ligands, hormones and mixtures thereof. Examples of small molecules include, but are not limited to, small organic molecules or compounds, such as any conventional reagents or drugs known to those skilled in the art.

[0168] In some embodiments, the active agent is a therapeutic agent or a salt or derivative thereof. Therapeutic agent derivatives may be therapeutically active themselves or they may be prodrugs that become active upon further modification. Thus, in one embodiment, the therapeutic agent derivative retains some or all of the therapeutic activity compared to the unmodified agent, while in another embodiment, the therapeutic agent derivative is a prodrug that lacks therapeutic activity but becomes active upon further modification.

[0169] Nucleic Acids

[0170] In certain embodiments, lipid granules of the present invention are associated with nucleic acid, thereby produce nucleic acid-lipid granules (for example, LNP).In some embodiments, nucleic acid is completely encapsulated in lipid granules.As used herein, term " nucleic acid " includes any oligonucleotide or polynucleotide with the fragment containing up to 60 nucleotides and the longer fragment called polynucleotides commonly referred to as oligonucleotides.In a specific embodiment, the length of oligonucleotides of the present invention is about 15 to about 60 nucleotides.Nucleic acid can be used separately in lipid granules of the present invention or with the lipid granules of the present invention comprising peptides, polypeptides or small molecules such as conventional drugs (for example, co-administered).

[0171] In the context of the present invention, the terms "polynucleotide" and "oligonucleotide" refer to polymers or oligomers of nucleotide monomers or nucleoside monomers composed of naturally occurring bases, sugars, and intersugar (backbone) linkages. The terms "polynucleotide" and "oligonucleotide" also include polymers or oligomers comprising non-naturally occurring monomers or functionally similar portions thereof. Such modified or substituted oligonucleotides are often superior to the native form because of properties such as, for example, enhanced cellular uptake, reduced immunogenicity, and increased stability in the presence of nucleases.

[0172] Oligonucleotides are generally classified as deoxyribonucleotides or ribonucleotides. Deoxyribonucleotides consist of a 5-carbon sugar called deoxyribose, which is covalently linked to a phosphate ester on the 5' and 3' carbons of this sugar to form an alternating non-branched polymer. Ribonucleotides consist of a similar repeating structure, in which the 5-carbon sugar is ribose.

[0173] Nucleic acid present in the lipid-nucleic acid particle according to the present invention includes known nucleic acid in any form.Nucleic acid used herein can be single-stranded DNA or RNA or double-stranded DNA or RNA or DNA-RNA hybrid.The example of double-stranded DNA is described herein and includes for example structural gene, gene including control region and terminator and self-replication system such as virus or plasmid DNA.The example of double-stranded RNA is described herein and includes for example siRNA and other RNAi agents, such as aiRNA and precursor miRNA.Single-stranded nucleic acid includes for example antisense oligonucleotide, ribozyme, mature miRNA and oligonucleotide (triplex-forming oligonucleotide) forming triplex.

[0174] Nucleic acid of the present invention can have various lengths, usually depending on the concrete form of nucleic acid.For example, in specific embodiments, the length of plasmid or gene can be about 1,000 to about 100,000 nucleotide residues.In specific embodiments, the length of oligonucleotide can be in the range of about 10 to about 100 nucleotides.In various related embodiments, the length of oligonucleotide of strand, double strand and triple strand can be in the range of about 10 to about 60 nucleotides, about 15 to about 60 nucleotides, about 20 to about 50 nucleotides, about 15 to about 30 nucleotides or about 20 to about 30 nucleotides.

[0175] In a specific embodiment, the oligonucleotide of the present invention (or its chain) specifically hybridizes with a target polynucleotide sequence or is complementary to a target polynucleotide sequence. As used herein, the terms "specific hybridization" and "complementation" indicate a sufficient degree of complementarity so that a stable and specific combination occurs between a DNA or RNA target and an oligonucleotide. It should be understood that an oligonucleotide does not need to be 100% complementary to its target nucleic acid sequence to be specifically hybridized. In a preferred embodiment, when the combination of an oligonucleotide with a target sequence interferes with the normal function of the target sequence to cause its practicality or expression loss, the oligonucleotide is specifically hybridizable, and there is a sufficient degree of complementarity to avoid the conditions of specific binding required therein, that is, in the case of in vivo determination or treatment under physiological conditions or in the case of in vitro determination under conditions where the oligonucleotide is measured and non-target sequence non-specific binding. Therefore, compared with the region of a gene or mRNA sequence targeted or specifically hybridized therewith, an oligonucleotide may include 1, 2, 3 or more base substitutions.

[0176] siRNA

[0177] The siRNA component of the nucleic acid-lipid particle of the present invention can silence the expression of the target gene of interest. The length of each chain of the siRNA duplex is generally about 15 to about 60 nucleotides, preferably about 15 to about 30 nucleotides in length. In certain embodiments, the siRNA comprises at least one modified nucleotide. The immunostimulatory property of the modified siRNA is generally smaller than that of the corresponding unmodified siRNA sequence and retains RNAi activity to the target gene of interest. In some embodiments, the modified siRNA contains at least one 2'OMe purine or pyrimidine nucleotide, such as 2'OMe-guanosine, 2'OMe-uridine, 2'OMe-adenosine and / or 2'OMe-cytosine nucleotide. In a preferred embodiment, one or more of the uridine and / or guanosine nucleotides are modified. The modified nucleotides may be present in one chain (i.e., sense or antisense) or two chains of the siRNA. The siRNA sequence may have an overhang (e.g., as in Elbashir et al., Genes Dev., 15:188 (2001) or et al., Cell, 107:309 (2001)), or may lack overhangs (ie, have blunt ends).

[0178] The modified siRNA typically comprises about 1% to about 100% (e.g., about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%) of modified nucleotides in the double-stranded region of the siRNA duplex. In certain embodiments, one, two, three, four, five, six, seven, eight, nine, ten or more nucleotides in the double-stranded region of the siRNA comprise modified nucleotides.

[0179] In some embodiments, less than about 25% (e.g., less than about 25%, 24%, 23%, 22%, 21%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1%) of the nucleotides in the double-stranded region of the siRNA comprise modified nucleotides.

[0180] In other embodiments, 1% to about 25% (e.g., about 1%-25%, 2%-25%, 3%-25%, 4%-25%, 5%-25%, 6%-25%, 7%-25%, 8%-25%, 9%-25%, 10%-25%, 11%-25%, 12%-25%, 13%-25%, 14%-25%, 15%-25%, 16%-25%, 17%-25%, 18%-25%, 19%-25%, 20%-25%, 21%-25%, 22%-25%, 23%-25%, 24%-25%, etc.) or about 1% to about 20% (e.g., about 1%-20%, 2%-20%, 3%-25%, 4%-25%, 5%-25%, 6%-25%, 7%-25%, 8%-25%, 9%-25%, 10%-25%, 11%-25%, 12%-25%, 13%-25%, 14%-25%, 15%-25%, 16%-25%, 17%-25%, 18%-25%, 19%-25%, 20%-25%, 21%-25%, 22%-25%, 23%-25%, 24%-25%, etc.) of the double-stranded region of the siRNA. %-20%, 4%-20%, 5%-20%, 6%-20%, 7%-20%, 8%-20%, 9%-20%, 10%-20%, 11%-20%, 12%-20%, 13%-20%, 14%-20%, 15%-20%, 16%-20%, 17%-20%, 18%-20%, 19% -20%, 1%-19%, 2%-19%, 3%-19%, 4%-19%, 5%-19%, 6%-19%, 7%-19%, 8%-19%, 9%-19%, 10%-19%, 11%-19%, 12%-19%, 13%-19%, 14%-19%, 15%-19%, 16%-19% , 17%-19%, 18%-19%, 1%-18%, 2%-18%, 3%-18%, 4%-18%, 5%-18%, 6%-18%, 7%-18%, 8%-18%, 9%-18%, 10%-18%, 11%-18%, 12%-18%, 13%-18%, 14%-18%, 15% -18%, 16%-18%, 17%-18%, 1%-17%, 2%-17%, 3%-17%, 4%-17%, 5%-17%, 6%-17%, 7%-17%, 8%-17%, 9%-17%, 10%-17%, 11%-17%, 12%-17%, 13%-17%, 14%-17% -16%, 15%-16%, 1%-15%, 2%-15%, 3%-15%, 4%-15%, 5%-15%, 6%-15%, 7%-15%, 8%-15%, 9%-16%, 10%-16%, 11%-16%, 12%-16%, 13%-16%, 14%-16%, 15%-16%, 1%-15%, 2%-15%, 3%-15%, 4%-15%, 5%-15%, 6%-15%, 7%-15%, 8%-15%, 9%-15%, 10%-15%, 11%-15%, 12%-15%, 13%-15%, 14%-15%, etc.) nucleotides include modified nucleotides.

[0181] In other embodiments, for example, when one or both strands of the siRNA are selectively modified at uridine and / or guanosine nucleotides, the resulting modified siRNA can comprise less than about 30% modified nucleotides (e.g., less than about 30%, 29%, 28%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1% modified nucleotides) or from about 1% to about 30% modified nucleotides (e.g., about 1%-30%. %, 2%-30%, 3%-30%, 4%-30%, 5%-30%, 6%-30%, 7%-30%, 8%-30%, 9%-30%, 10%-30%, 11%-30%, 12%-30%, 13%-30%, 14%-30%, 15%-30%, 16%-30%, 17%-30%, 18%-30%, 19%-30%, 20%-30%, 21%-30%, 22%-30%, 23%-30%, 24%-30%, 25%-30%, 26%-30%, 27%-30%, 28%-30%, or 29%-30% of modified nucleotides).

[0182] Selection of siRNA sequences

[0183] Suitable siRNA sequences can be identified using any method known in the art. Typically, the methods described in Elbashir et al., Nature, 411: 494-498 (2001) and Elbashir et al., EMBO J., 20: 6877-6888 (2001) are combined with the rational design rules listed in Reynolds et al., Nature Biotech., 22 (3): 326-330 (2004).

[0184] In general, the dinucleotide sequence 3' of the nucleotide sequence of the AUG start codon of the transcript of the target gene of interest is scanned (e.g., AA, NA, CC, GG or UU, wherein N═C, G or U) (see, e.g., Elbashir et al., EMBO J., 20: 6877-6888 (2001)). The nucleotides immediately adjacent to the 3' of the dinucleotide sequence are identified as possible siRNA sequences (i.e., target sequence or sense strand sequence). Typically, 19, 21, 23, 25, 27, 29, 31, 33, 35 or more nucleotides immediately adjacent to the 3' of the dinucleotide sequence are identified as possible siRNA sequences. In some embodiments, the dinucleotide sequence is an AA or NA sequence, and the 19 nucleotides immediately adjacent to the 3' of the AA or NA dinucleotide are identified as possible siRNA sequences. The siRNA sequences are typically spaced apart at different positions along the length of the target gene. To further enhance the silencing efficiency of the siRNA sequence, potential siRNA sequences can be analyzed to identify sites that do not contain regions homologous to other coding sequences, for example, in the target cell or organism. For example, a suitable siRNA sequence having about 21 base pairs will typically not have more than 16-17 adjacent base pairs homologous to the coding sequence in the target cell or organism. If the siRNA sequence will be expressed from an RNA Pol III promoter, select an siRNA sequence that lacks more than 4 adjacent A's or T's.

[0185] Once a potential siRNA sequence has been identified, a complementary sequence (i.e., an antisense strand sequence) can be designed. Potential siRNA sequences can also be analyzed using various criteria known in the art. For example, in order to enhance their silencing efficiency, siRNA sequences can be analyzed by identifying sequences having one or more of the following features through a rational design algorithm: (1) a G / C content of about 25% to about 60% G / C; (2) at least 3 A / Us at positions 15-19 of the sense strand; (3) no internal repeats; (4) A at position 19 of the sense strand; (5) A at position 3 of the sense strand; (6) U at position 10 of the sense strand; (7) no G / C at position 19 of the sense strand; and (8) no G at position 13 of the sense strand. siRNA design tools that incorporate appropriate values ​​for each of these features and algorithms for selecting siRNAs can be found, for example, at http: / / boz094.ust.hk / RNAi / siRNA. One skilled in the art will appreciate that sequences having one or more of the above characteristics may be selected for further analysis and testing as potential siRNA sequences.

[0186] In addition, potential siRNA sequences with one or more of the following criteria can often be omitted as siRNAs: (1) sequences containing stretches of 4 or more identical bases in a row; (2) sequences containing homopolymers of G (i.e., in order to reduce possible nonspecific effects due to the structural characteristics of these polymers; (3) sequences containing a three-base motif (e.g., GGG, CCC, AAA or TTT); (4) sequences containing stretches of 7 or more G / Cs in a row; and (5) sequences containing direct repeats of 4 or more bases within the candidate resulting in an internal fold-back structure. However, one skilled in the art will appreciate that sequences having one or more of the above characteristics can still be selected for further analysis and testing as possible siRNA sequences.

[0187] In some embodiments, the possible siRNA sequences can be further analyzed based on the siRNA duplex asymmetry as described in, for example, Khvorova et al., Cell, 115: 209-216 (2003); and Schwarz et al., Cell, 115: 199-208 (2003). In other embodiments, the possible siRNA sequences can be further analyzed based on the secondary structure at the target site as described in, for example, Luo et al., Biophys. Res. Commun., 318: 303-310 (2004). For example, the Mfold algorithm (available at http: / / www.bioinfo.rpi.edu / applications / mfold / rna / form1.cgi) can be used to model the secondary structure at the target site to select siRNA sequences that are conducive to entering the target site, where there are fewer secondary structures in the form of base pairing and stem-loops.

[0188] Once a possible siRNA sequence has been identified, the presence of any immunostimulatory properties of the sequence can be analyzed, for example, using an in vitro cytokine assay or an in vivo animal model. Motifs in the sense strand and / or antisense strand of the siRNA sequence, such as motifs rich in GU (e.g., 5'-GU-3', 5'-UGU-3', 5'-GUGU-3', 5'-UGUGU-3', etc.), can also provide an indication of whether the sequence may be immunostimulatory. Once it is found that the siRNA molecule is immunostimulatory, it can then be modified as described herein to reduce its immunostimulatory properties. As a non-limiting example, the siRNA sequence can be contacted with a mammalian response cell under conditions that allow the cell to produce a detectable immune response to determine whether the siRNA is an immunostimulatory or non-immunostimulatory siRNA. The mammalian response cell can be from a nascent mammal (i.e., a mammal that has not previously been contacted with the gene product of the siRNA sequence). The mammalian response cell can be, for example, a peripheral blood mononuclear cell (PBMC), a macrophage, etc. The detectable immune response may include the production of cytokines or growth factors such as, for example, TNF-α, IFN-α, IFN-β, IFN-γ, IL-6, IL-12, or a combination thereof. The siRNA molecules identified as immunostimulatory may then be modified to reduce their immunostimulatory properties by replacing at least one nucleotide on the sense strand and / or antisense strand with a modified nucleotide. For example, less than about 30% (e.g., less than about 30%, 25%, 20%, 15%, 10%, or 5%) of the nucleotides in the double-stranded region of the siRNA duplex may be replaced by modified nucleotides such as 2'OMe nucleotides. The modified siRNA may then be contacted with a mammalian responder cell as described above to confirm that its immunostimulatory properties are reduced or eliminated.

[0189] Suitable in vitro assays for detecting immune responses include, but are not limited to, the double monoclonal antibody sandwich immunoassay technique of David et al. (U.S. Pat. No. 4,376,110); the monoclonal-polyclonal antibody sandwich assay (Wide et al., in Kirkham and Hunter, eds., Radioimmunoassay Methods, E. and S. Livingstone, Edinburgh (1970)); the "Western blotting" method of Gordon et al. (U.S. Pat. No. 4,452,901); immunoprecipitation of labeled ligand (Brown et al., J. Biol. Chem., 255:4980-4983 (1980)); enzyme-linked immunosorbent assay (ELISA) as described, for example, by Raines et al., J. Biol. Chem., 257:5154-5160 (1982); immunocytochemical techniques, including the use of fluorescent dyes (Brooks et al., Clin. Exp. Immunol., 39:477 (1980)); and neutralization of activity (Bowen-Pope et al., Proc. Natl. Acad. Sci. USA, 81:2396-2400 (1984)). In addition to the immunoassays described above, many other immunoassays are available for use, including those described in U.S. Pat. Nos. 3,817,827; 3,850,752; 3,901,654; 3,935,074; 3,984,533; 3,996,345; 4,034,074; and 4,098,876. The disclosures of these references are incorporated herein by reference in their entirety for all purposes.

[0190] Non-limiting examples of in vivo models for detecting immune responses include in vivo mouse cytokine induction assays as described in, e.g., Judge et al., Mol. Ther., 13:494-505 (2006). In certain embodiments, the assays that may be performed are as follows: (1) siRNA may be administered by standard intravenous injection in the lateral tail vein; (2) blood may be collected by cardiac puncture approximately 6 hours after administration and processed into plasma for cytokine analysis; and (3) sandwich ELISA kits may be used according to the manufacturer's instructions to quantify cytokines (e.g., mouse and human IFN-α (PBL Biomedical; Piscataway, NJ); human IL-6 and TNF-α (eBioscience; San Diego, Calif.); and mouse IL-6, TNF-α, and IFN-γ (BD Biosciences; San Diego, Calif.)).

[0191] Monoclonal antibodies that specifically bind to cytokines and growth factors are commercially available from a variety of sources and can be produced using methods known in the art (see, e.g., Kohler et al., Nature, 256:495-497 (1975) and Harlow and Lane, ANTIBODIES, A LABORATORY MANUAL, Cold Spring Harbor Publication, New York (1999)). The production of monoclonal antibodies has been described previously and can be achieved by any means known in the art (Buhring et al., in Hybridoma, Vol. 10, No. 1, pp. 77-78 (1991)). In some methods, the monoclonal antibody is labeled (e.g., using any composition detectable by spectroscopic, photochemical, biochemical, electrical, optical or chemical means) to facilitate detection.

[0192] Generation of siRNA molecules

[0193] siRNA can be provided in several forms, including, for example, as one or more isolated small interfering RNA (siRNA) duplexes, as longer double-stranded RNA (dsRNA), or as siRNA or dsRNA transcribed from a transcription cassette in a DNA plasmid. The siRNA sequence can have overhangs (e.g., as described in Elbashir et al., Genes Dev., 15:188 (2001) or et al., Cell, 107:309 (2001)), or may lack overhangs (ie, have blunt ends).

[0194] RNA groups can be used to provide long precursor RNAs, or long precursor RNAs substantially or completely identical to the selected target sequence can be used to make siRNAs. RNA can be isolated from cells or tissues, synthesized and / or cloned according to methods well known to those skilled in the art. RNA can be a mixed population (obtained from cells or tissues, transcribed from cDNA, subtracted, selected, etc.), or can represent a single target sequence. RNA can be naturally occurring (e.g., isolated from tissue or cell samples), synthesized in vitro (e.g., using T7 or SP6 polymerase and PCR products or cloned cDNA) or chemically synthesized.

[0195] In order to form long dsRNA, for synthetic RNA, also in vitro transcription and hybridization complement to form dsRNA. If using naturally occurring RNA groups, also for example by transcribing cDNA corresponding to the RNA group or by using RNA polymerase to provide RNA complement (for example, to form a dsRNA for being digested by E. coli RNase III or Dicer). Then hybridize precursor RNA to form double-stranded RNA for digestion. Can directly administer dsRNA to subject or can digest the dsRNA in vitro before administration.

[0196] Methods for isolating RNA, synthesizing RNA, hybridizing nucleic acids, making and screening cDNA libraries, and performing PCR are well known in the art (see, e.g., Gubler and Hoffman, Gene, 25:263-269 (1983); Sambrook et al., supra; Ausubel et al., supra), as are PCR methods (see, U.S. Pat. Nos. 4,683,195 and 4,683,202; PCR Protocols: A Guide to Methods and Applications (Innis et al., eds., 1990)). Expression libraries are also well known to those skilled in the art. Additional basic texts disclosing the general methods used in the present invention include Sambrook et al., Molecular Cloning, A Laboratory Manual (2nd ed. 1989); Kriegler, Gene Transfer and Expression: A Laboratory Manual (1990); and Current Protocols in Molecular Biology (Ausubel et al., eds., 1994). The disclosures of these references are incorporated herein by reference in their entirety for all purposes.

[0197] Preferably, siRNA is chemically synthesized. Oligonucleotides comprising siRNA molecules of the present invention can be synthesized using any of a variety of techniques known in the art, such as those described in Usman et al., J. Am. Chem. Soc., 109: 7845 (1987); Scaringe et al., Nucl. Acids Res., 18: 5433 (1990); Wincott et al., Nucl. Acids Res., 23: 2677-2684 (1995); and Wincott et al., Methods Mol. Bio., 74: 59 (1997). The synthesis of oligonucleotides uses common nucleic acid protecting groups and coupling groups, such as dimethoxytrityl on the 5'-end and phosphoramidite on the 3'-end. As a non-limiting example, small-scale synthesis can be performed on an Applied Biosystems synthesizer using a 0.2 μmol scale protocol. Alternatively, synthesis at a 0.2 μmol scale can be performed on a 96-well plate synthesizer from Protogene (Palo Alto, Calif.). However, larger or smaller scale synthesis is also within the scope of the present invention. Suitable reagents for oligonucleotide synthesis, methods for RNA deprotection, and methods for RNA purification are known to those skilled in the art.

[0198] siRNA molecules can also be synthesized via tandem synthesis techniques, wherein both chains are synthesized as single continuous oligonucleotide fragments or chains separated by cleavable joints, which are subsequently cleaved to provide separated fragments or chains that hybridize to form siRNA duplexes. The joint can be a polynucleotide joint or a non-nucleotide joint. The tandem synthesis of siRNA can be easily adapted to multi-hole / multi-plate synthesis platforms and large-scale synthesis platforms using intermittent reactors, synthesis towers, etc. Alternatively, siRNA molecules can be assembled by two different oligonucleotides, wherein one oligonucleotide comprises the sense strand of siRNA and the other comprises the antisense strand of siRNA. For example, each chain can be synthesized separately and connected together by hybridization or connection after synthesis and / or deprotection. In some other examples, siRNA molecules can be synthesized as single continuous oligonucleotide fragments, wherein the self-complementary sense region and the antisense region hybridize to form a siRNA duplex with a hairpin secondary structure.

[0199] Modified siRNA sequence

[0200] In certain aspects, the siRNA molecule comprises a duplex with two chains and at least one modified nucleotide in the double-stranded region, wherein the length of each chain is about 15 to about 60 nucleotides. Advantageously, the immunostimulatory property of the modified siRNA is less than the immunostimulatory property of the corresponding unmodified siRNA sequence, but still retains the ability to silence the expression of the target sequence. In a preferred embodiment, the degree of chemical modification introduced into the siRNA molecule reaches a balance between the reduction or elimination of the immunostimulatory properties of the siRNA and the retention of RNAi activity. As a non-limiting example, the siRNA molecule targeting a gene of interest can be minimally modified (e.g., less than about 30%, 25%, 20%, 15%, 10% or 5% modified) on the selective uridine and / or guanosine nucleotides in the siRNA duplex to eliminate the immune response produced by the siRNA while retaining its ability to silence the expression of the target gene.

[0201] Examples of modified nucleotides suitable for use in the present invention include, but are not limited to, ribonucleotides with 2'-O-methyl (2'OMe), 2'-deoxy-2'-fluoro (2'F), 2'-deoxy, 5-C-methyl, 2'-O-(2-methoxyethyl) (MOE), 4'-sulfenyl, 2'-amino or 2'-C-allyl groups. Modified nucleotides with Northern conformation such as those described in, for example, Saenger, Principles of Nucleic Acid Structure, Springer-Verlag (1984) are also suitable for use in siRNA molecules. Such modified nucleotides include, but are not limited to, locked nucleic acid (LNA) nucleotides (e.g., 2'-O nucleotides, 4'-C-methylene-(D-ribofuranosyl) nucleotides), 2'-O-(2-methoxyethyl) (MOE) nucleotides, 2'-methyl-thio-ethyl nucleotides, 2'-deoxy-2'-fluoro (2'F) nucleotides, 2'-deoxy-2'-chloro (2'Cl) nucleotides, and 2'-azido nucleotides. In certain examples, the siRNA molecules described herein include one or more G-clamp nucleotides. G-clamp nucleotides refer to modified cytosine analogs in which the modification confers hydrogen bonding capabilities to both the Watson-Crick and Hoogsteen faces of the complementary guanine nucleotide within the duplex (see, e.g., Lin et al., J. Am. Chem. Soc., 120: 8531-8532 (1998)). In addition, nucleotides having nucleotide base analogs such as, for example, C-phenyl, C-naphthyl, other aromatic derivatives, inosine, azole carboxamide, and nitropyrrole derivatives such as 3-nitropyrrole, 4-nitroindole, 5-nitroindole, and 6-nitroindole (see, e.g., Loakes, Nucl. Acids Res., 29:2437-2447 (2001)) can be incorporated into siRNA molecules.

[0202] In certain embodiments, the siRNA molecule may further comprise one or more chemical modifications, such as a terminal cap moiety, a phosphate backbone modification, etc. Examples of terminal cap moieties include, but are not limited to, inverted deoxy abasic residues, glyceryl modifications, 4',5'-methylene nucleotides, 1-(β-D-erythrofuranosyl) nucleotides, 4'-thionucleotides, carbocyclic nucleotides, 1,5-anhydrohexitol nucleotides, L-nucleotides, α-nucleotides, modified base nucleotides, threofuranosyl nucleotides, acyclic 3',4'-closed nucleotides, acyclic 3,4-dihydroxybutyl nucleotides, acyclic 3,5-dihydroxypentyl nucleotides, 3'-3'-inverted nucleotide moieties, 3'-3'-inverted abasic moieties, 3'-2'-inverted nucleotide moieties, 3'-2'-inverted abasic moieties, 5'-5'-inverted nucleotide moieties, 5'-5'-inverted abasic moiety, 3'-5'-inverted deoxyabasic moiety, 5'-amino-alkyl phosphate, 1,3-diamino-2-propyl phosphate, 3-aminopropyl phosphate, 6-aminohexyl phosphate, 1,2-aminododecyl phosphate, hydroxypropyl phosphate, 1,4-butanediol phosphate, 3'-phosphoramidate, 5'-phosphoramidate, hexyl phosphate, aminohexyl phosphate, 3'-phosphate, 5'-amino, 3'-phosphorothioate, 5'-phosphorothioate, phosphorodithioate, and bridged or unbridged methyl phosphonate or 5'-thiol moieties (see, e.g., U.S. Pat. No. 5,998,203; Beaucage et al., Tetrahedron 49:1925 (1993)). Non-limiting examples of phosphate backbone modifications (i.e., generating modified internucleotide linkages) include phosphorothioates, phosphorodithioates, methylphosphonates, phosphotriesters, morpholinos, amidates, carbamates, carboxymethyls, acetamidoesters, polyamides, sulfonates, sulfonamides, sulfamates, formacetals, thioformal, and alkylsilyl substitutions (see, e.g., Hunziker et al., Nucleic Acid Analogues: Synthesis and Properties, in Modern Synthetic Methods, VCH, 331-417 (1995); Mesmaeker et al., Novel Backbone Replacements for Oligonucleotides, in Carbohydrate Modifications in Antisense Research, ACS, 24-39 (1994)). Such chemical modifications may occur at the 5'-end and / or 3'-end of the sense strand, antisense strand, or both strands of the siRNA. The disclosures of these references are incorporated herein by reference in their entirety for all purposes.

[0203] In some embodiments, the sense strand and / or antisense strand of the siRNA molecule may also include a 3'-terminal overhang having about 1 to about 4 (e.g., 1, 2, 3, or 4) 2'-deoxyribonucleotides and / or any combination of modified and unmodified nucleotides. Additional examples of types of modified nucleotides and chemical modifications that can be introduced into siRNA molecules are described in, for example, British Patent No. GB ​​2,397,818 B and U.S. Patent Publication Nos. 20040192626, 20050282188, and 20070135372, the disclosures of which are incorporated herein by reference in their entirety for all purposes.

[0204] The siRNA molecules described herein may optionally include one or more non-nucleotides in one or both chains of the siRNA. As used herein, the term "non-nucleotide" refers to any group or compound that can replace one or more nucleotide units incorporated into a nucleic acid chain, including sugar and / or phosphate substitutions, and allows the remaining bases to exhibit their activity. The group or compound is abasic because it does not contain recognized nucleotide bases such as adenosine, guanine, cytosine, uracil or thymine and therefore lacks a base at the 1'-position.

[0205] In other embodiments, the chemical modification of siRNA includes attaching a conjugate to the siRNA molecule. The conjugate can be attached via covalent attachment, such as a biodegradable linker, to the 5'-end and / or 3'-end of the sense strand and / or antisense strand of the siRNA. The conjugate can also be attached to the siRNA (see, e.g., U.S. Patent Publication Nos. 20050074771, 20050043219, and 20050158727), for example, by a carbamate group or other linking groups. In some instances, the conjugate is a molecule that facilitates the delivery of siRNA to cells. Examples of conjugate molecules suitable for attachment to siRNA include, but are not limited to, steroids such as cholesterol, glycols such as polyethylene glycol (PEG), human serum albumin (HSA), fatty acids, carotenoids, terpenes, bile acids, folates (e.g., folic acid, folate analogs and derivatives thereof), sugars (e.g., galactose, galactosamine, N-acetylgalactosamine, glucose, mannose, fructose, fucose, etc.), phospholipids, peptides, ligands of cellular receptors capable of mediating cellular uptake, and combinations thereof (see, e.g., U.S. Patent Publication Nos. 20030130186, 20040110296, and 20040249178; U.S. Patent No. 6,753,423). Other examples include lipophilic moieties, vitamins, polymers, peptides, proteins, nucleic acids, small molecules, oligosaccharides, carbohydrate clusters, intercalators, small groove adhesives, cleavage agents, and cross-linking agent conjugate molecules described in U.S. Patent Publication Nos. 20050119470 and 20050107325. Other examples include 2'-O-alkylamines, 2'-β-alkoxyalkylamines, polyamines, C5-cationically modified pyrimidines, cationic peptides, guanidine groups, amidinium groups, and cationic amino acid conjugate molecules described in U.S. Patent Publication No. 20050153337. Other examples include hydrophobic groups, membrane active compounds, cell penetrating compounds, cell targeting signals, interaction modifiers, and steric stabilizer conjugate molecules described in U.S. Patent Publication No. 20040167090. Additional examples include conjugate molecules described in U.S. Patent Publication No. 20050239739. The type of conjugate used and the degree of being conjugated to the siRNA molecule can be evaluated for the improved pharmacokinetic characteristics, bioavailability and / or stability of siRNA while retaining RNAi activity. Therefore, those skilled in the art can use any various well-known in vitro cell cultures or in vivo animal models to screen siRNA molecules with various conjugates attached thereto to identify siRNA molecules with improved properties and overall RNAi activity. The disclosure of the above patent document is incorporated herein by reference in its entirety for all purposes.

[0206] Target Gene

[0207] In certain embodiments, the nucleic acid (e.g., siRNA) components of nucleic acid-lipid particles described herein can be used to down-regulate or silence the translation (i.e., expression) of target genes. Target genes include, but are not limited to, genes related to viral infection and survival, genes related to metabolic diseases and disorders (e.g., liver diseases and disorders), genes related to tumorigenesis and cell transformation (e.g., cancer), angiogenesis genes, immunomodulatory genes such as those related to inflammatory and autoimmune responses, ligand receptor genes, and genes related to neurodegenerative disorders. In certain embodiments, target genes are expressed in hepatocytes.

[0208] Genes associated with viral infection and survival include those genes expressed by the virus in order to bind to, enter, and replicate in cells. Of particular interest are viral sequences associated with chronic viral diseases. Viral sequences of particular interest include sequences of the following viruses: filoviruses, such as Ebola and Marburg (see, e.g., Geisbert et al., J. Infect. Dis., 193: 1650-1657 (2006)); arenaviruses, such as Lassa, Junin, Machupo, Guanarito, and Sabia (Buchmeier et al., Arenaviridae: the viruses and their replication, In: FIELDS VIROLOGY, Knipe et al. (eds.), 4th ed., Lippincott-Raven, Philadelphia, (2001)); influenza viruses, such as influenza A, B, and C (see, e.g., Steinhauer et al., Annu Rev Genet., 36: 305-332 (2002); and Neumann et al., J. GenVirol., 83:2635-2662 (2002)); hepatitis viruses (see, e.g., Hamasaki et al., FEBS Lett., 543:51 (2003); Yokota et al., EMBO Rep., 4:602 (2003); Schlomai et al., Hepatology, 37:764 (2003); Wilson et al., Proc. Natl. Acad. Sci. USA, 100:2783 (2003); Kapadia et al., Proc. Natl. Acad. Sci. USA, 100:2014 (2003); and FIELDS VIROLOGY, Knipe et al. (eds.), 4th ed., Lippincott-Raven, Philadelphia (2001)); human immunodeficiency virus (HIV) (Banerjea et al., Mol. Ther., 8:62 (2003); Song et al., J. Virol., 77:7174 (2003); Stephenson, JAMA, 289:1494 (2003); Qin et al., Proc. Natl. Acad. Sci. USA, 100:183 (2003)); herpes virus (Jia et al., J. Virol., 77:3301 (2003)); and human papillomavirus (HPV) (Hall et al., J. Virol., 77:6066 (2003); Jiang et al., Oncogene, 21:6041 (2002)).

[0209] Exemplary filovirus nucleic acid sequences that can be silenced include, but are not limited to, nucleic acid sequences encoding structural proteins (e.g., VP30, VP35, nucleoprotein (NP), polymerase protein (L-pol)) and membrane-associated proteins (e.g., VP40, glycoprotein (GP), VP24). The complete genomic sequence for Ebola virus is listed in, for example, Genbank Accession Nos. NC_002549; AY769362; NC_006432; NC_004161; AY729654; AY354458; AY142960; AB050936; AF522874; AF499101; AF272001; and AF086833. The Ebola virus VP24 sequence is listed in, for example, Genbank Accession Nos. U77385 and AY058897. The Ebola virus L-pol sequence is listed in, for example, Genbank Accession No. X67110. The Ebola virus VP40 sequence is listed, for example, in Genbank Accession No. AY058896. The Ebola virus NP sequence is listed, for example, in Genbank Accession No. AY058895. The Ebola virus GP sequence is listed, for example, in Genbank Accession No. AY058898; Sanchez et al., Virus Res., 29:215-240 (1993); Will et al., J. Virol., 67:1203-1210 (1993); Volchkov et al., FEBS Lett., 305:181-184 (1992); and U.S. Patent No. 6,713,069. Additional Ebola virus sequences are listed, for example, in Genbank Accession Nos. L11365 and X61274. The complete genome sequence for Marburg virus is listed in, for example, Genbank Accession Nos. NC_001608; AY430365; AY430366 and AY358025. The Marburg virus GP sequence is listed in, for example, Genbank Accession Nos. AF005734; AF005733 and AF005732. The Marburg virus VP35 sequence is listed in, for example, Genbank Accession Nos. AF005731 and AF005730. Additional Marburg virus sequences are listed in, for example, Genbank Accession Nos. X64406; Z29337; AF005735 and Z12132. Non-limiting examples of siRNA molecules targeting Ebola virus and Marburg virus nucleic acid sequences include those described in U.S. Patent Publication No. 20070135370, the disclosure of which is incorporated herein by reference in its entirety for all purposes.

[0210] Exemplary influenza virus nucleic acid sequences that can be silenced include, but are not limited to, nucleic acid sequences encoding nucleoprotein (NP), matrix proteins (M1 and M2), nonstructural proteins (NS1 and NS2), RNA polymerases (PA, PB1, PB2), neuraminidase (NA), and hemagglutinin (HA). Influenza A virus NP sequences are, for example, in Genbank accession numbers NC_004522; AY818138; AB166863; AB188817; AB189046; AB189054; AB189062; AY646169; AY646177; AY651486; AY651493; AY651494; AY651495; AY651496; AY651497; AY651498; AY651499; AY651491; AY651493; AY651494; AY651495; AY651496; AY651497; AY651498; AY651499; AY651498; AY651499; AY651498; AY651499; AY651499; AY651499; AY651491; AY651493; AY651494; AY651495; AY666863; AB188817; AB189046; AB189054; AB189062; AY646169; AY646177; AY651486; AY651493; AY65149 listed in 1497;AY651498;AY651499;AY651500;AY651501;AY651502;AY651503;AY651504;AY651505;AY651506;AY651507;AY651509;AY651528;AY770996;AY790308;AY818138; and AY818140. The influenza A virus PA sequence is, for example, in Genbank accession numbers AY818132; AY790280; AY646171; AY818132; AY818133; AY646179; AY818134; AY551934; AY651613; AY651610; AY651620; AY651617; AY651600; AY651613; AY651614; AY651615; AY651616; AY651617; AY651618; AY651619; AY651619; AY651611; AY651613; AY651614; AY651615; AY651616; AY651617; AY651618; AY651619 ... 1611; AY651606; AY651618; AY651608; AY651607; AY651605; AY651609; AY651615; AY651616; AY651640; AY651614; AY651612; AY651621; AY651619; AY770995; and AY724786. Non-limiting examples of siRNA molecules targeting influenza virus nucleic acid sequences include those described in U.S. Patent Publication No. 20070218122, the disclosure of which is incorporated herein by reference in its entirety for all purposes.

[0211] Exemplary hepatitis virus nucleic acid sequences that can be silenced include, but are not limited to, nucleic acid sequences involved in transcription and translation (e.g., En1, En2, X, P) and nucleic acid sequences encoding structural proteins (e.g., core proteins including C protein and C-related proteins; capsid proteins and envelope proteins or fragments thereof including S protein, M protein and / or L protein) (see, e.g., FIELDS VIROLOGY, supra). Exemplary hepatitis C virus (HCV) nucleic acid sequences that can be silenced include, but are not limited to, 5'-untranslated region (5'-UTR), 3'-untranslated region (3'-UTR), polyprotein translation start codon region, internal ribosome entry site (IRES) sequence, and / or nucleic acid sequences encoding the following proteins: core protein, E1 protein, E2 protein, p7 protein, NS2 protein, NS3 protease / helicase, NS4A protein, NS4B protein, NS5A protein, and / or NS5B RNA-dependent RNA polymerase. HCV genome sequences are listed, for example, in Genbank accession numbers NC_004102 (HCV genotype 1a), AJ238799 (HCV genotype 1b), NC_009823 (HCV genotype 2), NC_009824 (HCV genotype 3), NC_009825 (HCV genotype 4), NC_009826 (HCV genotype 5), and NC_009827 (HCV genotype 6). Hepatitis A virus nucleic acid sequences are listed, for example, in Genbank Accession No. NC_001489; Hepatitis B virus nucleic acid sequences are listed, for example, in Genbank Accession No. NC_003977; Hepatitis D virus nucleic acid sequences are listed, for example, in Genbank Accession No. NC_001653; Hepatitis E virus nucleic acid sequences are listed, for example, in Genbank Accession No. NC_001434; and Hepatitis G virus nucleic acid sequences are listed, for example, in Genbank Accession No. NC_001710. Silencing sequences encoding genes associated with viral infection and survival can be conveniently used in combination with the administration of conventional agents used to treat viral conditions. Non-limiting examples of siRNA molecules targeting hepatitis virus nucleic acid sequences include those described in U.S. Patent Publication Nos. 20060281175; 20050058982 and 20070149470; U.S. Patent No. 7,348,314; and U.S. Provisional Application No. 61 / 162,127 filed on March 20, 2009, the disclosures of which are incorporated herein by reference in their entirety for all purposes.

[0212] Genes associated with metabolic diseases and disorders (e.g., disorders in which the liver is a target and liver diseases and disorders) include, for example, genes expressed in dyslipidemia (e.g., liver X receptors such as LXRα and LXRβ (Genbank Accession No. NM_007121), farnesoid X receptor (FXR) (Genbank Accession No. NM_005123), sterol regulatory element binding protein (SREBP), site-1 protease (S1P), 3-hydroxy-3-methylglutaryl coenzyme-A reductase (HMG-CoA reductase), apolipoprotein B (APOB) (Genbank Accession No. NM_000384), apolipoprotein CIII (APOC3) (Genbank Accession Nos. NM_000040 and NG_008949 REGION: 5001.8164), and ... protein E (APOE) (Genbank accession numbers NM_000041 and NG_007084REGION:5001.8612)); and genes expressed in diabetes (e.g., glucose 6-phosphatase) (see, e.g., Forman et al., Cell, 81:687 (1995); Seol et al., Mol. Endocrinol., 9:72 (1995); Zavacki et al., Proc. Natl. Acad. Sci. USA, 94:7909 (1997); Sakai et al., Cell, 85:1037-1046 (1996); Duncan et al., J. Biol. Chem., 272:12778-12785 (1997); Willy et al., Genes Dev., 9: 1033-1045 (1995); Lehmann et al., J. Biol. Chem., 272: 3137-3140 (1997); Janowski et al., Nature, 383: 728-731 (1996); and Peet et al., Cell, 93: 693-704 (1998)). It will be appreciated by those skilled in the art that genes associated with metabolic diseases and disorders (e.g., diseases and disorders in which the liver is a target and liver diseases and disorders) include genes expressed in the liver itself as well as genes expressed in other organs and tissues. Silencing sequences encoding genes associated with metabolic diseases and disorders can be conveniently used in combination with the administration of conventional agents used to treat the disease or disorder. Non-limiting examples of siRNA molecules targeting the ApoB gene include those described in U.S. Patent Publication No. 20060134189, the disclosure of which is incorporated herein by reference in its entirety for all purposes. Non-limiting examples of siRNA molecules targeting the ApoC3 gene include those described in U.S. Provisional Application No. 61 / 147,235, filed January 26, 2009, the disclosure of which is incorporated herein by reference in its entirety for all purposes.

[0213] Examples of gene sequences associated with tumorigenesis and cellular transformation (e.g., cancer or other neoplasia) include mitotic kinesins such as Eg5 (KSP, KIF11; Genbank Accession No. NM_004523); serine / threonine kinases such as polo-like kinase 1 (PLK-1) (Genbank Accession No. NM_005030; Barr et al., Nat. Rev. Mol. Cell. Biol., 5:429-440 (2004)); tyrosine kinases such as WEE1 (Genbank Accession Nos. NM_003390 and NM_001143976); apoptosis inhibitors such as XIAP (Genbank Accession No. NM_001143977); Accession No. NM_001167); COP9 signalosome subunits such as CSN1, CSN2, CSN3, CSN4, CSN5 (JAB1; Genbank Accession No. NM_006837); CSN6, CSN7A, CSN7B and CSN8; ubiquitin ligases such as COP1 (RFWD2; Genbank Accession Nos. NM_022457 and NM_001001740); and histone deacetylases such as HDAC1, HDAC2 (Genbank Accession No. NM_001527), HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, etc. Non-limiting examples of siRNA molecules targeting Eg5 and XIAP genes include those described in U.S. Patent Application Serial No. 11 / 807,872 filed May 29, 2007, the disclosure of which is incorporated herein by reference in its entirety for all purposes. Non-limiting examples of siRNA molecules targeting the PLK-1 gene include those described in U.S. Patent Publication Nos. 20050107316 and 20070265438; and U.S. Patent Application Serial No. 12 / 343,342 filed on December 23, 2008, the disclosure of which is incorporated herein by reference in its entirety for all purposes. Non-limiting examples of siRNA molecules targeting the CSN5 gene include those described in U.S. Provisional Application No. 61 / 045,251 filed on April 15, 2008, the disclosure of which is incorporated herein by reference in its entirety for all purposes.

[0214] Additional examples of gene sequences associated with tumorigenesis or cell transformation include translocation sequences such as MLL fusion genes, BCR-ABL (Wilda et al., Oncogene, 21:5716 (2002); Scherr et al., Blood, 101:1566 (2003)), TEL-AML1, EWS-FLI1, TLS-FUS, PAX3-FKHR, BCL-2, AML1-ETO and AML1-MTG8 (Heidenreich et al., Blood, 101:3157 (2003)); overexpressed sequences such as multidrug resistance genes (Nieth et al., FEBS Lett., 545:144 (2003); Wu et al., Cancer Res. 63:1515 (2003)), cell cycle proteins (Li et al., Cancer Res., 63:3593 (2003); Zou et al., Genes Dev., 16:2923 (2002)), β-catenin (Verma et al., Clin Cancer Res., 9:1291 (2003)), telomerase gene (Kosciolek et al., Mol Cancer Ther., 2:209 (2003)), c-MYC, N-MYC, BCL-2, growth factor receptors (e.g., EGFR / ErbBl (Genbank Accession Nos. NM_005228, NM_201282, NM_201283, and NM_201284; see also Nagy et al. Exp. Cell. Res., 285:39-49 (2003), ErbB2 / HER-2 (Genbank Accession Nos. NM_004448 and NM_001005862), ErbB3 (Genbank Accession Nos. NM_001982 and NM_001005915) and ErbB4 (Genbank Accession Nos. NM_005235 and NM_001042599); and mutant sequences such as RAS (reviewed in Tuschl and Borkhardt, Mol. Interventions, 2:158 (2002)). Non-limiting examples of siRNA molecules targeting EGFR genes include those described in U.S. patent application serial number 11 / 807,872 filed May 29, 2007, the disclosure of which is incorporated herein by reference in its entirety for all purposes.

[0215] Silencing sequences encoding DNA repair enzymes is used in combination with the administration of chemotherapeutic agents (Collis et al., Cancer Res., 63: 1550 (2003)). Genes encoding proteins associated with tumor migration also target sequences of interest, such as integrins, selectins, and metalloproteinases. The above examples are not exclusive. Those skilled in the art will appreciate that any whole or partial gene sequence that is beneficial to or promotes tumorigenesis or cell transformation, tumor growth, or tumor migration may be included as a template sequence.

[0216] Angiogenesis genes can promote the formation of new blood vessels. Of particular interest is vascular endothelial growth factor (VEGF) (Reich et al., Mol. Vis., 9:210 (2003)) or VEGFR. siRNA sequences targeting VEGFR are listed in, for example, GB2396864; U.S. Patent Publication No. 20040142895; and CA 2456444, the disclosures of which are incorporated herein by reference in their entirety for all purposes.

[0217] Anti-angiogenic genes can inhibit new blood vessel formation. These genes are particularly useful for treating those cancers in which angiogenesis plays a role in the pathological development of the disease. Examples of anti-angiogenic genes include, but are not limited to, endostatin (see, e.g., U.S. Pat. No. 6,174,861), angiostatin (see, e.g., U.S. Pat. No. 5,639,725), and VEGFR2 (see, e.g., Decaussin et al., J. Pathol., 188: 369-377 (1999)), the disclosure of which is incorporated herein by reference in its entirety for all purposes.

[0218] Immunomodulatory genes are genes that regulate one or more immune responses. Examples of immunomodulatory genes include, but are not limited to, cytokines such as growth factors (e.g., TGF-α, TGF-β, EGF, FGF, IGF, NGF, PDGF, CGF, GM-CSF, SCF, etc.), interleukins (e.g., IL-2, IL-4, IL-12 (Hill et al., J. Immunol., 171: 691 (2003)), IL-15, IL-18, IL-20, etc.), interferons (e.g., IFN-α, IFN-β, IFN-γ, etc.) and TNF. Fas gene and Fas ligand gene are also target immunomodulatory target sequences (Song et al., Nat. Med., 9: 347 (2003)). Genes encoding secondary signaling molecules in hematopoietic and lymphoid cells are also included in the present invention, for example, Tec family kinases such as Bruton's tyrosine kinase (Btk) (Heinonen et al., FEBS Lett., 527:274 (2002)).

[0219] Cell receptor ligands include those that can bind to cell surface receptors (e.g., insulin receptors, EPO receptors, G protein-coupled receptors, receptors with tyrosine kinase activity, cytokine receptors, growth factor receptors, etc.) to regulate (e.g., inhibit, activate, etc.) physiological pathways in which the receptors participate (e.g., glucose level regulation, blood cell development, mitogenesis, etc.). Examples of cell receptor ligands include, but are not limited to, cytokines, growth factors, interleukins, interferons, erythropoietin (EPO), insulin, glucagon, G protein-coupled receptor ligands, etc. Templates encoding amplification of trinucleotide repeat sequences (e.g., CAG repeat sequences) can be used to silence pathogenic sequences in neurodegenerative disorders caused by amplification of trinucleotide repeat sequences, such as spinal bulbar muscular atrophy and Huntington's disease (Caplen et al., Hum. Mol. Genet., 11: 175 (2002)).

[0220] Certain other target genes that can be targeted by nucleic acids (e.g., by siRNA) to downregulate or silence gene expression include, but are not limited to, actin, alpha 2, smooth muscle, Aorta (ACTA2), alcohol dehydrogenase 1A (ADH1A), alcohol dehydrogenase 4 (ADH4), alcohol dehydrogenase 6 (ADH6), Afamin (AFM), angiotensinogen (AGT), serine-pyruvate aminotransferase (AGXT), alpha-2-HS-glycoprotein (AHSG), aldo-keto reductase family 1 member C4 (AKR1C4), serum albumin (ALB), alpha-1-microglobulin / bikurin precursor (AMBP), angiopoietin-related protein 3 (ANGPTL3), serum amyloid P component (APCS), apolipoprotein A-II (APOA2), apolipoprotein B-100 (APOB), apolipoprotein C3 (APOC3), apolipoprotein C-IV (APOC4), apolipoprotein F (APOF), beta-2-glycoprotein 1 (APOH ), aquaporin 9 (AQP9), bile acid-CoA:amino acid N-acyltransferase (BAAT), C4b binding protein β chain (C4BPB), putative uncharacterized protein encoded by LINC01554 (C5orf27), complement factor 3 (C3), complement factor 5 (C5), complement component C6 (C6), complement component C8 α chain (C8A), complement component C8 β chain (C8B), complement component C8 γ chain (C8G), complement component C9 (C9), calcium regulator Protein binding transcription activator 1 (CAMTA1), CD38 (CD38), complement factor B (CFB), complement factor H related protein 1 (CFHR1), complement factor H related protein 2 (CFHR2), complement factor H related protein 3 (CFHR3), cannabinoid receptor 1 (CNR1), ceruloplasmin (CP), carboxypeptidase B2 (CPB2), connective tissue growth factor (CTGF), CXC motif chemokine 2 (CXCL2), cytochrome P450 1A2 (CYP1A2), cytochrome P450 2A6 (CYP2A6), cytochrome P450 2C8 (CYP2C8), cytochrome P450 2C9 (CYP2C9), cytochrome P450 family 2 subfamily D member 6 (CYP2D6), cytochrome P4502E1 (CYP2E1), phylloquinone ω-hydroxylase CYP4F2 (CYP4F2), 7-α-hydroxycholest-4-ene-3-one 12-α-hydroxylase (CYP8B1), dipeptidyl peptidase 4 (DPP4), coagulation factor 12 (F12), coagulation factor II (thrombin) (F2), coagulation factor IX (F9), fibrinogen α chain (FGA), fibrinogen β chain (FGB), fibrinogen γ chain (FGG), fibrinogen-like 1 (FGL1), flavin-containing monooxygenase 3 (FMO3), flavin-containing monooxygenase 5 ( FMO5), group-specific component (vitamin D binding protein) (GC), growth hormone receptor (GHR), glycine N-methyltransferase (GNMT), hyaluronan binding protein 2 (HABP2), hepcidin antimicrobial peptide (HAMP), hydroxy acid oxidase (glycolate oxidase) 1 (HAO1), HGF activator (HGFAC), haptoglobin-related protein; haptoglobin (HPR), hemoglobin (HPX), histidine-rich glycoprotein (HRG), hydroxysteroid (11-β) dehydrogenase 1 (HSD11B 1), hydroxysteroid (17-β) dehydrogenase 13 (HSD17B13), inter-α-trypsin inhibitor heavy chain H1 (ITIH1), inter-α-trypsin inhibitor heavy chain H2 (ITIH2), inter-α-trypsin inhibitor heavy chain H3 (ITIH3), inter-α-trypsin inhibitor heavy chain H4 (ITIH4), kallikrein (KLKB1), lactate dehydrogenase A (LDHA), liver expressed antimicrobial peptide 2 (LEAP2), leukocyte-derived chemokine 2 (LECT2), lipoprotein (a) (LPA), MASP2, MAT1A, NADPH oxidase 4 (NOX4), ADP-ribose polymerase 1 (PARP1), paraoxonase 1 (PON1), paraoxonase 3 (PON3), vitamin K-dependent protein C (PROC), retinol dehydrogenase 16 (RDH16), serum amyloid A4, constitutive (SAA4), serine dehydratase (SDS), Serpin family A member 1 (SERPINA1), SerpinA11 (SERPINA11), kallikrein inhibitor (SERPINA4), corticosteroid binding globulin (SERPINA6), antithrombin-III (SERPINC1), heparin cofactor 2 (SERPIND1), Serpin family H member 1 (SERPINH1), solute transporter family 5 member 2 (SLC5A2), sodium / bile acid cotransporter (SLC10A1), solute transporter family 13 member 5 (SLC13A5), solute transporter family 22 member 1 (SLC22A1), solute transporter family 25 member 47 (SLC25A47), solute transporter family 2, glucose-promoting Sugar transporter member 2 (SLC2A2), sodium-coupled neutral amino acid transporter 4 (SLC38A4), solute carrier organic anion transporter family 1B1 (SLCO1B1), sphingomyelin phosphodiesterase 1 (SMPD1), bile salt sulfotransferase (SULT2A1), tyrosine aminotransferase (TAT), tryptophan 2,3-dioxygenase (TDO2), UDP glucuronosyltransferase 2 family, polypeptide B10 (UGT2B10), UDP glucuronosyltransferase 2 family, polypeptide B15 (UGT2B15), UDP glucuronosyltransferase 2 family, polypeptide B4 (UGT2B4) and vitronectin (VTN).

[0221] In addition to being used to silence the expression of any of the above-described genes for therapeutic purposes, some nucleic acids described herein (e.g., siRNA) are also used for research and development applications and diagnosis, prevention, prognosis, clinical and other health care applications. As a non-limiting example, some nucleic acids (e.g., siRNA) can be used in target validation studies for testing whether a gene of interest may become a therapeutic target. Some nucleic acids (e.g., siRNA) can also be used in target identification studies for genes intended to be found as possible therapeutic targets.

[0222] CRISPR

[0223] Targeted genome editing has evolved from a niche technology to a method used by many biological researchers. The emergence of clustered regularly spaced short palindromic repeats (CRISPR) technology has largely promoted this progress (see, for example, Sander et al., Nature Biotechnology, 32 (4), 347-355, including supplementary information (2014) and international publications WO 2016 / 197132 and WO 2016 / 197133). Therefore, there is provided herein an improvement (such as lipid nanoparticles and their preparations) that can be used in combination with CRISPR technology to treat diseases such as HBV. With regard to the target using CRISPR, the guide RNA (gRNA) used in CRISPR technology can be designed to target a sequence specifically identified, such as a target gene of the HBV genome. Examples of such target sequences are provided in International Publication No. WO 2016 / 197132. In addition, International Publication No. WO 2013 / 151665 (e.g., see Table 6; the document is expressly incorporated herein by reference, particularly including Table 6, and the associated sequence listing) describes about 35,000 mRNA sequences claimed in the context of mRNA expression constructs. Certain embodiments of the present invention utilize CRISPR technology to target the expression of any of these sequences. Certain embodiments of the present invention may also utilize CRISPR technology to target the expression of target genes discussed herein.

[0224] aiRNA

[0225] Like siRNA, asymmetric interfering RNA (aiRNA) can recruit RNA-induced silencing complex (RISC) and lead to effective silencing of various genes in mammalian cells by mediating sequence-specific cleavage of target sequence between nucleotide 10 and nucleotide 11 relative to the 5' end of antisense strand (Sun et al., Nat. Biotech., 26: 1379-1382 (2008)). Generally, aiRNA molecules include short RNA duplexes with sense strand and antisense strand, wherein the duplexes contain overhangs on the 3' end and 5' end of the antisense strand. AiRNA is generally asymmetric because the sense strand is shorter on both ends when compared with the complementary antisense strand. In some aspects, aiRNA molecules can be designed, synthesized and annealed under conditions similar to those for siRNA molecules. As a non-limiting example, aiRNA sequences can be selected and generated using the method described above for selecting siRNA sequences.

[0226] In another embodiment, aiRNA duplexes of various lengths (e.g., about 10-25, 12-20, 12-19, 12-18, 13-17, or 14-17 base pairs, more typically 12, 13, 14, 15, 16, 17, 18, 19 or 20 base pairs) with overhangs on the 3' and 5' ends of the antisense strand can be designed to target a target mRNA. In certain examples, the sense strand of the aiRNA molecule is about 10-25, 12-20, 12-19, 12-18, 13-17, or 14-17 nucleotides in length, more typically 12, 13, 14, 15, 16, 17, 18, 19 or 20 nucleotides in length. In certain other examples, the antisense strand of the aiRNA molecule is about 15-60, 15-50, or 15-40 nucleotides in length, more typically about 15-30, 15-25, or 19-25 nucleotides in length, and preferably about 20-24, 21-22, or 21-23 nucleotides in length.

[0227] In some embodiments, the 5' antisense overhang contains one, two, three, four or more non-targeting nucleotides (e.g., "AA", "UU", "dTdT", etc.). In other embodiments, the 3' antisense overhang contains one, two, three, four or more non-targeting nucleotides (e.g., "AA", "UU", "dTdT", etc.). In certain aspects, the aiRNA molecules described herein may, for example, comprise one or more modified nucleotides in the double-stranded (duplex) region and / or in the antisense overhang. As a non-limiting example, the aiRNA sequence may comprise one or more modified nucleotides described above for the siRNA sequence. In preferred embodiments, the aiRNA molecule comprises 2'OMe nucleotides such as, for example, 2'OMe-guanosine nucleotides, 2'OMe-uridine nucleotides, or a mixture thereof.

[0228] In certain embodiments, the aiRNA molecule may comprise an antisense strand corresponding to the antisense strand of an siRNA molecule, such as one of the siRNA molecules described herein. In other embodiments, the aiRNA molecule can be used to silence the expression of any of the above-mentioned target genes, such as genes associated with viral infection and survival, genes associated with metabolic diseases and disorders, genes associated with tumorigenesis and cell transformation, angiogenesis genes, immunomodulatory genes (such as genes associated with inflammatory and autoimmune responses), ligand receptor genes, and genes associated with neurodegenerative disorders.

[0229] miRNA

[0230] Typically, microRNA (miRNA) is a single-stranded RNA molecule with a length of about 21-23 nucleotides that regulates gene expression. MiRNA is encoded by the gene that transcribes their DNA, but miRNA is not translated into protein (non-coding RNA); instead, each initial transcript (initial-miRNA) is processed into a short stem-loop structure called precursor-miRNA and eventually becomes a functional mature miRNA. Mature miRNA molecules are partially or completely complementary to one or more messenger RNA (mRNA) molecules, and their main function is to downregulate gene expression. The identification of miRNA molecules is described in, for example, Lagos-Quintana et al., Science, 294: 853-858; Lau et al., Science, 294: 858-862; and Lee et al., Science, 294: 862-864.

[0231] The gene encoding miRNA is much longer than the mature miRNA molecule processed. First, miRNA is transcribed as an initial transcript or an initial-miRNA with a cap and a poly A tail and is processed into a short, about 70 nucleotide stem-loop structure called precursor-miRNA in the nucleus. This processing is carried out in animals by a protein complex called a microprocessor complex composed of nuclease Drosha and double-stranded RNA binding protein Pasha (Denli et al., Nature, 432: 231-235 (2004)). These precursor-miRNAs are then processed into mature miRNAs in the cytoplasm by interacting with the endonuclease Dicer, which also initiates the formation of RNA-induced silencing complexes (RISC) (Bernstein et al., Nature, 409: 363-366 (2001)). The sense strand or antisense strand of DNA can be used as a template for generating miRNA.

[0232] When the dicer cleaves the precursor-miRNA stem-loop, two complementary short RNA molecules are formed, but only one is incorporated into the RISC complex. This chain is called the guide chain and is selected by the catalytically active RNA enzyme argonaute protein in the RISC complex based on the stability of the 5' end (Preall et al., Curr.Biol., 16:530-535 (2006)). The remaining chain called the anti-guide or passenger chain is degraded to a RISC complex substrate (Gregory et al., Cell, 123:631-640 (2005)). After being incorporated into the active RISC complex, miRNA base pairs with its complementary mRNA molecule and induces target mRNA degradation and / or translation silencing.

[0233] Mammalian miRNA molecules are usually complementary to sites in the 3'UTR of target mRNA sequences. In some instances, the annealing of miRNA to target mRNA inhibits protein translation by blocking the protein translation mechanism. In some other examples, the annealing of miRNA to target mRNA is conducive to the cracking and degradation of target mRNA by methods similar to RNA interference (RNAi). MiRNA can also target methylation of genomic sites corresponding to targeted mRNA. Generally, miRNA functions associated with the complement of proteins are collectively referred to as miRNPs.

[0234] In some aspects, the length of the miRNA molecule described herein is about 15-100, 15-90, 15-80, 15-75, 15-70, 15-60, 15-50 or 15-40 nucleotides, more generally about 15-30, 15-25 or 19-25 nucleotides in length, and preferably about 20-24, 21-22 or 21-23 nucleotides in length. In some other aspects, the miRNA molecule may include one or more modified nucleotides. As a non-limiting example, the miRNA sequence may include one or more modified nucleotides described above for the siRNA sequence. In a preferred embodiment, the miRNA molecule includes 2'OMe nucleotides such as 2'OMe-guanosine nucleotides, 2'OMe-uridine nucleotides or a mixture thereof.

[0235] In some embodiments, miRNA molecules can be used to silence the expression of any of the above-mentioned target genes, such as genes associated with viral infection and survival, genes associated with metabolic diseases and disorders, genes associated with tumorigenesis and cellular transformation, angiogenesis genes, immunomodulatory genes (such as genes associated with inflammatory and autoimmune responses), ligand receptor genes, and genes associated with neurodegenerative disorders.

[0236] In other embodiments, one or more agents that block the activity of the miRNA targeting target mRNA are administered using the lipid granules of the present invention (e.g., nucleic acid-lipid granules). Examples of blockers include, but are not limited to, steric blocking oligonucleotides, locked nucleic acid oligonucleotides, and morpholino oligonucleotides. Such blockers can be directly combined with miRNA or combined with the miRNA binding site on the target mRNA.

[0237] Antisense Oligonucleotides

[0238] In one embodiment, nucleic acid is an antisense oligonucleotide related to a target gene or sequence of interest. The term "antisense oligonucleotide" or "antisense" includes oligonucleotides complementary to a targeted polynucleotide sequence. Antisense oligonucleotides are single strands of DNA or RNA complementary to a selected sequence. Antisense RNA oligonucleotides prevent translation of complementary RNA chains by binding to RNA. Antisense DNA oligonucleotides can be used to target specific complementary (coding or non-coding) RNA. If binding occurs, this DNA / RNA hybrid can be degraded by the enzyme RNase H. In a specific embodiment, the antisense oligonucleotide comprises about 10 to about 60 nucleotides, more preferably about 15 to about 30 nucleotides. The term also encompasses antisense oligonucleotides that may not be precisely complementary to the desired target gene. Therefore, the present invention can be used in examples of using antisense to find non-target specific activity, or in examples of specific use in which the antisense sequence containing one or more mismatches with the target sequence is the most preferred.

[0239] Antisense oligonucleotides have been shown to be effective and targeted inhibitors of protein synthesis, and therefore can be used to specifically inhibit protein synthesis by targeting genes. The efficacy of antisense oligonucleotides for inhibiting protein synthesis is well established. For example, the synthesis of polygalactauronase and muscarinic type 2 acetylcholine receptors is inhibited by antisense oligonucleotides related to their corresponding mRNA sequences (see, U.S. Patent Nos. 5,739,119 and 5,759,829). In addition, examples of antisense inhibition have been demonstrated for nuclear protein cyclins, multidrug resistance gene (MDR1), ICAM-1, E-selectin, STK-1, striatal GABAA receptors, and human EGF (see Jaskulski et al., Science, 240: 1544-6 (1988); Vasanthakumar et al., Cancer Commun., 1: 225-32 (1989); Penis et al., Brain Res Mol Brain Res., 15; 57: 310-20 (1998); and U.S. Pat. Nos. 5,801,154; 5,789,573; 5,718,709 and 5,610,288). In addition, antisense constructs have also been described to inhibit and can be used to treat various abnormal cell proliferations such as cancer (see, U.S. Pat. Nos. 5,747,470; 5,591,317; and 5,783,683). The disclosures of these references are incorporated herein by reference in their entirety for all purposes.

[0240] Methods for producing antisense oligonucleotides are known in the art and can be readily adapted to produce antisense oligonucleotides targeting any polynucleotide sequence. The selection of an antisense oligonucleotide sequence specific for a given target sequence is based on analysis of the selected target sequence and the secondary structure, Tm , binding energy and relative stability. Antisense oligonucleotides can be selected based on their ability to relatively not form dimers, hairpins or other secondary structures, and the structure will reduce or prohibit specific binding to the target mRNA in the host cell. Highly preferred target regions of mRNA include those regions that are in or near the AUG translation start codon and those sequences that are substantially complementary to the 5' region of mRNA. These secondary structure analysis and target site selection considerations can be performed, for example, using OLIGO primer analysis software v.4 (Molecular Biology Insights) and / or BLASTN 2.0.5 algorithm software (Altschul et al., Nucleic Acids Res., 25:3389-402 (1997)).

[0241] Ribozyme

[0242] According to another embodiment of the present invention, the nucleic acid-lipid particle is associated with a ribozyme. Ribozymes are RNA-protein complexes with specific catalytic domains that possess endonuclease activity (see, Kim et al., Proc. Natl. Acad. Sci. USA., 84: 8788-92 (1987); and Forster et al., Cell, 49: 211-20 (1987)). For example, a large number of ribozymes accelerate highly specific phosphate transfer reactions, often cleaving only one of several phosphates in an oligonucleotide substrate (see, Cech et al., Cell, 27: 487-96 (1981); Michel et al., J. Mol. Biol., 216: 585-610 (1990); Reinhold-Hurek et al., Nature, 357: 173-6 (1992)). This specificity is due to the requirement for substrate binding to the internal guide sequence ("IGS") of the ribozyme via specific base pairing interactions prior to chemical reaction.

[0243] At least six basic species of naturally occurring enzymatic RNA molecules are currently known. Each can catalyze the hydrolysis of trans RNA phosphodiester bonds under physiological conditions (and therefore can cleave other RNA molecules). In general, enzymatic nucleic acids work by first binding to a target RNA. The binding occurs through the target binding portion of the enzymatic nucleic acid, which is kept in close proximity to the enzymatic portion of the molecule that acts to crack the target RNA. Therefore, the enzymatic nucleic acid first recognizes and then binds to the target RNA through complementary base pairing, and once bound to the appropriate site, it acts to cut the target RNA in an enzymatic manner. Strategically cleaving the target RNA will destroy its ability to guide the synthesis of coded proteins. After the enzymatic nucleic acid has bound and cracked its RNA target, it is released from that RNA to search for another target, and can repeatedly bind and crack new targets.

[0244] Enzymatic nucleic acid molecules can be formed, for example, in a hammerhead, hairpin, hepatitis delta virus, group I intron, or RNase P RNA (associated with an RNA guide sequence) or Neurospora VS RNA motif. Specific examples of hammerhead motifs are described, for example, in Rossi et al., Nucleic Acids Res., 20:4559-65 (1992). Examples of hairpin motifs are described, for example, in EP 0360257; Hampel et al., Biochemistry, 28:4929-33 (1989); Hampel et al., Nucleic Acids Res., 18:299-304 (1990); and U.S. Pat. No. 5,631,359. Examples of hepatitis delta virus motifs are described, for example, in Perrotta et al., Biochemistry, 31:11843-52 (1992). Examples of RNase P motifs are described, for example, in Guerrier-Takada et al., Cell, 35:849-57 (1983). Examples of Neurospora VS RNA ribozyme motifs are described, for example, in Saville et al., Cell, 61:685-96 (1990); Saville et al., Proc. Natl. Acad. Sci. USA, 88:8826-30 (1991); Collins et al., Biochemistry, 32:2795-9 (1993). Examples of group I introns are described, for example, in U.S. Pat. No. 4,987,071. An important feature of the enzymatic nucleic acid molecules used according to the present invention is that they have specific substrate binding sites that are complementary to one or more target gene DNA or RNA regions, and they have nucleotide sequences within or around the substrate binding sites that exert RNA cleavage activity on the molecules. Therefore, ribozyme constructs do not need to be limited to the specific motifs mentioned herein. The disclosures of these references are incorporated herein by reference in their entirety for all purposes.

[0245] Methods for producing ribozymes targeting any polynucleotide sequence are known in the art. Ribozymes can be designed as described in, for example, PCT Publication Nos. WO 93 / 23569 and WO 94 / 02595 and synthesized to test in vitro and / or in vivo as described therein. The disclosures of these PCT publications are incorporated herein by reference in their entirety for all purposes.

[0246] Ribozyme activity can be optimized by altering the length of the ribozyme binding arms or chemically synthesizing modified ribozymes that protect them from degradation by serum ribonucleases (see, e.g., PCT Publication Nos. WO 92 / 07065, WO 93 / 15187, WO 91 / 03162, and WO 94 / 13688; EP 92110298.4; and U.S. Pat. No. 5,334,711, which describe various chemical modifications that can be made to the sugar moieties of enzymatic RNA molecules, the disclosures of which are each incorporated herein by reference in their entirety for all purposes), modifications that enhance their efficacy in cells, and removal of the Stem II base to shorten RNA synthesis time and reduce chemical requirements.

[0247] Immunostimulatory oligonucleotides

[0248] The nucleic acid associated with the lipid particles of the present invention may be immunostimulatory, including immunostimulatory oligonucleotides (ISS; single-stranded or double-stranded) that can induce an immune response when administered to a subject, the subject may be a mammal such as a human. ISS includes, for example, certain palindromic sequences that lead to hairpin secondary structures (see, Yamamoto et al., J. Immunol., 148: 4072-6 (1992)) or CpG motifs and other known ISS features (such as poly-G domains; see PCT Publication No. WO 96 / 11266, the disclosure of which is incorporated herein by reference as a whole for all purposes).

[0249] Immunostimulatory nucleic acids are considered to be non-sequence specific when they are not required to specifically bind to a target sequence and reduce the expression of the target sequence in order to elicit an immune response. Thus, some immunostimulatory nucleic acids may comprise sequences corresponding to regions of naturally occurring genes or mRNAs, but they may still be considered to be non-sequence specific immunostimulatory nucleic acids.

[0250] In one embodiment, the immunostimulatory nucleic acid or oligonucleotide comprises at least one CpG dinucleotide. The oligonucleotide or CpG dinucleotide may be unmethylated or methylated. In another embodiment, the immunostimulatory nucleic acid comprises at least one CpG dinucleotide with a methylated cytosine. In one embodiment, the nucleic acid comprises a single CpG dinucleotide, wherein the cytosine in the CpG dinucleotide is methylated. In an alternative embodiment, the nucleic acid comprises at least two CpG dinucleotides, wherein at least one cytosine in the CpG dinucleotide is methylated. In other embodiments, each cytosine present in the CpG dinucleotide in the sequence is methylated. In another embodiment, the nucleic acid comprises a plurality of CpG dinucleotides, wherein at least one CpG dinucleotide comprises a methylated cytosine. Examples of immunostimulatory oligonucleotides suitable for use in the compositions and methods of the present invention are described in PCT Application No. PCT / US08 / 88676, PCT Publication No. WO 02 / 069369 and WO 01 / 15726, U.S. Patent No. 6,406,705, and Raney et al., J. Pharm. Exper. Ther., 298: 1185-92 (2001), the disclosures of which are each incorporated herein by reference in their entirety for all purposes. In certain embodiments, the oligonucleotides used in the compositions and methods of the present invention have a phosphodiester ("PO") backbone or a phosphorothioate ("PS") backbone, and / or have at least one methylated cytosine residue in a CpG motif.

[0251] mRNA

[0252] In certain embodiments, the nucleic acid is one or more mRNA molecules (eg, a mixture of mRNA molecules).

[0253] Modification of mRNA

[0254] The mRNA used in the practice of the present invention may contain one, two or more than two nucleoside modifications. In some embodiments, the modified mRNA exhibits reduced degradation in a cell into which the mRNA has been introduced relative to the corresponding unmodified mRNA.

[0255] In some embodiments, the modified nucleosides include pyridin-4-one ribonucleosides, 5-aza-uridine, 2-thio-5-aza-uridine, 2-thiouridine, 4-thio-pseudouridine, 2-thio-pseudouridine, 5-hydroxyuridine, 3-methyluridine, 5-carboxymethyl-uridine, 1-carboxymethyl-pseudouridine, 5-propynyl-uridine, 1-propynyl-pseudouridine, 5-taurine methyl uridine, 1-taurine methyl-pseudouridine, 5-taurine methyl-2-thio-uridine, 1-taurine methyl uridine, 2-thio-4-thio-uridine, 5-methyl-uridine, 1-methyl 1-pseudouridine, 4-thio-1-methyl 1-pseudouridine, 2-thio-1-methyl 1-pseudouridine, 1-methyl 1-1-deaza-pseudouridine, 2-thio-1-methyl-1-deaza-pseudouridine, dihydrouridine, dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-dihydropseudouridine, 2-methoxyuridine, 2-methoxy-4-thio-uridine, 4-methoxy-pseudouridine and 4-methoxy-2-thio-pseudouridine.

[0256] In some embodiments, the modified nucleosides include 5-aza-cytidine, pseudoisocytidine, 3-methyl-cytidine, N4-acetylcytidine, 5-formylcytidine, N4-methylcytidine, 5-hydroxymethylcytidine, 1-methyl-pseudoisocytidine, pyrrolo-cytidine, pyrrolo-pseudoisocytidine, 2-thio-cytidine, 2-thio-5-methyl-cytidine, 4-thio-pseudoisocytidine, 4-thio-1-methyl-pseudo isocytidine, 4-thio-1-methyl-1-deaza-pseudoisocytidine, 1-methyl-1-deaza-pseudoisocytidine, zebulan, 5-aza-zebulan, 5-methyl-zebulan, 5-aza-2-thio-zebulan, 2-thio-zebulan, 2-methoxy-cytidine, 2-methoxy-5-methyl-cytidine, 4-methoxy-pseudoisocytidine and 4-methoxy-1-methyl-pseudoisocytidine.

[0257] In other embodiments, the modified nucleosides include 2-aminopurine, 2,6-diaminopurine, 7-deaza-adenine, 7-deaza-8-aza-adenine, 7-deaza-2-aminopurine, 7-deaza-8-aza-2-aminopurine, 7-deaza-2,6-diaminopurine, 7-deaza-8-aza-2,6-diaminopurine, 1-methyladenosine, N6-methyladenosine, N 6-isopentenyl adenosine, N6-(cis-hydroxyisopentenyl)adenosine, 2-methylthio-N6-(cis-hydroxyisopentenyl)adenosine, N6-glycylcarbamoyladenosine, N6-threonylcarbamoyladenosine, 2-methylthio-N6-threonylcarbamoyladenosine, N6,N6-dimethyladenosine, 7-methyladenine, 2-methylthio-adenine and 2-methoxy-adenine.

[0258] In a specific embodiment, the modified nucleoside is 5'-0-(l-phosphorothioate)-adenosine, 5'-0-(1-phosphorothioate)-cytidine, 5'-0-(1-phosphorothioate)-guanosine, 5'-0-(1-phosphorothioate)-uridine or 5'-0-(1-phosphorothioate)-pseudouridine. The phosphate moiety of α-thio substitution is provided so as to impart stability to the RNA polymer by non-natural phosphorothioate backbone linkage. Phosphorothioate RNA has increased nuclease resistance and therefore has a longer half-life in the cellular environment. It is expected that the nucleic acid connected by phosphorothioate also reduces the innate immune response by the weaker binding / activation of the cell innate immune molecules.

[0259] In certain embodiments, for example, if precise timing of protein production is required, it is desirable to degrade the modified nucleic acid introduced into the cell intracellularly. Accordingly, the present invention provides a modified nucleic acid containing a degradation domain that can be acted upon in a directed manner intracellularly.

[0260] In other embodiments, modified nucleosides include inosine, 1-methyl-inosine, wyosine, wyosine, 7-deaza-guanosine, 7-deaza-8-aza-guanosine, 6-thio-guanosine, 6-thio-7-deaza-guanosine, 6-thio-7-deaza-8-aza-guanosine, 7-methyl-guanosine, 6-thio-7-methyl-guanosine, 7-methylinosine, 6-methoxy-guanosine, 1-methylguanosine, N2-methylguanosine, N2,N2-dimethylguanosine, 8-oxo-guanosine, 7-methyl-8-oxo-guanosine, 1-methyl-6-thio-guanosine, N2-methyl-6-thio-guanosine and N2,N2-dimethyl-6-thio-guanosine.

[0261] Optional components of modified nucleic acids

[0262] In other embodiments, the modified nucleic acid may include other optional components, which may be beneficial in some embodiments. These optional components include, but are not limited to, untranslated regions, kozak sequences, intronic nucleotide sequences, internal ribosome entry sites (IRES), caps, and poly A tails. For example, a 5' untranslated region (UTR) and / or a 3'UTR may be provided, either or both of which may independently contain one or more different nucleoside modifications. In such embodiments, nucleotide modifications may also be present in the translatable region. Nucleic acids containing Kozak sequences are also provided.

[0263] Additionally, nucleic acids are provided that contain one or more intronic nucleotide sequences that can be excised from the nucleic acid.

[0264] Untranslated region (UTR)

[0265] The untranslated region (UTR) of a gene is transcribed but not translated. The 5'UTR begins at the transcription start site and continues to the start codon, but does not include the start codon; while the 3'UTR starts immediately after the stop codon and continues until the transcription termination signal. There is increasing evidence that UTR plays a regulatory role in the stability and translation of nucleic acid molecules. The regulatory features of UTR can be incorporated into the mRNA used in the present invention to increase the stability of the molecule. The specific features can also be incorporated to ensure the controlled downregulation of transcripts in the case where the transcripts are misdirected to undesirable organ sites.

[0266] 5' Cap

[0267] The 5' cap structure of mRNA is involved in nuclear export, thereby increasing mRNA stability, and binds mRNA cap binding protein (CBP), which is responsible for mRNA stability and translation competence in cells through association of CBP with poly(A) binding protein to form mature circular mRNA species. The cap further helps remove 5' proximal introns during mRNA splicing.

[0268] Endogenous mRNA molecules can be 5'-capped, thereby generating a 5'-ppp-5'-triphosphate linkage between the terminal guanosine cap residue and the sense nucleotide transcribed at the 5' end of the mRNA molecule. This 5'-guanylate cap can then be methylated to produce an N7-methyl-guanylate residue. The ribose of the nucleotides transcribed at the terminal and / or pre-terminal end of the mRNA can also be optionally 2'-O-methylated. 5'-decapping can target nucleic acid molecules, such as mRNA molecules, for degradation by hydrolysis and cleavage of the guanylate cap structure.

[0269] IRES sequence

[0270] mRNA containing an internal ribosome entry site (IRES) can also be used to implement the present invention. IRES can be used as a unique ribosome binding site or can be used as one of multiple ribosome binding sites of mRNA. mRNA containing more than one functional ribosome binding site can encode several peptides or polypeptides that are translated independently by ribosomes ("polycistronic mRNA"). When mRNA has an IRES, a second translatable region is further optionally provided. Examples of IRES sequences that can be used according to the present invention include, but are not limited to, those from the following viruses: picornaviruses (e.g., FMDV), insect viruses (CFFV), polioviruses (PV), encephalomyocarditis viruses (ECMV), foot-and-mouth disease virus (FMDV), hepatitis C virus (HCV), classic swine fever virus (CSFV), murine leukemia virus (MLV), simian immunodeficiency virus (S1V) or cricket paralysis virus (CrPV).

[0271] Poly A tail

[0272] During RNA processing, long chains of adenine nucleotides (poly A tails) can be added to polynucleotides such as mRNA molecules to increase stability. Immediately after transcription, the 3' end of the transcript can be cleaved to release the 3' hydroxyl. Poly A polymerase then adds adenine nucleotide chains to RNA. The process (referred to as polyadenylation) adds a poly A tail that can be between 100 and 250 residues in length.

[0273] In general, the length of the poly A tail is greater than 30 nucleotides. In another embodiment, the poly A tail is greater than 35 nucleotides in length (e.g., at least or greater than about 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2,000, 2,500, and 3,000 nucleotides).

[0274] In this context, the poly A tail can be greater than the modified mRNA by 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100% in length. The poly A tail can also be designed as a part of the modified nucleic acid to which it belongs. In this context, the poly A tail can be 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% or 90% or more of the total length of the modified mRNA or the modified mRNA minus the poly A tail.

[0275] Producing mRNA molecules

[0276] Methods for isolating RNA, synthesizing RNA, hybridizing nucleic acids, preparing and screening cDNA libraries, and performing PCR are well known in the art (see, e.g., Gubler and Hoffman, Gene, 25:263-269 (1983); Sambrook et al., Molecular Cloning, A Laboratory Manual (2nd ed. 1989)); as are PCR methods (see, U.S. Pat. Nos. 4,683,195 and 4,683,202; PCR Protocols: A Guide to Methods and Applications (Innis et al., eds., 1990)). Expression libraries are also well known to those skilled in the art. Additional basic texts disclosing the general methods used in the present invention include Kriegler, Gene Transfer and Expression: A Laboratory Manual (1990); and Current Protocols in Molecular Biology (Ausubel et al., eds., 1994). The disclosures of these references are incorporated herein by reference in their entirety for all purposes.

[0277] Encoded polypeptide

[0278] The mRNA component of the nucleic acid-lipid particles described herein can be used to express the target polypeptide. Certain diseases of people are caused by the absence or damage of functional proteins in cell types where proteins are normally present and active. Due to, for example, transcriptional inactivation of the coding gene or mutations in the coding gene that make the protein completely or partially non-functional, the functional protein may be completely or partially missing. Examples of human diseases caused by complete or partial inactivation of proteins include X-linked severe combined immunodeficiency (X-SCID) and adrenoleukodystrophy (X-ALD). X-SCID is caused by one or more mutations in the gene encoding the common γ chain protein, which is a component of several interleukin receptors involved in the development and maturation of B cells and T cells in the immune system. X-ALD is caused by one or more mutations in the peroxisomal membrane transporter gene called ABCD1. Individuals with X-ALD have very high levels of long-chain fatty acids in tissues throughout the body, which lead to a variety of symptoms that may lead to mental disorders or death.

[0279] Gene therapy has been attempted to treat some diseases caused by the lack or impairment of functional proteins in cell types where the proteins are normally present and active. Gene therapy generally involves introducing a vector containing a gene encoding a functional form of the affected protein into a person with the disease, and expressing the functional protein to treat the disease. To date, gene therapy has had limited success. In addition, certain aspects of the use of LNPs to deliver mRNA are described, for example, in International Publication Nos. WO 2018 / 006052 and WO 2015 / 011633.

[0280] Thus, there is a continuing need for improvements to express functional forms of proteins in people suffering from diseases caused by the complete or partial absence of functional proteins, and for improved nucleic acid (e.g., mRNA) delivery by methods and compositions that can, for example, trigger less immune responses to therapy. Certain embodiments of the present invention are useful in this context. Therefore, in certain embodiments, the expression of polypeptides improves one or more symptoms of a disease or illness. Certain compositions and methods of the present invention can be used to treat human diseases caused by a lack or reduced level of functional polypeptides in the human body. In other embodiments, certain compositions and methods of the present invention can be used to express vaccine antigens for the treatment of cancer.

[0281] Self-amplifying RNA

[0282] In certain embodiments, the nucleic acid is one or more self-amplifying RNA molecules. Self-amplifying RNA (sa-RNA) may also be referred to as self-replicating RNA, replication-competent RNA, replicon, or RepRNA. RepRNA (referred to as self-amplifying mRNA), when derived from a positive-strand virus, is produced from a viral genome lacking at least one structural gene; it can be translated and replicated (thus "self-amplified") without producing infectious progeny viruses. In certain embodiments, RepRNA technology can be used to insert a gene cassette encoding a desired target antigen. For example, the alphavirus genome is divided into two open reading frames (ORFs): the first ORF encodes a protein of an RNA-dependent RNA polymerase (replicase), and the second ORF encodes a structural protein. In the sa-RNA vaccine construct, the ORF encoding the viral structural protein can be replaced with any selected antigen, while the viral replicase remains a component of the vaccine and drives the intracellular amplification of the RNA after immunization.

[0283] Other active agents

[0284] In certain embodiments, the activating agent associated with the lipid granules of the present invention may include one or more therapeutic proteins, polypeptides or small organic molecules or compounds. The limiting examples of such therapeutic effective agents or medicines include tumor drugs (for example, chemotherapeutic drugs, hormone therapy agents, immunotherapeutic agents, radiotherapeutic agents, etc.), lipid-lowering agents, antiviral drugs, anti-inflammatory compounds, antidepressants, stimulants, analgesics, antibiotics, birth control agents, antipyretics, vasodilators, anti-angiogenic agents, cell vascular agents (cytovascular agent), signal transduction inhibitors, cardiovascular drugs such as antiarrhythmic agents, hormones, vasoconstrictors and steroids. These activating agents can be used alone in the lipid granules of the present invention or can be used in combination (for example, co-administered) with the lipid granules of the present invention comprising nucleic acids such as interfering RNA or mRNA.

[0285] Non-limiting examples of chemotherapeutic drugs include platinum-based drugs (e.g., oxaliplatin, cisplatin, carboplatin, spiroplatin, iproplatin, satraplatin, etc.), alkylating agents (e.g., cyclophosphamide, ifosfamide, chlorambucil, busulfan, melphalan, nitrogen mustard, uramustine, etc.), mustine), thiotepa, nitrosourea, etc.), antimetabolites (e.g., 5-fluorouracil (5-FU), azathioprine, methotrexate, leucovorin, capecitabine, cytarabine, floxuridine, fludarabine, gemcitabine, pemetrexed, raltitrexed, etc.), plant alkaloids (e.g., vincristine, vinblastine, vinorelbine, vindesine, podophyllotoxin, paclitaxel (taxol), docetaxel, etc.), topoisomerase inhibitors (e.g., irinotecan (CPT-11; irinotecan hydrochloride (Camptosar)), topotecan, amsacrine, etoposide (VP16), etoposide phosphate, teniposide, etc.), antitumor antibiotics (e.g., doxorubicin, adriamycin, daunorubicin, epirubicin, actinomycin, bleomycin, mitomycin, mitoxantrone, plicamycin, etc.), tyrosine kinase inhibitors (e.g., gefitinib, Sunitinib ( SU11248), erlotinib ( OSI-1774), lapatinib (GW572016; GW2016), canertinib (CI 1033), semaxinib (SU5416), vatalanib (PTK787 / ZK222584), sorafenib (BAY 43-9006), imatinib ( STI571), dasatinib (BMS-354825), leflunomide (SU101), vandetanib (Zactima TM; ZD6474) etc.), pharmaceutically acceptable salts thereof, stereoisomers thereof, derivatives thereof, analogs thereof and combinations thereof.

[0286] Examples of conventional hormone therapeutics include, but are not limited to, steroids (eg, dexamethasone), finasteride, aromatase inhibitors, tamoxifen, and goserelin and other gonadotropin-releasing hormone agonists (GnRH).

[0287] Examples of conventional immunotherapeutic agents include, but are not limited to, immunostimulants (e.g., bacillus Calmette-Guérin (BCG), levamisole, interleukin-2, α-interferon, etc.), monoclonal antibodies (e.g., anti-CD20, anti-HER2, anti-CD52, anti-HLA-DR, and anti-VEGF monoclonal monomers), immunotoxins (e.g., anti-CD33 monoclonal antibody-calicheamicin conjugate, anti-CD22 monoclonal antibody-Pseudomonas exotoxin conjugate, etc.), and radioimmunotherapy (e.g., conjugated to 111 In, 90 Y or 131 I and other anti-CD20 monoclonal antibodies).

[0288] Examples of conventional radiotherapeutic agents include, but are not limited to, radionuclides such as 47 Sc, 64 Cu, 67 Cu, 89 Sr. 86 Y. 87 Y. 90 Y. 105 Rh, 111 Ag, 111 In, 117m Sn, 149 Pm, 153 Sm, 166 Ho, 177 Lu, 186 Re, 188 Re, 211 At and 212 Bi, optionally conjugated to an antibody against a tumor antigen.

[0289] Additional oncology drugs that can be used according to the present invention include, but are not limited to, alkeline, allopurinol, hexamethylmelamine, amifostine, anastrozole, araC, arsenic trioxide, bexarotene, biCNU, carmustine, CCNU, celecoxib, cladribine, cyclosporine A, cytarabine, cyclophosphamide, dexrazoxane, DTIC, estramustine, exemestane, FK506, gemtuzumab-ozogamicin, hydrea, hydroxyurea, idarubicin, interferon, letrozole, leustatin, leuprolide, e), alitretinoin, megastrol, L-PAM, mesna, methoxsalen, plicamycin, nitrogen mustard, pamidronate, Pegademase, pentostatin, porfimersodium, prednisone, rituxan, streptozocin, STI-571, taxotere, temozolamide, VM-26, toremifene, tretinoin, ATRA, valrubicin and vinblastine. Other examples of tumor drugs that can be used according to the present invention are ellipticin and ellipticin analogs or derivatives, epothilone, intracellular kinase inhibitors and camptothecin.

[0290] Non-limiting examples of lipid-lowering agents for treating lipid diseases or conditions associated with elevated triglycerides, cholesterol, and / or glucose include statins, fibrates, ezetimibe, thiazolidinediones, niacin, beta-blockers, nitroglycerin, calcium antagonists, fish oils, and mixtures thereof.

[0291] Examples of antiviral drugs include, but are not limited to, abacavir, aciclovir, acyclovir, adefovir, amantadine, amprenavir, arbidol, atazanavir, atripla, cidofovir, combivir, darunavir, delavirdine, didanosine, docosanol, edoxudine, efavirenz, emtricitabine, enfuvir, irtide), entecavir, entry inhibitors, famciclovir, fixed-dose combinations, fomivirsen, fosamprenavir, foscarnet, fosfonet, fusion inhibitors, ganciclovir, ibacitabine, immunovir, idoxuridine, imiquimod, indinavir, inosine, integrase inhibitors, type III interferons (e.g., IFN-λ molecules such as IFN-λ1, IFN-λ2, and IFN-λ3), type II interferons (e.g., IFN-γ), type I interferons (e.g.,IFN-α (e.g., PEGylated IFN-α, IFN-β, IFN-κ, IFN-δ, IFN-ε, IFN-τ, IFN-ω, and IFN-ζ), interferon, lamivudine, lopinavir, loviride, MK-0518, maraviroc, moroxydine, nelfinavir, nevirapine, nexavir, nucleoside analogs , oseltamivir, penciclovir, peramivir, pleconaril, podophyllotoxin, protease inhibitors, reverse transcriptase inhibitors, ribavirin, rimantadine, ritonavir, saquinavir, stavudine, synergistic enhancers, tenofovir, tenofovir disoproxil fumarate disoproxil), tipranavir, trifluridine, trizivir, tromantadine, truvada, valaciclovir, valganciclovir, vicriviroc, adenosine, viramidine, zalcitabine, zanamivir, zidovudine, pharmaceutically acceptable salts thereof, stereoisomers thereof, derivatives thereof, analogs thereof, and mixtures thereof.

[0292] Lipid particles

[0293] Lipid granules of the present invention generally comprise activating agent or therapeutic agent, ionizable lipid of the present invention, noncationic lipid and the lipid of the conjugation that suppresses particle aggregation.In some embodiments, activating agent or therapeutic agent are completely encapsulated in the lipid part of lipid granules, so that the activating agent or therapeutic agent in lipid granules are resistant to the enzymatic degradation such as caused by nuclease or protease in aqueous solution.In other embodiments, lipid granules described herein are substantially nontoxic to mammals such as people.Lipid granules of the present invention generally have the average diameter of about 40nm to about 150nm, about 40nm to about 80nm, about 40nm to about 60nm, about 50nm to about 80nm, about 50nm to about 60nm, about 50nm to about 150nm, about 60nm to about 130nm, about 70nm to about 110nm or about 70 to about 90nm.

[0294] In preferred embodiments, the lipid granules of the present invention are serum-stable nucleic acid-lipid granules (LNPs), which include one or more nucleic acid molecules, such as interfering RNA (e.g., siRNA, aiRNA and / or miRNA) or mRNA; ionizable lipids of the present invention (e.g., cationic lipids of Formula I); non-cationic lipids (e.g., cholesterol alone or a mixture of one or more phospholipids and cholesterol); and conjugated lipids (e.g., one or more PEG-lipid conjugates) that inhibit particle aggregation. LNPs may include at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more unmodified and / or modified nucleic acid molecules. Nucleic acid-lipid particles and methods for their preparation are described, for example, in U.S. Patent Nos. 5,753,613; 5,785,992; 5,705,385; 5,976,567; 5,981,501; 6,110,745 and 6,320,017 and PCT Publication No. WO 96 / 40964, the disclosures of which are each incorporated herein by reference in their entirety for all purposes.

[0295] Ionizable lipids

[0296] In one embodiment, the present invention provides an ionizable lipid, the ionizable lipid consisting of: Formula -NR 2 R 3 An ionizable group, where R 2 It is C 1 -C 4 Alkyl, and R 3 It is C 1 -C 4 alkyl; 15-40 carbon atoms; 30-80 hydrogen atoms; 0-10 oxygen atoms; 0-10 nitrogen atoms; 0-4 fluorine; and 0-5 sulfur atoms, wherein the ionizable lipid has a clearance rate such that <10% of the parent ionizable lipid remains within seven (7) days after administration (e.g., in an assay described in Example 32 herein).

[0297] In one embodiment, the ionizable lipid comprises at least one group of formula -C(=O)-O-.

[0298] In one embodiment, the ionizable lipid comprises at least two groups of formula -C(=O)-O-.

[0299] In one embodiment, the ionizable lipid comprises at least one 4 )(R 5 )-, wherein R 4 It is C 2 -C 30 A hydrocarbon group; and R5 It is C 2 -C 30 Hydrocarbon.

[0300] In one embodiment, the ionizable lipid comprises at least one 4 )-, wherein R 4 It is C 2 -C 30 A hydrocarbon group; and R 5 It is C 2 -C 30 Hydrocarbon.

[0301] In one embodiment, the ionizable lipid comprises at least one 4 )(R 5 )-, wherein R 4 It is C 2 -C 30 A hydrocarbon group; and R 5 It is C 2 -C 30 Hydrocarbon.

[0302] In one embodiment, the ionizable lipid comprises at least one of the formula -CHF-C(=O)-O- or -CF 2 -C(=O)-O- group.

[0303] In one embodiment, X is -CH 2 -.

[0304] In one embodiment, X is -C(=O)-.

[0305] In one embodiment, X is -O-.

[0306] In one embodiment, R 2 It's methyl.

[0307] In one embodiment, R 2 It is ethyl.

[0308] In one embodiment, R 2 It is propyl.

[0309] In one embodiment, R 3 It's methyl.

[0310] In one embodiment, R 3 It is ethyl.

[0311] In one embodiment, R 3 It is propyl.

[0312] In one embodiment, m is 1.

[0313] In one embodiment, m is 2.

[0314] In one embodiment, m is 3.

[0315] In one embodiment, the group:

[0316]

[0317] Selected from the group consisting of: (CH 3 ) 2 NCH 2 CH 2 C(=O)-, (CH 3 ) 2 NCH 2 CH 2 CH 2 C(=O)-, (CH 3 ) 2 NCH 2 CH 2 CH 2 CH 2 C(=O)-, (CH 3 ) 2 NCH 2 CH 2 -、(CH 3 ) 2 NCH 2 CH 2 CH-, 5-pyrrolidin-1-ylpentanoyl and (CH 3 ) 2 NCH 2 CH 2 CH 2 O-.

[0318] In one embodiment, the group:

[0319]

[0320] Selected from the group consisting of: (CH 3 ) 2 NCH 2 CH 2 C(=O)-, (CH 3 ) 2 NCH 2 CH 2 CH 2 C(=O)-, (CH 3 ) 2 NCH 2 CH 2 CH2 CH 2 C(=O)-, (CH 3 ) 2 NCH 2 CH 2 -、(CH 3 ) 2 NCH 2 CH 2 CH- and (CH 3 ) 2 NCH 2 CH 2 CH 2 O-.

[0321] In one embodiment, R 1 It is C 5 -C 25 Hydrocarbon.

[0322] In one embodiment, R 1 It is C 2 -C 25 alkyl.

[0323] In one embodiment, R 1 It is C 5 -C 25 alkyl.

[0324] In one embodiment, R 1 It is C 5 -C 25 Alkenyl.

[0325] In one embodiment, R 1 It is 1-nonyl or 1-decyl.

[0326] In one embodiment, o is 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15.

[0327] In one embodiment, o is 10, 11, 12, 13, 14 or 15.

[0328] In one embodiment, o is 2, 3, 4, 5, 6, 7, 8, 9 or 10.

[0329] In one embodiment, o is 2, 3, 4 or 5.

[0330] In one embodiment, L 2 is -(C=O)-O-, -(C=O)N(H)N(R 4 )-、-(C=O)N(H)-N=C(R 4 )-、-(C=O)N(H)N(H)C(R4 )(R 5 )- or -(C=O)-O-CH 2 -R z .

[0331] In one embodiment, L 2 It is -(C=O)-O-.

[0332] In one embodiment, L 2 is -(C=O)N(H)N(R 4 )-. In one embodiment, L 2 is -(C=O)-O-CH 2 -R z In one embodiment, a is H.

[0333] In one embodiment, a is F.

[0334] In one embodiment, b is H.

[0335] In one embodiment, b is F.

[0336] In one embodiment, R 6 It is C 2 -C 25 Hydrocarbon.

[0337] In one embodiment, R 6 It is C 5 -C 25 Hydrocarbon.

[0338] In one embodiment, R 6 It is C 2 -C 25 alkyl.

[0339] In one embodiment, R 6 It is C 5 -C 25 alkyl.

[0340] In one embodiment, R 6 It is C 5 -C 25 Alkenyl.

[0341] In one embodiment, the group:

[0342]

[0343] Selected from the group consisting of:

[0344]

[0345]

[0346]

[0347]

[0348] In one embodiment, the group:

[0349]

[0350] Selected from the group consisting of:

[0351]

[0352] In one embodiment, Y is -CH 2 -.

[0353] In one embodiment, Y is -C(=O)-.

[0354] In one embodiment, Y is -O-.

[0355] In one embodiment, n is 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15.

[0356] In one embodiment, n is 10, 11, 12, 13, 14 or 15.

[0357] In one embodiment, n is 2, 3, 4, 5, 6, 7, 8, 9 or 10.

[0358] In one embodiment, n is 2, 3, 4 or 5.

[0359] In one embodiment, L 1 does not exist; and L 2 is -(C=O)-O-, -(C=O)N(H)N(R 4 )-、-(C=O)N(H)-N=C(R 4 )-、-(C=O)N(H)N(H)C(R 4 )(R 5 )- or -(C=O)-O-CH 2 -R z .

[0360] In one embodiment, L 1 is -(C=O)-O-, -(C=O)N(H)N(R 4 )-、-(C=O)N(H)-N=C(R 4 )-、-(C=O)N(H)N(H)C(R 4 )(R5 )- or -(C=O)-O-CH 2 -R a ; and L 2 Does not exist.

[0361] In one embodiment, L 1 is -(C=O)-O-, -(C=O)N(H)N(R 4 )-、-(C=O)N(H)-N=C(R 4 )-、-(C=O)N(H)N(H)C(R 4 )(R 5 )- or -(C=O)-O-CH 2 -R a .

[0362] In one embodiment, L 1 It is -(C=O)-O.

[0363] In one embodiment, L 1 is -(C=O)N(H)N(R 4 )-.

[0364] In one embodiment, L 1 is -(C=O)-O-CH 2 -R z .

[0365] In one embodiment, c is H.

[0366] In one embodiment, c is F.

[0367] In one embodiment, d is H.

[0368] In one embodiment, d is F.

[0369] In one embodiment, R 7 It is C 2 -C 25 Hydrocarbon.

[0370] In one embodiment, R 7 It is C 5 -C 25 Hydrocarbon.

[0371] In one embodiment, R 7 It is C 2 -C 25 alkyl.

[0372] In one embodiment, R 7 It is C 5 -C 25 alkyl.

[0373] In one embodiment, R 7 It is C 5 -C 25 Alkenyl.

[0374] In one embodiment, the group:

[0375]

[0376] Selected from the group consisting of:

[0377]

[0378]

[0379] In one embodiment, the group:

[0380]

[0381] Selected from the group consisting of:

[0382]

[0383] In one embodiment, R 4 It is C 2 -C 25 In one embodiment, R 4 It is C 5 -C 25 Hydrocarbon.

[0384] In one embodiment, R 4 It is C 2 -C 25 alkyl.

[0385] In one embodiment, R 4 It is C 5 -C 25 alkyl.

[0386] In one embodiment, R 4 It is C 5 -C 25 Alkenyl.

[0387] In one embodiment, R 5 It is C 2 -C 25 Hydrocarbon.

[0388] In one embodiment, R 5 It is C 5 -C 25 Hydrocarbon.

[0389] In one embodiment, R 5 It is C 2 -C 25 alkyl.

[0390] In one embodiment, R 5 It is C 5 -C 25 alkyl.

[0391] In one embodiment, R 5 It is C 5 -C 25 Alkenyl.

[0392] In one embodiment, R 4’ It is C 2 -C 25 Hydrocarbon.

[0393] In one embodiment, R' 4 It is C 5 -C 25 Hydrocarbon.

[0394] In one embodiment, R 4’ It is C 2 -C 25 alkyl.

[0395] In one embodiment, R 4’ It is C 5 -C 25 alkyl.

[0396] In one embodiment, R 4’ It is C 5 -C 25 Alkenyl.

[0397] In one embodiment, R' 5 It is C 2 -C 25 Hydrocarbon.

[0398] In one embodiment, R' 5’ It is C 5 -C 25 Hydrocarbon.

[0399] In one embodiment, R 5’ It is C 2 -C 25 alkyl.

[0400] In one embodiment, R 5 It is C 5 -C 25 alkyl.

[0401] In one embodiment, R5’ It is C 5 -C 25 Alkenyl.

[0402] In one embodiment, R z is 1 or 2 independently selected from C 2 -C 10 In one embodiment, each C 2 -C 10 The hydrocarbon groups are independently selected from C 5 -C 10 In one embodiment, each C 2 -C 10 The hydrocarbon groups are independently selected from C 2 -C 10 In one embodiment, each C 2 -C 10 The hydrocarbon groups are independently selected from C 5 -C 10 In one embodiment, each C 2 -C 10 The hydrocarbon groups are independently selected from C 5 -C 10 A group consisting of alkenyl groups.

[0403] In one embodiment, R z’ is 1 or 2 independently selected from C 2 -C 10 In one embodiment, each C 2 -C 10 The hydrocarbon groups are independently selected from C 5 -C 10 In one embodiment, each C 2 -C 10 The hydrocarbon groups are independently selected from C 2 -C 10 In one embodiment, each C 2 -C 10 The hydrocarbon groups are independently selected from C 5 -C 10 In one embodiment, each C 2 -C 10 The hydrocarbon groups are independently selected from C 5 -C 10 A group consisting of alkenyl groups.

[0404] In one embodiment, the ionizable lipid is selected from the compounds of Examples 1, 16, 17, 43, 46, 90, 101 and 115 and salts thereof.

[0405] In one embodiment, X is -C(=O)-, and Y is absent or is -O-.

[0406] In one embodiment, X is -C(=O)-, and Y is -O-.

[0407] In one embodiment, Y is -CH 2 -;L 1 is not present; and c and d are each H.

[0408] In one embodiment, a is F, or b is H.

[0409] In one embodiment, a is F and b is F.

[0410] In one embodiment, a is F; b is H; and L 1 It is -(C=O)-O-.

[0411] In one embodiment, a is F; b is F; and L 1 It is -(C=O)-O-.

[0412] In one embodiment, R 2 and R 3 Each is a methyl group.

[0413] In one embodiment, L 1 is not present; and c and d are each H.

[0414] In one embodiment, L 1 is not present; and a, b, c and d are each H.

[0415] In one embodiment, L 1 and L 2 One of them is -(C=O)-O-.

[0416] In one embodiment, L 1 is -(C=O)-O-, and R 7 It is a branched chain C 2 -C 25 Hydrocarbon.

[0417] In one embodiment, L 1 is -(C=O)-O-, and R 7 Is with L 1 The branched C is within 3 carbons of the attachment point 5 -C 25 Hydrocarbon.

[0418] In one embodiment, L 1is -(C=O)-O-, and R 7 Is with L 1 The branched C is within 2 carbons of the attachment point 4 -C 25 Hydrocarbon.

[0419] In one embodiment, L 1 is -(C=O)-O-, and R 7 Is with L 1 The branched C 3 -C 25 Hydrocarbon.

[0420] In one embodiment, L 1 and L 2 One of them is -(C=O)-O-, and R 7 It is a branched chain C 2 -C 25 Hydrocarbon.

[0421] In one embodiment, L 1 and L 2 One of them is -(C=O)-O-, and R 7 is a C branched at a carbon within 3 carbons of the point of attachment to L1 5 -C 25 Hydrocarbon.

[0422] In one embodiment, L 1 and L 2 One of them is -(C=O)-O-, and R 7 is a C branched at a carbon within 2 carbons of the point of attachment to L1 4 -C 25 Hydrocarbon.

[0423] In one embodiment, L 1 and L 2 One of them is -(C=O)-O-, and R 7 is a C branched at the carbon attached to L1 3 -C 25 Hydrocarbon.

[0424] In one embodiment, Y is absent or -O-; N is O; c is H; d is H; L 1 does not exist; and R 7 It is C 2 -C 25 Hydrocarbon.

[0425] In one embodiment, Y is absent or -O-; N is O; c is H; d is H; L 1 does not exist; and R7 It is C 5 -C 15 Hydrocarbon.

[0426] In one embodiment, Y is absent or -O-; N is O; c is H; d is H; L 1 does not exist; and R 7 It is C 10 Hydrocarbon.

[0427] In one embodiment, Y is absent or -O-; N is O; c is H; d is H; L 1 does not exist; and R 7 is a C branched at a carbon within 3 carbons of the point of attachment to the rest of the compound of formula (I) 5 -C 15 Hydrocarbon.

[0428] In one embodiment, Y is absent or -O-; N is O; c is H; d is H; L 1 does not exist; and R 7 is a C branched at a carbon within 2 carbons of the point of attachment to the rest of the compound of formula (I) 5 -C 15 Hydrocarbon.

[0429] In one embodiment, Y is absent or -O-; N is O; c is H; d is H; L 1 does not exist; and R 7 is a C branched at the carbon to which the rest of the compound of formula (I) is attached 5 -C 15 Hydrocarbon.

[0430] In one embodiment, Y is absent or -O-; N is O; c is H; d is H; L 1 does not exist; and R 7 is a C branched at a carbon within 3 carbons of the point of attachment to the rest of the compound of formula (I) 10 Hydrocarbon.

[0431] In one embodiment, Y is absent or -O-; N is O; c is H; d is H; L 1 does not exist; and R 7 is a C branched at a carbon within 2 carbons of the point of attachment to the rest of the compound of formula (I) 10 Hydrocarbon.

[0432] In one embodiment, Y is absent or -O-; N is O; c is H; d is H; L 1 does not exist; and R 7 is a C branched at the carbon to which the rest of the compound of formula (I) is attached10 Hydrocarbon.

[0433] In one embodiment, L 2 is -(C=O)-O-, and R 6 It is a branched chain C 2 -C 25 Hydrocarbon.

[0434] In one embodiment, L 2 is -(C=O)-O-, and R 6 Is with L 2 The branched C is within 3 carbons of the attachment point 5 -C 25 Hydrocarbon.

[0435] In one embodiment, L 2 is -(C=O)-O-, and R 6 Is with L 2 The branched C is within 2 carbons of the attachment point 4 -C 25 Hydrocarbon.

[0436] In one embodiment, L 2 is -(C=O)-O-, and R 6 Is with L 2 The branched C 3 -C 25 Hydrocarbon.

[0437] In one embodiment, L 2 is -(C=O)-O-; a is F; b is H; and R 6 It is a branched chain C 2 -C 25 Hydrocarbon.

[0438] In one embodiment, L 2 is -(C=O)-O-; a is F; b is H; and R 6 Is with L 2 The branched C is within 3 carbons of the attachment point 5 -C 25 Hydrocarbon.

[0439] In one embodiment, L 2 one of which is -(C=O)-O-; a is F; b is H; and R 6 Is with L 2 The branched C is within 2 carbons of the attachment point 4 -C 25 Hydrocarbon.

[0440] In one embodiment, L2 is -(C=O)-O-; a is F; b is H; and R 6 Is with L 2 The branched C 3 -C 25 Hydrocarbon.

[0441] In one embodiment, L 2 is -(C=O)-O-; a is F; b is F; and R 6 It is a branched chain C 2 -C 25 Hydrocarbon.

[0442] In one embodiment, L 2 is -(C=O)-O-; a is F; b is F; and R 6 Is with L 2 The branched C is within 3 carbons of the attachment point 5 -C 25 Hydrocarbon.

[0443] In one embodiment, L 2 is -(C=O)-O-; a is F; b is F; and R 6 Is with L 2 The branched C is within 2 carbons of the attachment point 4 -C 25 Hydrocarbon.

[0444] In one embodiment, L 2 is -(C=O)-O-; a is F; b is F; and R 6 Is with L 2 The branched C 3 -C 25 Hydrocarbon.

[0445] In one embodiment, the present invention provides a compound of formula (I):

[0446]

[0447] or a salt thereof, wherein:

[0448] X is -CH 2 -, -O-, -O(C=O)- or -C(=O)-

[0449] Y is -CH 2 -、-O-、-SO 2 - or -C(=O)-;

[0450] R 1 It is C 2 -C 25 Hydrocarbon;

[0451] R 2 It is C 1 -C 3 alkyl; and R 3 It is C 1 -C 3 Alkyl; or R 2 and R 3 Together with the nitrogen to which they are attached they form an aziridino, azetidinino or pyrrolidino ring;

[0452] m is 0, 1, 2, 3, 4, 5, or 6;

[0453] n is 0-15;

[0454] o is 0-15;

[0455] L 1 does not exist, is -(C=O)-O-, -(C=O)N(H)N(R 4 )-、-(C=O)N(H)-N=C(R 4 )-、-(C=O)N(H)N(H)C(R 4 )(R 5 )-、-(C=O)-O-CH 2 -R z or -O(C=O)-R w -;

[0456] L 2 does not exist, is -(C=O)-O-, -(C=O)N(H)N(R 4’ )-、-(C=O)N(H)-N=C(R 4’ )-、-(C=O)N(H)N(H)C(R 4’ )(R 5’ )-、-(C=O)-O-CH 2 -R z’ or -O(C=O)-R x -

[0457] a is H or F;

[0458] b is H or F;

[0459] c is H or F; and d is H or F; or c and d together with the carbon to which they are attached form -C(=O)-;

[0460] R 4 Is H or C 2 -C 25 Hydrocarbon;

[0461] R 5 Is H or C2 -C 25 Hydrocarbon;

[0462] R 4’ Is H or C 2 -C 25 Hydrocarbon;

[0463] R 5’ Is H or C 2 -C 25 Hydrocarbon;

[0464] R 6 It is C 2 -C 25 Hydrocarbon;

[0465] R 7 It is C 2 -C 25 Hydrocarbon;

[0466] R w Does not exist, is -C(F)H- or -C(F) 2 -;

[0467] R x Does not exist, is -C(F)H- or -C(F) 2 -;

[0468] R z is 1, 2 or 3 independently selected from C 2 -C 10 a phenyl group substituted with a hydrocarbyl group; and

[0469] R z’ is 1, 2 or 3 independently selected from C 2 -C 10 A phenyl group substituted with a hydrocarbyl group.

[0470] In one embodiment, the present invention provides a compound of formula (I):

[0471]

[0472] or a salt thereof, wherein:

[0473] X is -CH 2 -, -O-, -O(C=O)- or -C(=O)-

[0474] Y is -CH 2 -、-O-、-SO 2 - or -C(=O)-;

[0475] R 1 It is C 2 -C 25 Hydrocarbon;

[0476] R 2 It is C 1 -C 3 alkyl; and R 3 It is C 1 -C 3 Alkyl; or R 2 and R 3 Together with the nitrogen to which they are attached they form an aziridino, azetidinino or pyrrolidino ring;

[0477] m is 0, 1, 2, 3, 4, 5, or 6;

[0478] n is 0-15;

[0479] o is 0-15;

[0480] L 1 Absent or -(C=O)-O-;

[0481] L 2 Absent or -(C=O)-O-;

[0482] a is H or F;

[0483] b is H or F;

[0484] c is H or F; and d is H or F; or c and d together with the carbon to which they are attached form -C(=O)-;

[0485] R 4 Is H or C 2 -C 25 Hydrocarbon;

[0486] R 5 Is H or C 2 -C 25 Hydrocarbon;

[0487] R 4’ Is H or C 2 -C 25 Hydrocarbon;

[0488] R 5’ Is H or C 2 -C 25 Hydrocarbon;

[0489] R 6 It is C 2 -C 25 Hydrocarbon;

[0490] R 7 It is C 2 -C 25 Hydrocarbon;

[0491] R w Does not exist, is -C(F)H- or -C(F) 2 -;

[0492] R x Does not exist, is -C(F)H- or -C(F) 2 -;

[0493] R z is 1, 2 or 3 independently selected from C 2 -C 10 a phenyl group substituted with a hydrocarbyl group; and

[0494] R z’ is 1, 2 or 3 independently selected from C 2 -C 10 A phenyl group substituted with a hydrocarbyl group.

[0495] Specific implementation plan

[0496] In a specific embodiment, the present invention provides an ionizable lipid of formula (I), wherein X is -C(=O)-. Such ionizable lipids generally exhibit high activity.

[0497] In a specific embodiment, the present invention provides an ionizable lipid of formula (I), wherein X is -C(=O)-, and Y is -O-. Such ionizable lipids generally exhibit high activity and have desirable pKa properties.

[0498] In one embodiment, the present invention provides an ionizable lipid of formula (I), wherein Y is -CH 2 -;L 1 and c and d are each H. Such ionizable lipids generally exhibit high activity.

[0499] In one embodiment, the present invention provides an ionizable lipid of formula (I), wherein R 2 is a methyl group, and R 3 This type of ionizable lipids usually exhibits high activity.

[0500] In one embodiment, the present invention provides an ionizable lipid of formula (I), wherein L 1 and c and d are each H. Such ionizable lipids generally exhibit high activity.

[0501] In one embodiment, the present invention provides an ionizable lipid of formula (I), wherein L 2 is -(C=O)-O-, and R 6 Is with L 2Branching at the carbon atom connected or at a distance from L 2 The branching point is at the carbon atom of the two carbons or at a distance from L 2 The connection point is the branched C at the carbon atom of the 3 carbon 2 -C 25 Hydrocarbon groups. These ionizable lipids generally exhibit high activity.

[0502] When the hydrocarbon group is in 1 or L 2 Branching at the carbon atom connected to L 1 or L 2 The branching point is at a carbon atom 2 carbons away from the L 1 or L 2 When the hydrocarbon group is branched at a carbon atom with 3 carbon atoms as the point of attachment, it is understood that the hydrocarbon group is branched at one of the carbons shown in the following formula:

[0503]

[0504] In one embodiment, the present invention provides a nucleic acid-lipid particle, the nucleic acid-lipid particle comprising:

[0505] (a) one or more nucleic acid molecules;

[0506] (b) non-cationic lipids;

[0507] (c) conjugating lipids; and

[0508] (d) The compound of formula (I) or a salt thereof, wherein the one or more nucleic acid molecules are encapsulated within the lipid particle.

[0509] In one embodiment, the compound or salt comprises from about 30 mol % to about 85 mol % of the total lipids present in the particle; the non-cationic lipid comprises from about 13 mol % to about 49.5 mol % of the total lipids present in the particle; and the conjugated lipid comprises from about 0.1 mol % to about 10 mol % of the total lipids present in the particle.

[0510] In one embodiment, the compound or salt comprises from about 30 mol % to about 85 mol % of the total lipids present in the particle; the non-cationic lipid comprises from about 13 mol % to about 49.5 mol % of the total lipids present in the particle; and the conjugated lipid comprises from about 0.1 mol % to about 10 mol % of the total lipids present in the particle.

[0511] In one embodiment, the nucleic acid is selected from the group consisting of small interfering RNA (siRNA), Dicer-substrate dsRNA, small hairpin RNA (shRNA), asymmetric interfering RNA (aiRNA), micro RNA (miRNA), mRNA, tRNA, rRNA, viral RNA (vRNA), self-amplifying RNA, and combinations thereof.

[0512] In one embodiment, the nucleic acid is an mRNA molecule.

[0513] In one embodiment, the nucleic acid comprises a double-stranded siRNA molecule.

[0514] In one embodiment, the double-stranded siRNA molecule comprises at least one modified nucleotide.

[0515] In one embodiment, the siRNA comprises at least one 2'-O-methyl (2'OMe) nucleotide.

[0516] In one embodiment, the non-cationic lipid comprises cholesterol or a derivative thereof.

[0517] In one embodiment, cholesterol or a derivative thereof comprises from about 31.5 mol % to about 42.5 mol % of the total lipid present in the particle.

[0518] In one embodiment, the non-cationic lipid comprises a phospholipid.

[0519] In one embodiment, the non-cationic lipid comprises a mixture of phospholipids and cholesterol or a derivative thereof.

[0520] In one embodiment, the phospholipid comprises dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), or a mixture thereof.

[0521] In one embodiment, the phospholipids comprise from about 4 mol% to about 10 mol% of the total lipids present in the particle, and cholesterol comprises from about 30 mol% to about 40 mol% of the total lipids present in the particle.

[0522] In one embodiment, the phospholipids comprise about 10 mol% to about 30 mol% of the total lipids present in the particle, and cholesterol comprises about 10 mol% to about 30 mol% of the total lipids present in the particle.

[0523] In one embodiment, the conjugated lipid comprises a polyethylene glycol (PEG)-lipid conjugate.

[0524] In one embodiment, the PEG-lipid conjugate comprises a compound of formula (I):

[0525]

[0526] or a salt thereof, wherein:

[0527] R 1 is H, (C 1 -C 6 ) alkyl or (C 1 -C 6 )alkanoyl;

[0528] n is an integer in the range of about 10 to about 150; and

[0529] L is absent and X is -C(=O)NR 2 R 3 ;or

[0530] L is (C 1 -C 6 )alkyl, and X is selected from the group consisting of: -N(R 4 )C(=O)CH(R 2 )(R 3 )、-OCH(R 2 )(R 3 )、-C(=O)OCH 2 CH(R 2 )(R 3 )、-N(R 4 )C(=O)N(R 2 )(R 3 ) and -SO 2 N(R 2 )(R 3 );

[0531] R 2 Yes (C 10 -C 20 )alkyl;

[0532] R 3 Yes (C 10 -C 20 )alkyl; and

[0533] R 4 is H or (C 1 -C 6 )alkyl.

[0534] In one embodiment, the PEG-lipid conjugate comprises a compound selected from the group consisting of:

[0535]

[0536]

[0537] or a salt thereof.

[0538] In one embodiment, the PEG-lipid conjugate comprises a compound of the formula:

[0539]

[0540] Where n is 45-50.

[0541] In one embodiment, the PEG-lipid conjugate comprises a PEG-diacylglycerol (PEG-DAG) conjugate, a PEG-dialkyloxypropyl (PEG-DAA) conjugate, or a mixture thereof.

[0542] In one embodiment, the PEG-DAA conjugate comprises a PEG-dimyristyloxypropyl (PEG-DMA) conjugate, a PEG-distearyloxypropyl (PEG-DSA) conjugate, or a mixture thereof.

[0543] In one embodiment, the PEG-DAA conjugate comprises a PEG-dimyristyloxypropyl (PEG-DMA) conjugate.

[0544] In one embodiment, the polyethylene glycol (PEG)-lipid conjugate is a compound of the formula:

[0545] ABC

[0546] or a salt thereof, wherein:

[0547] A is (C 1 -C 6 ) alkyl, (C 3 -C 8 )cycloalkyl, (C 3 -C 8 )cycloalkyl(C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, (C 1 -C 6 )alkanoyl, (C 1 -C 6 ) alkoxycarbonyl, (C 1 -C 6 )alkylthio or (C 2 -C 6 )alkanoyloxy, wherein any (C 1 -C 6 ) alkyl, (C 3 -C 8 )cycloalkyl, (C3 -C 8 )cycloalkyl(C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, (C 1 -C 6 )alkanoyl, (C 1 -C 6 ) alkoxycarbonyl, (C 1 -C 6 ) alkylthio and (C 2 -C 6 )alkanoyloxy is substituted with one or more anion precursor groups, and any (C 1 -C 6 ) alkyl, (C 3 -C 8 )cycloalkyl, (C 3 -C 8 )cycloalkyl(C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, (C 1 -C 6 )alkanoyl, (C 1 -C 6 ) alkoxycarbonyl, (C 1 -C 6 ) alkylthio and (C 2 -C 6 )alkanoyloxy is optionally substituted by one or more groups independently selected from the group consisting of halo, hydroxy, (C 1 -C 3 ) alkoxy, (C 1 -C 6 )alkanoyl, (C 1 -C 3 ) alkoxycarbonyl, (C 1 -C 3 )alkylthio or (C 2 -C 3 )alkanoyloxy;

[0548] B is a polyethylene glycol chain having a molecular weight of about 550 Daltons to about 10,000 Daltons;

[0549] C is -LR a

[0550] L is selected from the group consisting of: direct bond, -C(O)O-, -C(O)NR b -、-NR b -、-C(O)-、-NR b C(O)O-、-NR b C(O)NR b -、-SS-、-O-、-(O)CCH 2 CH 2 C(O)- and -NHC(O)CH 2 CH 2 C(O)NH-;

[0551] R a Is a branched chain (C 10 -C 50 ) alkyl or branched (C 10 -C 50 ) alkenyl, wherein the branched chain (C 10 -C 50 ) alkyl or branched (C 10 -C 50 ) one or more carbon atoms of the alkenyl group have been replaced by -O-; and

[0552] Each R b are independently H or (C 1 -C 6 )alkyl.

[0553] In one embodiment, PEG has an average molecular weight of about 2,000 Daltons.

[0554] In one embodiment, the conjugated lipid comprises about 1 mol % to about 2 mol % of the total lipid present in the particle.

[0555] In one embodiment, after incubation of the nucleic acid-lipid particles in serum at 37°C for 30 minutes, the nucleic acid in the particles is not substantially degraded.

[0556] In one embodiment, the nucleic acid is completely encapsulated within the nucleic acid-lipid particle.

[0557] In one embodiment, the nucleic acid-lipid particle has a lipid:nucleic acid mass ratio of about 5 to about 15.

[0558] In one embodiment, the nucleic acid-lipid particle has a lipid:nucleic acid mass ratio of about 5 to about 30.

[0559] In one embodiment, the nucleic acid-lipid particle has a median diameter of about 40 nm to about 150 nm.

[0560] In one embodiment, the compound or salt comprises about 56.5 mol % to about 66.5 mol % of the total lipid present in the particle; the non-cationic lipid comprises cholesterol or a derivative thereof comprising about 31.5 mol % to about 42.5 mol % of the total lipid present in the particle; and the PEG-lipid conjugate comprises about 1 mol % to about 2 mol % of the total lipid present in the particle.

[0561] In one embodiment, the nucleic acid-lipid particle comprises about 61.5 mol % of the compound or salt, about 36.9 % of cholesterol or a derivative thereof, and about 1.5 mol % of a PEG-lipid conjugate.

[0562] In one embodiment, the compound or salt comprises about 52 mol% to about 62 mol% of the total lipid present in the particle; the non-cationic lipid comprises a mixture of phospholipids and cholesterol or a derivative thereof comprising about 36 mol% to about 47 mol% of the total lipid present in the particle; and the PEG-lipid conjugate comprises about 1 mol% to about 2 mol% of the total lipid present in the particle.

[0563] In one embodiment, the nucleic acid-lipid particle comprises about 57.1 mol % of the compound or salt, about 7.1 mol % of the phospholipid, about 34.3 mol % of cholesterol or a derivative thereof, and about 1.4 mol % of the PEG-lipid conjugate.

[0564] In one embodiment, the nucleic acid-lipid particle comprises about 57.1 mol % of the compound or salt, about 20 mol % of the phospholipid, about 20 mol % of cholesterol or a derivative thereof, and about 1.4 mol % of the PEG-lipid conjugate.

[0565] In one embodiment, the compound or salt constitutes 50 mol% to 65 mol% of the total lipids present in the particle; the non-cationic lipid comprises a mixture of phospholipids and cholesterol or a derivative thereof, wherein the phospholipids constitute 4 mol% to 10 mol% of the total lipids present in the particle, and the cholesterol or a derivative thereof constitutes 30 mol% to 40 mol% of the total lipids present in the particle; and the conjugated lipid constitutes 0.5 mol% to 2 mol% of the total lipids present in the particle.

[0566] In one embodiment, the compound or salt constitutes 50 mol% to 65 mol% of the total lipids present in the particle; the non-cationic lipid comprises a mixture of phospholipids and cholesterol or a derivative thereof, wherein the phospholipids constitute 3 mol% to 15 mol% of the total lipids present in the particle, and the cholesterol or a derivative thereof constitutes 30 mol% to 40 mol% of the total lipids present in the particle; and the conjugated lipid constitutes 0.5 mol% to 2 mol% of the total lipids present in the particle.

[0567] In one embodiment, the compound or salt comprises 50 mol% to 65 mol% of the total lipid present in the particle; the non-cationic lipid comprises up to 49.5 mol% of the total lipid present in the particle; and cholesterol or a derivative thereof comprises 30 mol% to 40 mol% of the total lipid present in the particle;

[0568] And the conjugated lipids account for 0.5 mol% to 2 mol% of the total lipids present in the particles.

[0569] In one embodiment, the compound or salt comprises 50 mol% to 85 mol% of the total lipids present in the particle; the non-cationic lipid comprises 13 mol% to 49.5 mol% of the total lipids present in the particle; and the conjugated lipid comprises 0.5 mol% to 2 mol% of the total lipids present in the particle.

[0570] In one embodiment, the compound or salt comprises about 30 mol % to about 50 mol % of the total lipids present in the particle; the non-cationic lipid comprises a mixture of phospholipids and cholesterol or a derivative thereof comprising about 47 mol % to about 69 mol % of the total lipids present in the particle; and the conjugated lipid comprises about 1 mol % to about 3 mol % of the total lipids present in the particle.

[0571] In one embodiment, the non-cationic lipid comprises a mixture of cholesterol and DSPC; and the conjugated lipid is:

[0572]

[0573] where n is chosen so that the resulting polymer chain has a molecular weight of about 2000 Daltons

[0574] wherein the conjugated lipid accounts for about 2 mol% of the total lipids present in the particle; DSPC accounts for about 10 mol% of the total lipids present in the particle; cholesterol accounts for about 48 mol% of the total lipids present in the particle; and the compound or salt accounts for about 40 mol% of the total lipids present in the particle.

[0575] In one embodiment, the non-cationic lipid comprises a mixture of cholesterol and DSPC; and the conjugated lipid is:

[0576]

[0577] wherein n is selected so that the resulting polymer chain has a molecular weight of about 2000 Daltons;

[0578] wherein the conjugated lipid accounts for about 2 mol% of the total lipids present in the particle; DSPC accounts for about 10 mol% of the total lipids present in the particle; cholesterol accounts for about 48 mol% of the total lipids present in the particle; and the compound or salt accounts for about 40 mol% of the total lipids present in the particle.

[0579] In one embodiment, the non-cationic lipid comprises a mixture of cholesterol and DSPC; and the conjugated lipid is:

[0580]

[0581] wherein n is selected so that the resulting polymer chain has a molecular weight of about 2000;

[0582] wherein the conjugated lipid accounts for about 1.6 mol% of the total lipids present in the particle; DSPC accounts for about 10.9 mol% of the total lipids present in the particle; cholesterol accounts for about 32.8 mol% of the total lipids present in the particle; and the compound or salt accounts for about 54.9 mol% of the total lipids present in the particle.

[0583] In one embodiment, the lipid to nucleic acid ratio is about 24.

[0584] In one embodiment, the nucleic acid-lipid particle comprises two or more different compounds of formula (I) or salts thereof.

[0585] Non-cationic lipids

[0586] The non-cationic lipid used in the lipid particles (eg, LNPs) of the present invention can be any of a variety of neutral uncharged, zwitterionic or anionic lipids that are capable of producing a stable complex.

[0587] Non-limiting examples of non-cationic lipids include phospholipids such as phosphatidylcholine, phosphatidylethanolamine, lysolecithin, lysolecithin, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, sphingomyelin, egg sphingomyelin (ESM), cephalin, cardiolipin, phosphatidic acid, cerebrosides, dicetyl phosphate, distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), dioleoylphosphatidylethanolamine (DOPE), palmitoyloleoyl-phosphatidylcholine (POPC), palmitoyloleoyl-phosphatidylcholine (DPPC), ethanolamine (POPE), palmitoyloleyl-phosphatidylglycerol (POPG), dioleoylphosphatidylethanolamine 4-(N-maleimidomethyl)-cyclohexane-1-carboxylate (DOPE-mal), dipalmitoyl-phosphatidylethanolamine (DPPE), dimyristoyl-phosphatidylethanolamine (DMPE), distearoyl-phosphatidylethanolamine (DSPE), monomethyl-phosphatidylethanolamine, dimethyl-phosphatidylethanolamine, ditrans-oleoyl-phosphatidylethanolamine (DEPE), stearoyloleoyl-phosphatidylethanolamine (SOPE), lysophosphatidylcholine, dilinoleoylphosphatidylcholine and mixtures thereof. Other diacylphosphatidylcholine and diacylphosphatidylethanolamine phospholipids may also be used. The acyl groups in these lipids are preferably derived from C 10 -C 24 The acyl group of a carbon chain fatty acid, for example, lauroyl, myristoyl, palmitoyl, stearoyl or oleoyl.

[0588] Further examples of non-cationic lipids include sterols, such as cholesterol and its derivatives, such as cholesterol, cholestanone, cholestenone, coprostanol, cholesteryl-2'-hydroxyethyl ether, cholesteryl-4'-hydroxybutyl ether, and mixtures thereof.

[0589] In some embodiments, the non-cationic lipid present in lipid granules (e.g., LNP) comprises cholesterol or its derivatives or consists of it, for example, does not contain the lipid granule preparation of phospholipid.In other embodiments, the non-cationic lipid present in lipid granules (e.g., LNP) comprises one or more phospholipids or consists of it, for example, does not contain the lipid granule preparation of cholesterol.In other embodiments, the non-cationic lipid present in lipid granules (e.g., LNP) comprises a mixture of one or more phospholipids and cholesterol or its derivatives or consists of it.

[0590] Other examples of non-cationic lipids suitable for use in the present invention include phosphorus-free lipids such as linolenic acid, acetyl palmitate, glycerol ricinoleate, cetyl stearate, isopropyl myristate, amphoteric acrylic acid polymers, triethanolamine dodecyl sulfate, alkyl-aryl sulfate polyethoxylated fatty acid amides, ceramides, sphingomyelin, and the like.

[0591] In some embodiments, the non-cationic lipid comprises about 13 mol % to about 49.5 mol %, about 20 mol % to about 45 mol %, about 25 mol % to about 45 mol %, about 30 mol % to about 45 mol %, about 35 mol % to about 45 mol %, about 20 mol % to about 40 mol %, about 25 mol % to about 40 mol %, or about 30 mol % to about 40 mol % (or any fraction or range therein) of the total lipid present in the particle.

[0592] In certain embodiments, the cholesterol present in the lipid particles without phospholipids accounts for about 30mol% to about 45mol%, about 30mol% to about 40mol%, about 35mol% to about 45mol% or about 35mol% to about 40mol% of the total lipid present in the particle. As a non-limiting example, the lipid particles without phospholipids can include about 37mol% of the cholesterol of the total lipid present in the particle.

[0593] In certain other embodiments, the cholesterol present in the lipid granules of the mixture containing phospholipid and cholesterol accounts for about 30mol% to about 40mol%, about 30mol% to about 35mol% or about 35mol% to about 40mol% of the total lipid present in the granule. As a non-limiting example, the lipid granules comprising a mixture of phospholipid and cholesterol can include the cholesterol of about 34mol% of the total lipid present in the granule. As other non-limiting examples, the granule can include 33% or 38.5% cholesterol.

[0594] In other embodiments, the cholesterol present in the lipid granules of the mixture containing phospholipid and cholesterol accounts for about 10mol% to about 30mol%, about 15mol% to about 25mol% or about 17mol% to about 23mol% of the total lipid present in the granules. As a non-limiting example, the lipid granules comprising a mixture of phospholipid and cholesterol can comprise the cholesterol of about 20mol% of the total lipid present in the granules.

[0595] In embodiments where the lipid particle contains a mixture of phospholipids and cholesterol or a cholesterol derivative, the mixture may comprise up to about 40 mol%, 45 mol%, 50 mol%, 55 mol% or 60 mol% of the total lipid present in the particle. In certain examples, the phospholipid component in the mixture can account for about 2 mol% to about 20 mol%, about 2 mol% to about 15 mol%, about 2 mol% to about 12 mol%, about 2 mol% to about 10 mol%, about 2 mol% to about 9 mol%, about 2 mol% to about 8 mol%, 4 mol% to about 20 mol%, about 4 mol% to about 15 mol%, about 4 mol% to about 12 mol%, about 4 mol% to about 10 mol%, about 4 mol% to about 9 mol%, about 4 mol% to about 8 mol%, 6 mol% to about 20 mol%, about 6 mol% to about 15 mol%, about 6 mol% to about 12 mol%, about 6 mol% to about 10 mol%, about 6 mol% to about 9 mol%, about 2 mol% to about 8 mol%, 8 mol% to about 20 mol%, about 8 mol% to about 15 mol%, about 8 mol% to about 12 mol%, about 8 mol% to about 10 mol%, about 8 mol% to about 9 mol%, As non-limiting examples, the lipid granules comprising a mixture of phospholipids and cholesterol can comprise the phospholipids such as DPPC or DSPC (for example, in a mixture with about 34mol% cholesterol) of about 7mol% of the TL present in the particle. In some other examples, the phospholipid component in the mixture can account for about 10mol% to about 30mol%, about 10mol% to about 15mol%, about 15mol% to about 20mol%, about 15mol% to about 25mol% or about 17mol% to about 23mol% of the TL present in the particle. As another non-limiting example, the lipid granules comprising a mixture of phospholipids and cholesterol can comprise the phospholipids such as DPPC or DSPC (for example, in a mixture with about 20mol% cholesterol) of about 20mol% of the TL present in the particle.

[0596] Lipid conjugates

[0597] Except cationic lipid and non-cationic lipid, lipid granule of the present invention (for example, LNP) also can comprise lipid conjugate.The lipid of conjugation is useful, because it prevents the gathering of particle.The lipid of conjugation that is applicable includes but not limited to PEG-lipid conjugate, ATTA-lipid conjugate, cationic polymer-lipid conjugate (CPL), POZ poly-oxazoline (POZ)-lipid, polysarcosine (pSAR)-lipid and their mixture.In certain embodiments, particle comprises PEG-lipid conjugate or ATTA-lipid conjugate together with CPL.

[0598] In preferred embodiments, lipid conjugates are PEG-lipids. The example of PEG-lipids includes but is not limited to PEG (PEG-DAA) coupled to dialkyloxypropyl as described in for example PCT Publication No. WO 05 / 026372, PEG (PEG-DAG) coupled to diacylglycerol as described in for example U.S. Patent Publication Nos. 20030077829 and 2005008689, PEG (PEG-PE) coupled to phospholipids such as phosphatidylethanolamine, PEG conjugated to ceramide as described in for example U.S. Patent No. 5,885,613, PEG conjugated to cholesterol or its derivatives and their mixture. The disclosure of these patent documents is incorporated herein by reference in its entirety for all purposes. Other PEG-lipids include but are not limited to PEG-C-DOMG, 2KPEG-DMG and their mixture.

[0599] PEG is a linear, water-soluble polymer of ethylene glycol repeating units. PEG is classified by its molecular weight; for example, PEG 2000 has an average molecular weight of about 2,000 Daltons, and PEG 5000 has an average molecular weight of about 5,000 Daltons. PEG is commercially available from Sigma Chemical Co. and other companies, and includes, for example, the following: monomethoxy polyethylene glycol (MePEG-OH), monomethoxy polyethylene glycol-succinate (MePEG-S), monomethoxy polyethylene glycol-succinimidyl succinate (MePEG-S-NHS), monomethoxy polyethylene glycol-amine (MePEG-NH 2 ), monomethoxy polyethylene glycol-tribenzoate (MePEG-TRES) and monomethoxy polyethylene glycol-imidazolyl-carbonyl (MePEG-IM). Other PEGs such as those described in U.S. Pat. Nos. 6,774,180 and 7,053,150 (e.g., mPEG (20 KDa) amine) are also useful in preparing the PEG-lipid conjugates of the present invention. The disclosures of these patents are incorporated herein by reference in their entirety for all purposes. In addition, monomethoxy polyethylene glycol acetic acid (MePEG-CH 2 COOH) are particularly useful for preparing PEG-lipid conjugates including, for example, PEG-DAA conjugates.

[0600] The PEG portion of the PEG-lipid conjugates described herein may comprise an average molecular weight in the range of about 550 daltons to about 10,000 daltons. In certain instances, the PEG portion has an average molecular weight of about 750 daltons to about 5,000 daltons (e.g., about 1,000 daltons to about 5,000 daltons, about 1,500 daltons to about 3,000 daltons, about 750 daltons to about 3,000 daltons, about 750 daltons to about 2,000 daltons, etc.). In preferred embodiments, the PEG portion has an average molecular weight of about 2,000 daltons or about 750 daltons.

[0601] In some instances, PEG may be optionally substituted with an alkyl, alkoxy, acyl or aryl group. PEG may be directly conjugated to a lipid or may be connected to a lipid via a linker moiety. Any linker moiety suitable for coupling PEG to a lipid may be used, including, for example, a linker moiety containing a non-ester and an ester-containing linker moiety. In a preferred embodiment, the linker moiety is a linker moiety containing a non-ester. As used herein, the term "linker moiety containing a non-ester" refers to a linker moiety that does not contain a carboxylate bond (—OC(O)—). Suitable linker moieties containing non-esters include, but are not limited to, amide (—C(O)NH—), amino (—NR—), carbonyl (—C(O)—), carbamate (—NHC(O)O—), urea (—NHC(O)NH—), disulfide (—S—S—), ether (—O—), succinyl (—(O)CCH 2 CH 2 C(O)—), succinamide (—NHC(O)CH 2 CH 2 C(O)NH—), ethers, disulfides, and combinations thereof (such as linkers containing a carbamate linker moiety and an amide linker moiety). In a preferred embodiment, a carbamate linker is used to couple PEG to a lipid.

[0602] In other embodiments, an ester-containing linker moiety is used to couple PEG to a lipid. Suitable ester-containing linker moieties include, for example, carbonate (—OC(O)O—), succinyl, phosphate (—O—(O)POH—O—), sulfonate, and combinations thereof.

[0603] Additional PEG-lipid conjugates suitable for use in the present invention include, but are not limited to, compounds of the formula:

[0604] ABC

[0605] or a salt thereof, wherein:

[0606] A is (C 1 -C 6 ) alkyl, (C 3 -C 8)cycloalkyl, (C 3 -C 8 )cycloalkyl(C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, (C 1 -C 6 )alkanoyl, (C 1 -C 6 ) alkoxycarbonyl, (C 1 -C 6 )alkylthio or (C 2 -C 6 )alkanoyloxy, wherein any (C 1 -C 6 ) alkyl, (C 3 -C 8 )cycloalkyl, (C 3 -C 8 )cycloalkyl(C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, (C 1 -C 6 )alkanoyl, (C 1 -C 6 ) alkoxycarbonyl, (C 1 -C 6 ) alkylthio and (C 2 -C 6 )alkanoyloxy is substituted with one or more anion precursor groups, and any (C 1 -C 6 ) alkyl, (C 3 -C 8 )cycloalkyl, (C 3 -C 8 )cycloalkyl(C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, (C 1 -C 6)alkanoyl, (C 1 -C 6 ) alkoxycarbonyl, (C 1 -C 6 ) alkylthio and (C 2 -C 6 )alkanoyloxy is optionally substituted by one or more groups independently selected from the group consisting of halo, hydroxy, (C 1 -C 3 ) alkoxy, (C 1 -C 6 )alkanoyl, (C 1 -C 3 ) alkoxycarbonyl, (C 1 -C 3 )alkylthio or (C 2 -C 3 )alkanoyloxy;

[0607] B is a polyethylene glycol chain having a molecular weight of about 550 Daltons to about 10,000 Daltons;

[0608] C is -LR a ;

[0609] L is selected from the group consisting of: direct bond, -C(O)O-, -C(O)NR b -、-NR b -、-C(O)-、-NR b C(O)O-、-NR b C(O)NR b -、-SS-、-O-、-(O)CCH 2 CH 2 C(O)- and -NHC(O)CH 2 CH 2 C(O)NH-;

[0610] R a Is a branched chain (C 10 -C 50 ) alkyl or branched (C 10 -C 50 ) alkenyl, wherein the branched chain (C 10 -C 50 ) alkyl or branched (C 10 -C 50 ) one or more carbon atoms of the alkenyl group have been replaced by -O-; and

[0611] Each R b are independently H or (C 1 -C 6 )alkyl.

[0612] The conjugated lipid may comprise a PEG-lipid, including, for example, a PEG-diacylglycerol (DAG), an A-PEG dialkyloxypropyl (DAA), an A-PEG-phospholipid, an A-PEG-ceramide (Cer), or a mixture thereof, wherein A is (C 1 -C 6 ) alkyl, (C 3 -C 8 )cycloalkyl, (C 3 -C 8 )cycloalkyl(C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, (C 1 -C 6 )alkanoyl, (C 1 -C 6 ) alkoxycarbonyl, (C 1 -C 6 )alkylthio or (C 2 -C 6 )alkanoyloxy, wherein any (C 1 -C 6 ) alkyl, (C 3 -C 8 )cycloalkyl, (C 3 -C 8 )cycloalkyl(C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, (C 1 -C 6 )alkanoyl, (C 1 -C 6 ) alkoxycarbonyl, (C 1 -C 6 ) alkylthio and (C 2 -C 6 )alkanoyloxy is substituted with one or more anion precursor groups, and any (C 1 -C 6 ) alkyl, (C 3 -C 8 )cycloalkyl, (C 3 -C 8 )cycloalkyl(C 1-C 6 ) alkyl, (C 1 -C 6 ) alkoxy, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, (C 1 -C 6 )alkanoyl, (C 1 -C 6 ) alkoxycarbonyl, (C 1 -C 6 ) alkylthio and (C 2 -C 6 )alkanoyloxy is optionally substituted by one or more groups independently selected from the group consisting of halo, hydroxy, (C 1 -C 3 ) alkoxy, (C 1 -C 6 )alkanoyl, (C 1 -C 3 ) alkoxycarbonyl, (C 1 -C 3 )alkylthio or (C 2 -C 3 The A-PEG-DAA conjugate can be A-PEG-dilauryloxypropyl (C12), A-PEG-dimyristyloxypropyl (C14), A-PEG-dipalmityloxypropyl (C16) or A-PEG-distearyloxypropyl (C18) or a mixture thereof.

[0613] Phosphatidylethanolamines with various acyl chain groups of varying chain lengths and degrees of saturation can be conjugated to PEG to form lipid conjugates. Such phosphatidylethanolamines are commercially available or can be isolated or synthesized using conventional techniques known to those skilled in the art. Preferred are phosphatidylethanolamines containing saturated or unsaturated fatty acids with carbon chain lengths between C 10 To C 20 Phosphatidylethanolamines within the range of phosphatidylethanolamines. Phosphatidylethanolamines with a mixture of monounsaturated fatty acids or diunsaturated fatty acids and saturated and unsaturated fatty acids can also be used. Suitable phosphatidylethanolamines include, but are not limited to, dimyristoyl-phosphatidylethanolamine (DMPE), dipalmitoyl-phosphatidylethanolamine (DPPE), dioleoyl-phosphatidylethanolamine (DOPE) and distearoyl-phosphatidylethanolamine (DSPE).

[0614] The term "ATTR" or "polyamide" refers to, but is not limited to, compounds described in U.S. Pat. Nos. 6,320,017 and 6,586,559, the disclosures of which are incorporated herein by reference in their entirety for all purposes. These compounds include compounds having the formula:

[0615]

[0616] wherein R is a member selected from the group consisting of hydrogen, alkyl and acyl; R 1 is a member selected from the group consisting of hydrogen and alkyl; or optionally, R and R 1 and the nitrogen to which they are bound form an azido moiety; R 2 is a member selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted aryl, and the side chain of an amino acid; R 3 is selected from hydrogen, halogen, hydroxyl, alkoxy, thiol, hydrazine, amino and NR 4 R 5 The members of the group, where R 4 and R 5 is independently hydrogen or alkyl; n is 4 to 80; m is 2 to 6; p is 1 to 4; and q is 0 or 1. Those skilled in the art will appreciate that other polyamides can be used in the compounds of the present invention.

[0617] The term "diacylglycerol" refers to a fatty acid having two acyl chains R 1 and R 2 (the fatty acyl chains each independently have between 2 and 30 carbons bonded to the 1-position and 2-position of glycerol via ester linkages). The acyl groups may be saturated or have varying degrees of unsaturation. Suitable acyl groups include, but are not limited to, lauryl (C 12 ), myristyl (C 14 ), palmityl (C 16 ), stearyl (C 18 ) and eicosyl (C 20 ). In a preferred embodiment, R 1 and R 2 are the same, that is, R 1 and R 2 Both are myristyl (i.e. dimyristyl), R 1 and R 2 Both are stearyl (i.e., distearyl), etc. Diacylglycerols have the following general formula:

[0618]

[0619] The term "dialkyloxypropyl" refers to a group having two alkyl chains R 1 and R 2(the alkyl chains independently have between 2 and 30 carbons). The alkyl groups may be saturated or have varying degrees of unsaturation. The dialkyloxypropyl group has the following general formula:

[0620]

[0621] In a preferred embodiment, the PEG-lipid is a PEG-DAA conjugate having the formula:

[0622]

[0623] Where R 1 and R 2 is independently selected and is a long chain alkyl group having about 10 to about 22 carbon atoms; PEG is polyethylene glycol; and L is a non-ester containing linker moiety or an ester containing linker moiety as described above. The long chain alkyl group may be saturated or unsaturated. Suitable alkyl groups include, but are not limited to, lauryl (C 12 ), myristyl (C 14 ), palmityl (C 16 ), stearyl (C 18 ) and eicosyl (C 20 ). In a preferred embodiment, R 1 and R 2 are the same, that is, R 1 and R 2 Both are myristyl (i.e. dimyristyl), R 1 and R 2 Both are stearyl (ie, distearyl), and so on.

[0624] In the above formula VII, PEG has an average molecular weight in the range of about 550 daltons to about 10,000 daltons. In some instances, PEG has an average molecular weight of about 500 daltons to about 5,000 daltons (e.g., about 1,000 daltons to about 5,000 daltons, about 1,500 daltons to about 3,000 daltons, about 750 daltons to about 3,000 daltons, about 750 daltons to about 2,000 daltons, etc.). In a preferred embodiment, PEG has an average molecular weight of about 2,000 daltons or about 750 daltons. PEG can be optionally substituted by alkyl, alkoxy, acyl or aryl. In certain embodiments, the terminal hydroxyl group is substituted by methoxy or methyl.

[0625] In a preferred embodiment, "L" is a non-ester containing linker moiety. Suitable non-ester containing linkers include, but are not limited to, amide linker moieties, amino linker moieties, carbonyl linker moieties, carbamate linker moieties, urea linker moieties, ether linker moieties, disulfide linker moieties, succinyl linker moieties, and combinations thereof. In a preferred embodiment, the non-ester containing linker moiety is a carbamate linker moiety (i.e., PEG-C-DAA conjugate). In another preferred embodiment, the non-ester containing linker moiety is an amide linker moiety (i.e., PEG-A-DAA conjugate). In yet another preferred embodiment, the non-ester containing linker moiety is a succinyl linker moiety (i.e., PEG-S-DAA conjugate).

[0626] In certain embodiments, the PEG-lipid conjugate is selected from:

[0627]

[0628] In one embodiment, n is selected such that the resulting polymer chain has a molecular weight of about 2000.

[0629] The PEG-DAA conjugates are synthesized using standard techniques and reagents known to those skilled in the art. It will be appreciated that the PEG-DAA conjugates will contain various amide, amine, ether, thiol, carbamate and urea bonds. Those skilled in the art will recognize that the methods and reagents for forming these bonds are well known and readily available. See, for example, March, ADVANCED ORGANIC CHEMISTRY (Wiley 1992); Larock, COMPREHENSIVE ORGANIC TRANSFORMATIONS (VCH 1989); and Furniss, VOGEL'S TEXTBOOK OF PRACTICAL ORGANIC CHEMISTRY, 5th Edition (Longman 1989). It will also be appreciated that any functional groups present may require protection and deprotection at different points in the synthesis of the PEG-DAA conjugates. Those skilled in the art will recognize that such techniques are well known. See, for example, Green and Wuts, PROTECTIVE GROUPS IN ORGANIC SYNTHESIS (Wiley 1991).

[0630] Preferably, the PEG-DAA conjugate is dilauryloxypropyl (C 12 )-PEG conjugate, dimyristyloxypropyl (C 14 )-PEG conjugate, dipalmityloxypropyl (C 16 )-PEG conjugate or distearyloxypropyl (C 18Those skilled in the art will readily appreciate that other dialkyloxypropyl groups can be used in the PEG-DAA conjugates of the present invention.

[0631] In addition to the foregoing, it will be readily apparent to those skilled in the art that other hydrophilic polymers may be used in place of PEG. Examples of suitable polymers that may be used in place of PEG include, but are not limited to, polyvinylpyrrolidone, polymethyloxazoline, polyethyloxazoline, polyhydroxypropylmethacrylamide, polymethacrylamide and polydimethylacrylamide, polylactic acid, polyglycolic acid, and derived cellulose such as hydroxymethylcellulose or hydroxyethylcellulose.

[0632] The charges on the polycationic moieties can be distributed around the entire particle portion, or alternatively, they can be a discrete concentration of charge density, such as a charge spike, in a specific region of the particle portion. If the charge density is distributed on the particle, the charge density can be uniformly distributed or non-uniformly distributed. The present invention encompasses all variations in the charge distribution of the polycationic moieties.

[0633] In some instances, the polycationic portion may have an attached ligand, such as a targeting ligand or chelating moiety for complexing calcium. Preferably, after the ligand is attached, the cationic portion maintains a positive charge. In some instances, the attached ligand has a positive charge. Suitable ligands include, but are not limited to, compounds or devices with reactive functional groups and include lipids, amphipathic lipids, carrier compounds, bioaffinity compounds, biomaterials, biopolymers, biomedical devices, analytical detectable compounds, therapeutically active compounds, enzymes, peptides, proteins, antibodies, immunostimulants, radiolabels, fluorophores, biotin, drugs, haptens, DNA, RNA, polysaccharides, liposomes, virions, micelles, immunoglobulins, functional groups, other targeting moieties or toxins.

[0634] The lipid conjugate (e.g., PEG-lipid) typically comprises about 0.1 mol% to about 10 mol%, about 0.5 mol% to about 10 mol%, about 1 mol% to about 10 mol%, about 2 mol% to about 10 mol%, about 2 mol% to about 8 mol%, about 2 mol% to about 5 mol%, about 2 mol% to about 4 mol%, about 0.6 mol% to about 1.9 mol%, about 0.7 mol% to about 1.8 mol%, about 0.8 mol% to about 1.7 mol%, about 0.9 mol% to about 1.6 mol%, about 0.9 mol% to about 1.8 mol%, about 1 mol% to about 1.8 mol%, about 1 mol% to about 1.7 mol%, about 1.2 mol% to about 1.8 mol%, about 1.2 mol% to about 1.7 mol%, about 1.3 mol% to about 1.6 mol%, or about 1.4 mol% to about 1.5 mol% of the total lipid present in the particle.

[0635] One skilled in the art will appreciate that the concentration of the lipid conjugate may vary depending on the lipid conjugate employed and the rate at which the nucleic acid-lipid particle becomes fusogenic.

[0636] By controlling the composition and concentration of lipid conjugates, the rate at which the lipid conjugates are exchanged from nucleic acid-lipid particles can be controlled, and in turn the rate at which the nucleic acid-lipid particles become fusogenic. For example, when PEG-phosphatidylethanolamine conjugates or PEG-ceramide conjugates are used as lipid conjugates, the rate at which the nucleic acid-lipid particles become fusogenic can be changed, for example, by changing the concentration of the lipid conjugates, by changing the molecular weight of PEG, or by changing the chain length and saturation of the acyl chains on phosphatidylethanolamine or ceramide. In addition, other variables include, for example, pH, temperature, ionic strength, etc., which can be used to change and / or control the rate at which the nucleic acid-lipid particles become fusogenic. When reading this disclosure, other methods that can be used to control the rate at which the nucleic acid-lipid particles become fusogenic will become clear to those skilled in the art.

[0637] Preparation of lipid particles

[0638] The lipid particles (e.g., LNPs) of the present invention can be formed by any method known in the art, including but not limited to continuous mixing methods or direct dilution methods, wherein active agents or therapeutic agents such as nucleic acids are encapsulated in the lipid bilayer and protected from degradation.

[0639] In a preferred embodiment, the non-cationic lipid is egg sphingomyelin (ESM), distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), 1-palmitoyl-2-oleoyl-phosphatidylcholine (POPC), dipalmitoyl-phosphatidylcholine (DPPC), monomethyl-phosphatidylethanolamine, dimethyl-phosphatidylethanolamine, 14:0PE (1,2-dimyristoyl-phosphatidylethanolamine (DMPE)), 16:0PE (1,2-dipalmitoyl-phosphatidylethanolamine (DPPE)), 18 ... :0PE (1,2-distearoyl-phosphatidylethanolamine (DSPE)), 18:1PE (1,2-dioleoyl-phosphatidylethanolamine (DOPE)), 18:1 trans-PE (1,2-di-trans-oleoyl-phosphatidylethanolamine (DEPE)), 18:0-18:1PE (1-stearoyl-2-oleoyl-phosphatidylethanolamine (SOPE)), 16:0-18:1PE (1-palmitoyl-2-oleoyl-phosphatidylethanolamine (POPE)), polyethylene glycol-based polymers (e.g., PEG 2000, PEG 5000, PEG-modified diacylglycerols or PEG-modified dialkoxypropyl), cholesterol, or a combination thereof.

[0640] In certain embodiments, the invention provides LNPs produced via a continuous mixing method, the continuous mixture method being, for example, a method comprising the following steps: providing an aqueous solution comprising a nucleic acid (such as interfering RNA or mRNA) in a first tank, providing an organic lipid solution in a second tank, and mixing the aqueous solution with the organic lipid solution so that the organic lipid solution is mixed with the aqueous solution, thereby substantially instantaneously producing liposomes encapsulating nucleic acids (e.g., interfering RNA or mRNA). This method and an apparatus for carrying out this method are described in detail in U.S. Patent Publication No. 20040142025, the disclosure of which is incorporated herein by reference in its entirety for all purposes.

[0641] Continuously introducing lipid and buffer solution into the mixed environment such as the action in the mixing chamber causes the continuous dilution of lipid solution with buffer solution, thereby substantially instantaneously producing liposomes when mixing. As used herein, the phrase "continuous dilution of lipid solution with buffer solution" (and variations) generally means diluting lipid solution sufficiently and rapidly in the hydration process with enough forces to achieve vesicle generation. In the presence of buffer solution (i.e., aqueous solution), the organic lipid solution is subjected to continuous stepwise dilution to produce nucleic acid-lipid particles by mixing an aqueous solution comprising nucleic acid with an organic lipid solution.

[0642] The LNPs formed using the continuous mixing process typically have a size of about 40 nm to about 150 nm, about 40 nm to about 80 nm, about 40 nm to about 60 nm, about 50 nm to about 60 nm, about 50 nm to about 150 nm, about 60 nm to about 130 nm, about 70 nm to about 110 nm, or about 70 nm to about 90 nm. The particles thus formed do not aggregate and are optionally sized to achieve a uniform particle size.

[0643] In another embodiment, the invention provides LNP produced via a direct dilution method, the direct dilution method comprising forming a liposome solution and immediately and directly introducing the liposome solution into a collection vessel containing a controlled amount of dilution buffer. In a preferred aspect, the collection vessel comprises one or more elements configured to stir the contents of the collection vessel to dilute. In one aspect, the amount of dilution buffer present in the collection vessel is substantially equal to the volume of the liposome solution introduced therein. As a non-limiting example, when introduced into a collection vessel containing an equal volume of dilution buffer, a liposome solution in 45% ethanol will advantageously produce smaller particles.

[0644] In another embodiment, the present invention provides LNP produced via a direct dilution method, wherein a third tank fluid containing a dilution buffer is connected to a second mixing zone. In this embodiment, the liposome solution formed in the first mixing zone is immediately and directly mixed with the dilution buffer in the second mixing zone. In a preferred aspect, the second mixing zone includes a T-connector, which is arranged so that the liposome solution flow and the dilution buffer flow meet and flow in the opposite direction at 180°; however, a connector providing a smaller angle of, for example, about 27° to about 180° can be used. The pump mechanism delivers a controllable flow of buffer to the second mixing zone. In one aspect, the flow rate of the dilution buffer provided to the second mixing zone is controlled to be substantially equal to the flow rate at which the liposome solution is introduced from the first mixing zone. On the other hand, the flow rate of the dilution buffer provided to the second mixing zone is controlled to be substantially different from the flow rate at which the liposome solution is introduced from the first mixing zone. This embodiment advantageously allows more control of the flow rate of the dilution buffer mixed with the liposome solution in the second mixing zone, and therefore also controls the concentration of the liposome solution in the buffer throughout the second mixing process. Such control of the dilution buffer flow rate advantageously allows small particle size formation at reduced concentrations.

[0645] These methods and apparatus for performing these direct dilution methods are described in detail in US Patent Publication No. 20070042031, the disclosure of which is incorporated herein by reference in its entirety for all purposes.

[0646] The LNPs formed using the direct dilution method typically have a size of about 40 nm to about 150 nm, about 40 nm to about 80 nm, about 40 nm to about 60 nm, about 50 nm to about 60 nm, about 50 nm to about 150 nm, about 60 nm to about 130 nm, about 70 nm to about 110 nm, or about 70 nm to about 90 nm. The particles thus formed do not aggregate and are optionally sized to achieve a uniform particle size.

[0647] If desired, lipid particles of the present invention (e.g., LNP) can be sized by any method available for liposome size setting. Size setting can be performed to achieve a desired size range and relatively narrow particle size distribution.

[0648] Several techniques are available for setting the size of the particles to the desired size. A method for setting the size for liposomes and equally applicable to the particles of the present invention is described in U.S. Patent No. 4,737,323, the disclosure of which is incorporated herein by reference in its entirety for all purposes. Ultrasound of the particle suspension by bath or probe ultrasound produces particles whose size is gradually reduced to a size less than about 50nm. Homogenization is another method that relies on shear energy to break larger particles into smaller particles. In a common homogenization process, the particles are circulated through a standard emulsion homogenizer until the selected particle size is observed, usually between about 60nm and about 80nm. In both methods, the particle size distribution can be monitored by conventional laser beam particle size identification or QELS.

[0649] Extrusion of particles through a small pore polycarbonate membrane or an asymmetric ceramic membrane is also an effective method for reducing particle size to a relatively well-defined size distribution. Typically, the suspension is cycled through the membrane one or more times until the desired particle size distribution is achieved. Gradual size reduction can be achieved by extruding particles through membranes with increasingly smaller pores.

[0650] In some embodiments, the nucleic acid in the LNP is pre-condensed as described, for example, in U.S. Patent Application Serial No. 09 / 744,103, the disclosure of which is incorporated herein by reference in its entirety for all purposes.

[0651] In other embodiments, the method will further include using the composition of the present invention to add a non-lipid polycation for achieving cell lipofection. Examples of suitable non-lipid polycations include hexadimethrine bromide (trade name Other suitable polycations include, for example, salts of poly-L-ornithine, poly-L-arginine, poly-L-lysine, poly-D-lysine, polyacrylamine, and polyethyleneimine. These salts are preferably added after the particles have been formed.

[0652] In some embodiments, the nucleic acid and lipid ratio (mass / mass ratio) in the LNP formed will be in the scope of about 0.01 to about 0.2, about 0.02 to about 0.1, about 0.03 to about 0.1 or about 0.01 to about 0.08. The ratio of starting material also falls within this scope. In other embodiments, LNP preparation uses about 400 μ g nucleic acid or about 0.01 to about 0.08 nucleic acid and lipid mass ratio of every 10 mg total lipid, and more preferably about 0.04, which is corresponding to every 50 μ g nucleic acid 1.25 mg total lipid. In other preferred embodiments, the nucleic acid of particle: lipid mass ratio is about 0.08.

[0653] In other embodiments, the lipid to nucleic acid ratio (mass / mass ratio) in the formed LNP will be between about 1 (1:1) and about 100 (100:1), about 5 (5:1) and about 100 (100:1), about 1 (1:1) and about 50 (50:1), about 2 (2:1) and about 50 (50:1), about 3 (3:1) and about 50 (50:1), about 4 (4:1) and about 50 (50:1), about 5 (5:1) and about 50 (50:1), about 1 (1:1) and about 25 (25:1), about 2 (2:1) and about 25 (25:1), about 3 (3:1) and about 25 (25:1), about 4 (4:1) and about 25 (25:1), about 5 (5:1) and about 50 (50:1). 1), about 5 (5:1) to about 15 (15:1), about 5 (5:1) to about 10 (10:1), about 5 (5:1), 6 (6:1), 7 (7:1), 8 (8:1), 9 (9:1), (10:1), 11 (11:1), 12 (12:1), 13 (13:1), 14 (14:1), 15 (15:1), 16 (16:1), 17 (17:1), 18 (18:1), 19 (19:1), 20 (20:1), 21 (21:1), 22 (22:1), 23 (23:1), 24 (24:1), 25 (25:1), 26 (26:1), 27 (27:1), 28 (28:1), 29 (29:1) or 30 (30:1). The ratio of the starting materials also usually falls within this range.

[0654] As previously discussed, the conjugated lipid may further include a CPL. Various general methods for making LNP-CPL (LNP containing CPL) are discussed herein. Two general techniques include: a "post-insertion" technique, in which the CPL is inserted into, for example, a preformed LNP; and a "standard" technique, in which the CPL is included in the lipid mixture during, for example, the LNP formation step. The post-insertion technique produces LNPs with CPL primarily in the outer surface of the LNP bilayer membrane, while the standard technique provides LNPs with CPL both on the inner and outer surfaces. The method is particularly useful for vesicles made from phospholipids (which may contain cholesterol) and also for vesicles containing PEG-lipids (such as PEG-DAA and PEG-DAG). Methods of making LNP-CPL are taught, for example, in U.S. Patent Nos. 5,705,385; 6,586,410; 5,981,501; 6,534,484 and 6,852,334; U.S. Patent Publication No. 20020072121; and PCT Publication No. WO 00 / 62813, the disclosures of which are incorporated herein by reference in their entirety for all purposes.

[0655] Other methods for producing LNPs can be found, for example, in U.S. Pat. No. 9,005,654 and PCT Publication No. WO 2007 / 012191, the disclosures of which are herein incorporated by reference in their entireties for all purposes.

[0656] Pill Box

[0657] The present invention also provides the lipid granule (for example, LNP) in the form of a medicine box. The medicine box can include a container that is divided into compartments for accommodating the various elements (for example, activating agent or therapeutic agent such as the independent lipid component of nucleic acid and granule) of lipid granule. In some embodiments, the medicine box can also include an endosomal membrane destabilizer (for example, calcium ion). Medicine box usually contains lipid granule compositions of the present invention, preferably in dehydrated form, and the instructions for its rehydration and use.

[0658] As explained herein, lipid particles (e.g., LNP) of the present invention can be customized to preferentially target specific target tissues, organs, or tumors. In some instances, the preferential targeting of lipid particles such as LNPs can be carried out by controlling the composition of the particles themselves. For example, as described in Example 11, it has been found that 1:57PEG-cDSALNP preparations can be used for preferentially targeting tumors outside the liver, while 1:57PEG-cDMALNP preparations can be used for preferentially targeting liver (including liver tumors).

[0659] In certain other examples, it is desirable to attach a targeting moiety to the surface of the lipid particle to further enhance the targeting of the particle. Methods for attaching a targeting moiety (e.g., an antibody, protein, etc.) to a lipid (such as those used in the particles of the present invention) are known to those skilled in the art.

[0660] Administration of lipid particles

[0661] Once formed, lipid granule of the present invention (for example, LNP) can be used for activating agent or therapeutic agent (for example, nucleic acid such as interfering RNA or mRNA) is introduced into cell.Therefore, the present invention also provides the method for activating agent or therapeutic agent such as nucleic acid (for example, interfering RNA or mRNA) is introduced into cell.By first forming granule as above and then making granule and cell contact enough for activating agent or therapeutic agent to be delivered to cell for a period of time and carry out described method in vitro or in vivo.

[0662] Lipid granules of the present invention (for example, LNP) can be absorbed into almost any cell type mixed with it or contacted.Once absorbed, granule can be endocytosed by a part of cell, exchanges lipid with cell membrane, or merges with cell.Transfer or mixing of the activating agent or therapeutic agent (for example, nucleic acid) part of granule can occur via any one of these approaches.Specifically, when fusion occurs, granule membrane is incorporated in the cell membrane and the content of granule is combined with intracellular fluid.

[0663] Lipid granule of the present invention (for example, LNP) can be used individually or with the pharmaceutically acceptable carrier (for example, physiological saline or phosphate buffer) mixed administration selected according to route of administration and standard drug practice.Usually, physiological buffered saline (for example, 135-150mM NaCl) will be adopted as pharmaceutically acceptable carrier.Other suitable carriers include, for example, water, buffered water, 0.4% saline, 0.3% glycine, etc., including glycoproteins for enhancing stability, such as albumin, lipoprotein, globulin, etc. Suitable carriers are described in, for example, REMINGTON'S PHARMACEUTICAL SCIENCES, Mack Publishing Company, Philadelphia, Pa., the 17th edition (1985).As used herein, "carrier" includes any and all solvents, dispersion media, vehicles, coatings, diluents, antibacterial and antifungal agents, isotonic agents and absorption delay agents, buffers, carrier solutions, suspensions, colloids, etc. The phrase "pharmaceutically acceptable" refers to molecular entities and compositions that do not produce an allergic or similar untoward reaction when administered to a human.

[0664] The pharmaceutically acceptable carrier is usually added after the particles are formed. Thus, after the particles are formed, the particles can be diluted into a pharmaceutically acceptable carrier such as physiologically buffered saline.

[0665] The particle concentration in the pharmaceutical preparation can vary widely, i.e., from less than about 0.05% by weight, typically at or at least about 2% to 5% by weight to as much as about 10% to 90% by weight, and will be selected primarily by fluid volume, viscosity, etc., according to the specific mode of administration selected. For example, the concentration can be increased to reduce the fluid load associated with the treatment. This can be particularly desirable in patients with congestive heart failure or severe hypertension associated with atherosclerosis. Alternatively, the particles consisting primarily of irritating lipids can be diluted to low concentrations to reduce inflammation at the site of administration.

[0666] The pharmaceutical composition of the present invention can be sterilized by conventional well-known sterilization techniques. The aqueous solution can be packaged for use or filtered and lyophilized under aseptic conditions, and the lyophilized preparation is mixed with a sterile aqueous solution before administration. When it is necessary to approach physiological conditions, the composition may contain pharmaceutically acceptable auxiliary substances, such as pH regulators and buffers, tension regulators, etc., such as sodium acetate, sodium lactate, sodium chloride, potassium chloride and calcium chloride. In addition, the particle suspension may include a lipid protective agent that protects lipids from free radicals and lipid peroxidation damage during storage. Lipophilic free radical quenchers such as alpha tocopherol and water-soluble iron-specific chelators such as ferrochlore are suitable.

[0667] In vivo administration

[0668] Systemic delivery for in vivo therapy has been achieved using nucleic acid-lipid particles such as those described in PCT Publication Nos. WO 05 / 007196, WO 05 / 121348, WO 05 / 120152, and WO 04 / 002453, for example, therapeutic nucleic acids are delivered to distal target cells via body systems such as circulation, the disclosures of which are incorporated herein by reference in their entirety for all purposes. The present invention also provides fully encapsulated lipid particles that protect nucleic acids from nuclease degradation in serum, are non-immunogenic, small in size, and are suitable for repeated administration.

[0669] For in vivo administration, administration can be by any means known in the art, such as by injection, oral administration, inhalation (e.g., intranasal or intratracheal), transdermal application, or rectal administration. Administration can be accomplished via a single dose or divided doses. The pharmaceutical composition can be administered parenterally, i.e., intraarticularly, intravenously, intraperitoneally, subcutaneously, or intramuscularly. In some embodiments, the pharmaceutical composition is administered intravenously or intraperitoneally by bolus injection (see, e.g., U.S. Patent No. 5,286,634). Intracellular nucleic acid delivery is also discussed in Straubringer et al., Methods Enzymol., 101: 512 (1983); Mannino et al., Biotechniques, 6: 682 (1988); Nicolau et al., Crit. Rev. Ther. Drug Carrier Syst., 6: 239 (1989); and Behr, Acc. Chem. Res., 26: 274 (1993). Other methods of administering lipid-based therapeutic agents are described in, for example, U.S. Pat. Nos. 3,993,754; 4,145,410; 4,235,871; 4,224,179; 4,522,803 and 4,588,578. The lipid particles can be administered by direct injection at the disease site or by injection at a site away from the disease site (see, for example, Culver, HUMAN GENE THERAPY, MaryAnn Liebert Inc.,, Publishers, New York. Pages 70-71 (1994)). The disclosures of the above references are incorporated herein by reference in their entirety for all purposes.

[0670] The compositions of the present invention, alone or in combination with other suitable components, can be prepared into aerosol formulations (i.e., they can be "nebulized") to be administered via inhalation (e.g., intranasally or intratracheally) (see, Brigham et al., Am. J. Sci., 298: 278 (1989)). Aerosol formulations can be placed in pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, etc.

[0671] In certain embodiments, pharmaceutical compositions can be delivered by intranasal spray, inhalation and / or other aerosol delivery vehicles. The method for directly delivering nucleic acid compositions to the lungs via nasal aerosol spray has been described in, for example, U.S. Patent Nos. 5,756,353 and 5,804,212. Similarly, intranasal microparticle resins and lysophosphatidyl-glycerol compound delivery drugs (U.S. Patent No. 5,725,871) are also well known in the pharmaceutical field. Similarly, transmucosal drug delivery in the form of polytetrafluoroethylene carrier matrix is ​​described in U.S. Patent No. 5,780,045. The disclosure of the above patent is incorporated herein by reference as a whole for all purposes.

[0672] Formulations suitable for parenteral administration, such as by intraarticular (in a joint), intravenous, intramuscular, intradermal, intraperitoneal and subcutaneous routes, include aqueous and non-aqueous isotonic sterile injection solutions, which may contain antioxidants, buffers, bacteriostats and solutes that make the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions, which may include suspending agents, solubilizers, thickeners, stabilizers and preservatives. In the practice of the present invention, the composition is preferably administered, for example, by intravenous infusion, oral, topical, intraperitoneal, intravesical or intrathecal administration.

[0673] Usually, when intravenously administered, lipid granule preparations are formulated with suitable pharmaceutical carriers. Many pharmaceutically acceptable carriers can be adopted in the compositions and methods of the present invention. Suitable preparations for the present invention are for example found in REMINGTON'S PHARMACEUTICAL SCIENCES, Mack Publishing Company, Philadelphia, Pa., the 17th edition (1985). Various aqueous carriers can be used, such as water, buffered water, 0.4% saline, 0.3% glycine, etc., and glycoproteins for enhancing stability can be included, such as albumin, lipoprotein, globulin, etc. Usually, physiological buffered saline (135mM-150mMNaCl) will be adopted as a pharmaceutically acceptable carrier, but other suitable carriers will also meet the needs. These compositions can be sterilized by conventional liposome sterilization techniques such as filtration. When it is necessary to approach physiological conditions, the composition may contain pharmaceutically acceptable auxiliary substances, such as pH regulators and buffers, tension regulators, wetting agents, etc., such as sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, triethanolamine oleate, etc. These compositions can be sterilized using the above-mentioned techniques, or alternatively these compositions can be produced under aseptic conditions. The resulting aqueous solution can be packaged for use or filtered and lyophilized under aseptic conditions, and the lyophilized preparation is combined with a sterile aqueous solution before administration.

[0674] In some applications, lipid particles disclosed herein can be delivered to individuals via oral administration. Particles can be merged with excipients and used in the form of ingestible tablets, buccal tablets, lozenges, capsules, pills, lozenges, elixirs, mouthwashes, suspensions, oral sprays, syrups, wafers, etc. (see, for example, U.S. Patent Nos. 5,641,515, 5,580,579 and 5,792,451, the disclosure of which is incorporated herein by reference as a whole for all purposes). These oral dosage forms may also contain the following substances: adhesives, gelatin; excipients, lubricants and / or flavorings. When the unit dosage form is a capsule, it may contain a liquid carrier in addition to the material described above. Various other materials may exist as a coating or otherwise modify the physical form of the dosage unit. Of course, any material used to prepare any unit dosage form should be pharmaceutically pure and substantially nontoxic in the case of the amount employed.

[0675] Typically, these oral formulations can contain at least about 0.1% lipid particles or more, although the percentage of particles can certainly change and can be conventionally about 1% or 2% and about 60% or 70% or more of the weight or volume of the total preparation. Naturally, the amount of particles in each therapeutically useful composition can be prepared in a manner suitable for the dosage to be obtained in any given unit dose of the compound. The skilled person in the field of preparing such pharmaceutical preparations will think of factors such as solubility, bioavailability, biological half-life, route of administration, product validity period and other pharmacological considerations, and similarly, various dosages and treatment regimens can be desirable.

[0676] Formulations suitable for oral administration may consist of: (a) liquid solutions, such as an effective amount of a packaged therapeutic agent such as a nucleic acid (e.g., interfering RNA or mRNA) suspended in a diluent such as water, saline or PEG 400; (b) capsules, sachets or tablets, each containing a predetermined amount of a therapeutic agent such as a nucleic acid (e.g., interfering RNA or mRNA) in liquid, solid, granular or gelatin form; (c) a suspension in an appropriate liquid; and (d) a suitable emulsion. Tablet forms may contain one or more of the following: lactose, sucrose, mannitol, sorbitol, calcium phosphate, corn starch, potato starch, microcrystalline cellulose, gelatin, colloidal silicon dioxide, talc, magnesium stearate, stearic acid and other excipients, colorants, fillers, binders, diluents, buffers, wetting agents, preservatives, flavoring agents, dyes, disintegrants, and pharmaceutically compatible carriers. Lozenge forms may contain the therapeutic agent such as a nucleic acid (e.g., interfering RNA or mRNA) in a flavoring such as sucrose as well as lozenges containing the therapeutic agent in an inert matrix such as gelatin and glycerin or sucrose and acacia emulsions, gels, and the like containing, in addition to the therapeutic agent, carriers known in the art.

[0677] In another example of its use, lipid particles can be incorporated into a wide range of topical dosage forms. For example, a suspension containing nucleic acid-lipid particles such as LNPs can be formulated into and applied in the form of gels, oils, emulsions, topical creams, pastes, ointments, lotions, foams, mousses, etc.

[0678] When preparing pharmaceutical preparations of the lipid particles of the invention, it is preferred to use large quantities of such particles that have been purified to reduce or eliminate empty particles or particles having a therapeutic agent such as a nucleic acid associated with the outer surface.

[0679] The methods of the present invention can be practiced in various hosts. Preferred hosts include mammalian species, such as primates (e.g., humans and chimpanzees and other non-human primates), dogs, cats, horses, cattle, sheep, goats, rodents (e.g., rats and mice), lagomorphs, and pigs.

[0680] The amount of particles administered will depend on the ratio of therapeutic agent (e.g., nucleic acid) to lipid, the specific therapeutic agent (e.g., nucleic acid) used, the disease or condition being treated, the age, weight and condition of the patient, and the judgment of the clinician, but will generally be between about 0.01 mg / Kg body weight and about 50 mg / Kg body weight, preferably between about 0.1 mg / Kg body weight and about 5 mg / Kg body weight, or about 100 mg / kg per administration (e.g., injection). 8 -10 10 A particle.

[0681] In vitro administration

[0682] For in vitro applications, therapeutic agents such as nucleic acids (e.g., interfering RNA or mRNA) can be delivered to any cell grown in culture, whether of plant or animal origin, vertebrate or invertebrate, and of any tissue or type. In a preferred embodiment, the cell is an animal cell, more preferably a mammalian cell, and most preferably a human cell.

[0683] When the contact between the cell and the lipid particles occurs in a biocompatible culture medium in vitro. The concentration of the particles varies widely depending on the specific application, but is generally between about 1 μmol and about 10 mmol. The treatment of cells with lipid particles is generally carried out at physiological temperature (about 37° C.) for a period of about 1 to 48 hours, preferably about 2 to 4 hours.

[0684] In a preferred embodiment, the lipid particle suspension is added to the cells at a density of about 10 3 to about 10 5 cells / ml, more preferably about 2×10 4The concentration of the suspension added to the cells is preferably about 0.01 μg / ml to 0.2 μg / ml, more preferably about 0.1 μg / ml.

[0685] Using the endosomal release parameter (ERP) determination, the delivery efficiency of the LNP of the present invention or other lipid particles can be optimized. ERP is determined in detail in U.S. Patent Publication No. 20030077829, and the disclosure of the patent is incorporated herein by reference as a whole for all purposes. More specifically, the purpose of ERP determination is to distinguish the various cationic lipids of LNP and the effect of assisting lipid components based on its relative effect on the binding / absorption or fusion / destabilization of the endosomal membrane. This determination allows people to quantitatively determine how each component of LNP or other lipid particles affects the delivery efficiency, thereby optimizing LNP or other lipid particles. Generally, ERP determination measures the expression of measurement reporter proteins (e.g., luciferase, beta-galactosidase, green fluorescent protein (GFP) etc.), and in some instances, the LNP formulation optimized for expression plasmids will also be applicable to encapsulation of interfering RNA or mRNA. In other instances, ERP determination may be applicable to measuring the transcription or translation down-regulation of the target sequence in the presence or absence of interfering RNA (e.g., siRNA). In other instances, ERP determination may be applicable to measuring the expression of target protein in the presence or absence of mRNA. By comparing the ERPs for each of the various LNPs or other lipid particles, one can readily determine the optimized system, eg, the LNP or other lipid particle that has the greatest uptake in cells.

[0686] Cells for delivery of lipid particles

[0687] The compositions and methods of the present invention are used to treat a variety of cell types in vivo and in vitro. Suitable cells include, for example, hematopoietic precursor (stem) cells, fibroblasts, keratinocytes, hepatocytes, endothelial cells, skeletal and smooth muscle cells, osteoblasts, neurons, dormant lymphocytes, terminally differentiated cells, slow-circulating or non-circulating primary cells, parenchymal cells, lymphoid cells, epithelial cells, osteocytes, etc. In a preferred embodiment, an active agent or therapeutic agent such as one or more nucleic acid molecules (e.g., interfering RNA (e.g., siRNA) or mRNA) is delivered to cancer cells, such as lung cancer cells, colon cancer cells, rectal cancer cells, anal cancer cells, bile duct cancer cells, small intestine cancer cells, stomach (gastric) cancer cells, esophageal cancer cells, gallbladder cancer cells, liver cancer cells, pancreatic cancer cells, appendix cancer cells, breast cancer cells, ovarian cancer cells, cervical cancer cells, prostate cancer cells, renal cancer cells, cancer cells of the central nervous system, glioblastoma tumor cells, skin cancer cells, lymphoma cells, choriocarcinoma tumor cells, head and neck cancer cells, osteogenic sarcoma tumor cells, and blood cancer cells.

[0688] In vivo delivery of liposomal particles, such as LNPs encapsulating one or more nucleic acid molecules (e.g., interfering RNA (e.g., siRNA) or mRNA) is suitable for targeting cells of any cell type. The methods and compositions of the present invention can be employed for a wide variety of vertebrates, including mammals such as dogs, cats, horses, cattle, sheep, goats, rodents (e.g., mice, rats and guinea pigs), lagomorphs, pigs, and primates (e.g., monkeys, chimpanzees and humans).

[0689] Depending on the extent to which tissue culture of cells may be required, it is well known in the art. For example, Freshney, Culture of Animal Cells, a Manual of Basic Technique, 3rd Edition, Wiley-Liss, New York (1994); Kuchler et al., Biochemical Methods in Cell Culture and Virology, Dowden, Hutchinson and Ross Inc. (1977), and references cited therein provide general guidance for cell culture. Cultured cell systems will often be in the form of a cell monolayer, although cell suspensions are also used.

[0690] Detection of lipid particles

[0691] In some embodiments, lipid granule of the present invention (for example, LNP) can be detected in subject under about 1,2,3,4,5,6,7,8 or more hours.In other embodiments, lipid granule of the present invention (for example, LNP) can be detected in subject when about 8,12,24,48,60,72 or 96 hours or about 6,8,10,12,14,16,18,19,22,24,25 or 28 days after particle administration.The existence of particle can be detected in cell, tissue or other biological samples from experimenter.Particle can be detected for example by directly detecting particle, detecting therapeutic nucleic acid such as interfering RNA (for example, siRNA) sequence or mRNA sequence, detecting target target sequence (that is, by detecting the expression of target sequence or the expression of reduction) or its combination.

[0692] Particle detection

[0693] Can use any method as known in the art to detect lipid granule of the present invention such as LNP.For example, can use method well known in the art directly or indirectly label is coupled to the component of lipid granule.Can use various labels, wherein the selection of label depends on required sensitivity, the ease of putting together with lipid granule component, stability requirement and available instrument and protection condition.Suitable label includes but is not limited to spectral labeling such as fluorescent dye (for example, fluorescein and derivative, such as fluorescein isothiocyanate (FITC) and Oregon Green TM ; Rhodamine and its derivatives such as Texas Red, tetramethylrhodamine isothiocyanate (TRITC), digoxigenin, biotin, phycoerythrin, AMCA, CyDyes TM etc.; radioactive labels such as 3 H. 125 I. 35 S. 14 C. 32 P. 33 P, etc.; enzymes such as horseradish peroxidase, alkaline phosphatase, etc.; spectral colorimetric labels such as colloidal gold or colored glass or plastic beads such as polystyrene, polypropylene, latex, etc. The label can be detected using any method known in the art.

[0694] Nucleic acid detection

[0695] Nucleic acids (e.g., interfering RNA or mRNA) are detected and quantified herein by any of a number of means well known to those skilled in the art. Detection of nucleic acids can be performed by well-known methods such as DNA analysis, RNA analysis, gel electrophoresis, PCR, radiolabeling, scintillation counting, and affinity chromatography. Additional analytical biochemical methods such as spectrophotometry, radiography, electrophoresis, capillary electrophoresis, high performance liquid chromatography (HPLC), thin layer chromatography (TLC), and high diffusion chromatography can also be used.

[0696] The choice of nucleic acid hybridization format is not critical. Various nucleic acid hybridization formats are known to those skilled in the art. For example, common formats include sandwich assays and competition or displacement assays. Hybridization techniques are generally described in, for example, "Nucleic Acid Hybridization, A Practical Approach," by Hames and Higgins, IRL Press (1985).

[0697] The sensitivity of hybridization assays can be enhanced by using nucleic acid amplification systems that multiply the target nucleic acid detected. In vitro amplification techniques suitable for amplifying sequences for use as molecular probes or for generating nucleic acid fragments for subsequent subcloning are known. Amplification techniques including polymerase chain reaction (PCR), ligase chain reaction (LCR), Qβ-replicase amplification, and other RNA polymerase-mediated techniques (e.g., NASBA TM Examples of such in vitro amplification methods are sufficient to guide the skilled artisan in the art in Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press (2000); and Ausubel et al., SHORT PROTOCOLS IN MOLECULAR BIOLOGY, eds., Current Protocols, Greene Publishing Associates, Inc. and John Wiley & Sons, Inc. (2002); and U.S. Pat. No. 4,683,202; PCR Protocols, A Guide to Methods and Applications (Innis et al., eds.) Academic Press Inc. San Diego, Calif. (1990); Arnheim and Levinson (October 1, 1990), C&EN 36; The Journal Of NIH Research, 3:81 (1991); Kwoh et al., Proc. Natl. Acad. Sci. USA, 86:1173 (1989); Guatelli et al., Proc. Natl. Acad. Sci. USA, 87:1874 (1990); Lomell et al., J. Clin. Chem., 35:1826 (1989); Landegren et al., Science, 241:1077 (1988); Van Brunt, Biotechnology, 8:291 (1990); Wu and Wallace, Gene, 4:560 (1989); Barringer et al., Gene, 89:117 (1990); and Sooknanan and Malek, Biotechnology, 13:563 (1995). Improved methods for in vitro cloning of amplified nucleic acids are described in U.S. Pat. No. 5,426,039. Other methods described in the art are nucleic acid sequence-based amplification (NASBA) TM, Cangene, Mississauga, Ontario) and Qβ-replicase systems. These systems can be used to directly identify mutants in which PCR or LCR primers are designed to be extended or ligated only when the selection sequence is present. Alternatively, the selection sequence can be amplified using, for example, nonspecific PCR primers and a target region that is subsequently probed for amplification of specific sequences that indicate mutations. The disclosures of the above references are incorporated herein by reference in their entirety for all purposes.

[0698] Nucleic acids used as probes, gene probes or inhibitor components, for example, are typically chemically synthesized according to the solid phase phosphoramidite triester method described by Beaucage et al., Tetrahedron Letts., 22: 1859 1862 (1981), for example using an automatic synthesizer as described in Needham VanDevanter et al., Nucleic Acids Res., 12: 6159 (1984). Where necessary, polynucleotides are typically purified by native acrylamide gel electrophoresis or by anion exchange HPLC as described in Pearson et al., J. Chrom., 255: 137 149 (1983). The sequence of the synthetic polynucleotide can be verified using the chemical degradation method of Maxam and Gilbert (1980) in Grossman and Moldave (eds.) Academic Press, New York, Methods in Enzymology, 65: 499.

[0699] An alternative for determining transcription levels is in situ hybridization. In situ hybridization assays are well known and generally described in Angerer et al., Methods Enzymol., 152:649 (1987). In in situ hybridization assays, cells are fixed to a solid support, usually a glass slide. If DNA is detected, the cells are denatured with heat or alkali. The cells are then contacted with a hybridization solution at a moderate temperature to allow the labeled specific probe to anneal. The probe is preferably labeled with a radioisotope or a fluorescent reporter molecule.

[0700] Ionizable lipids

[0701] Ionizable cationic lipids are usually the main lipid components in lipid nanoparticles (LNPs). They are designed to be charge neutral at standard physiological pH (about 7), but acquire a positive charge at lower (acidic) pH. This facilitates nucleic acid payload encapsulation and intracellular delivery during LNP formation (positive charges on ionizable lipids are required for the endosomal fusion step).

[0702] Ionizable lipids such as MC3 (used in the FDA-approved siRNA-LNP product Onpattro) and 3D-P-DMA have shown excellent activity and tolerability in various applications. However, they are not rapidly metabolized and require weeks to be cleared from target tissues. This makes them less attractive for applications that require multiple dosing, especially for short dosing intervals and / or chronic indications.

[0703] One way to achieve more favorable characteristics is to include carboxylate groups in the hydrophobic domain of the lipid. Ester groups are broken down by enzymes in the body, and this has been reported to improve lipid clearance in target tissues (Maier et al. 2013). However, the chemical structure around the ester must be considered because it will affect the effectiveness of the strategy. ALC-0315 is an ionizable lipid in BNT162b2 (also known as the Pfizer COVID vaccine) that has a carboxylate in its hydrophobic domain, but was found to be metabolized at a similar rate to MC3 [reference: Comirnaty evaluation report, European Medicines Agency]. In addition, esters must be incorporated while maintaining favorable activity and tolerability characteristics.

[0704] To this end, a series of ionizable cationic lipids incorporating ester functional groups have been designed, synthesized, and evaluated as follows:

[0705] Formulability (particle size, polydispersity, payload encapsulation, pKa)

[0706] Efficacy (mouse liver expression model, delivery of luciferase encoding and OTC mRNA)

[0707] Tolerance (mouse immunostimulation model, cytokine readouts)

[0708] Lipid clearance (mouse model - clearance from target tissue (liver))

[0709] The present invention will be described in more detail by specific examples. The following examples are provided for illustrative purposes and are not intended to limit the present invention in any way. Those skilled in the art will readily appreciate that various noncritical parameters can be changed or modified to produce substantially the same results.

[0710] Example

[0711] Preparation Example 1. Synthesis of Heptadecan-9-ylidenehydrazine

[0712]

[0713] Step 1. Synthesis of 9-heptadecanol

[0714]

[0715] The Grignard reagent was prepared from 1-bromooctane (6 g, 31 mmol) and magnesium (808 mg, 33 mmol) in THF and stirred at 45 °C for 2 hr. The reaction was cooled to 10 °C and ethyl formate (2.6 mL, 32 mmol) in THF (5 mL) was added dropwise. 2 O (3 mL) and 6 M HCl (8 mL) were added to dissolve the residual magnesium. 2 The organics were washed with brine and dried (MgSO 4 ), filtered and concentrated in vacuo. The residue was stirred in EtOH with a solution of KOH (1.6 g) in water (3 mL). The ethanol was removed in vacuo and the residue was partitioned between 6M HCl and hexanes. The organics were washed with H 2 O and brine, dried (MgSO 4 ), filtered and concentrated in vacuo. The crude product was purified by automated flash chromatography (0%-20% EtOAc / Hex) to give 9-heptadecanol (3.2 g, 81.2%).

[0716] Step 2.9-Synthesis of Heptadecanone

[0717]

[0718] 9-Heptadecanol (3.2 g, 12.6 mmol) and PCC-SiO 2 (1:1) (16.3 g, 38 mmol) was stirred in DCM (100 mL) at RT for 16 hr. The reaction was filtered through silica and eluted with EtOAc. The organics were concentrated in vacuo and purified by automated flash chromatography (0%-10% EtOAc / Hex) to give 9-heptadecanone (3.2 g, 99.6%).

[0719] Step 3. Synthesis of N'-(heptadecan-9-ylidene)tert-butoxycarbohydrazide

[0720]

[0721] tert-Butoxycarbohydrazide (195 mg, 1.47 mmol), 9-heptadecanone (750 mg, 2.9 mmol) and AcOH (catalytic amount) were stirred in MeOH (10 mL) under reflux for 15 hr. The reaction was concentrated in vacuo and purified by automated flash chromatography (0%-20% EtOAc / Hex) to give N'-(heptadecan-9-ylidene)tert-butoxycarbohydrazide (320 mg, 58.9%).

[0722] Step 4. Synthesis of heptadecan-9-ylidenehydrazine

[0723]

[0724] N'-(heptadecan-9-ylidene)tert-butoxycarbohydrazide (320 mg, 0.9 mmol) was stirred in 25% TFA in DCM (40 mL) at RT until the reaction was complete. The solvent was removed in vacuo to give heptadecan-9-ylidenehydrazide (231 mg, 99.1%) which was used without further purification.

[0725] Preparation Example 2. Synthesis of ((6Z,15Z)-heneicosahedral-6,15-diene-11-ylidene)hydrazine

[0726]

[0727] ((6Z,15Z)-heneicosae-6,15-dien-11-ylidene)hydrazine was prepared using a similar method as described above.

[0728] Preparation Example 3. Synthesis of Heptadecan-9-ylhydrazine

[0729]

[0730] Step 1. Synthesis of N'-(heptadecan-9-yl)tert-butoxycarbohydrazide

[0731]

[0732] tert-Butoxycarbohydrazide (412 mg, 3.1 mmol), 9-heptadecanone (794 mg, 3.1 mmol), AcOH (0.75 mL, 3.2 mmol) and NaBH(OAc) 3 (2.0 g, 9.4 mmol) was stirred in DCM (20 mL) at RT for 2 days and at 40 °C for another 20 hr. The reaction was washed with saturated NaHCO 3 and washed with brine, dried (MgSO 4 ), filtered and concentrated in vacuo. The residue was purified by automated flash chromatography (0%-12% EtOAc / Hex) to afford N'-(heptadecan-9-yl)tert-butoxycarbohydrazide (700 mg, 60.5%).

[0733] Step 2 Synthesis of heptadecan-9-ylhydrazine

[0734]

[0735] N'-(Heptadecan-9-yl)tert-butoxycarbohydrazide (700 mg, 1.9 mmol) was stirred with 25% TFA in DCM (10 mL) at RT for 1.5 hr. The reaction was concentrated in vacuo to give heptadecan-9-ylhydrazine (500 mg, 97.9%) which was used without purification.

[0736] Preparation Example 4. Synthesis of ((6Z,15Z)-heneicosahedral-6,15-dien-11-yl)hydrazine

[0737] ((6Z,15Z)-heneicosa-6,15-dien-11-yl)hydrazine was prepared using a similar procedure as described above.

[0738]

[0739] Preparation Example 5. Synthesis of 1,1-dioctylhydrazine

[0740]

[0741] Step 1 Synthesis of N', N'-dioctyl tert-butoxycarbohydrazide

[0742]

[0743] Octanal (2.4mL, 15.0mmol), tert-butoxycarbohydrazide (1g, 7.6mmol) and AcOH (7.6mmol) were stirred in anhydrous MeOH at 75°C for 1hr under nitrogen atmosphere. After cooling to RT, NaBH3CN (1.9g, 30.3mmol) was added and the mixture was stirred at RT for 15hr. The solvent was removed in vacuo and the residue was dissolved in EtOAc, washed with H2O and brine, dried (MgSO4), filtered and concentrated. The crude material was purified by automatic flash chromatography (0%-10% EtOAc / Hex) to give N', N'-dioctyl tert-butoxycarbohydrazide (2.0g, 74.3%).

[0744] Step 2 Synthesis of 1,1-dioctylhydrazine

[0745]

[0746] N',N'-Dioctyl tert-butoxycarbohydrazide (1.1 g, 3.0 mmol) was stirred in 30% TFA in DCM (20 mL) at 0°C until fully warmed to RT. The solvent was removed in vacuo to give 1,1-dioctylhydrazine (782 mg, quantitative) which was used without purification.

[0747] Preparation Example 6. Synthesis of 1,1-di((Z)-dec-4-en-1-yl)hydrazine

[0748]

[0749] A similar method was used to prepare 1,1-di((Z)-dec-4-en-1-yl)hydrazine

[0750] Preparation Example 7. General Method for Synthesis of Branched Alkyl Alcohols (a) - Illustrated by the Synthesis of 5-Octyltridec-4-en-1-ol

[0751] Step 1. Synthesis of 9-(4-bromobutyl)heptadecan-9-ol

[0752]

[0753] In anhydrous Et 2 The Grignard reagent was prepared from Mg (2.6 g, 105 mmol) and 1-bromooctane (20.0 g, 105 mmol) in 2% CO (35 mL) and refluxed for 1 hr. The reaction was cooled and ethyl 5-bromovalerate (8.0 g, 38.3 mmol) was added dropwise in anhydrous Et 2 O (25 mL) and then refluxed for another 1 hr. The reaction was cooled to RT and poured into 100 mL of saturated ice / NH 4 Cl solution. 2 O to extract the aqueous portion and dry the organic matter (MgSO 4 ), filtered and concentrated in vacuo. The crude material was purified by automated flash chromatography (0%-20% EtOAc / Hex) to give 9-(4-bromobutyl)heptadecan-9-ol (10.6 g, 70.7%).

[0754] Step 2. Synthesis of 9-(4-bromobutylene)heptadecane

[0755]

[0756] 9-(4-bromobutyl)heptadecan-9-ol (10.6 g, 27.0 mmol) and p-TsOH. 2 O (93 mg, 0.54 mmol) in N 2 Stir at 130° C. for 2 hr under atmosphere. The crude material was purified by automated flash chromatography (0%-4% EtOAc / Hex) to give 9-(4-bromobutylidene)heptadecane (8.84 g, 87.5%).

[0757] Step 3. Synthesis of 5-octyltridec-4-en-1-ol

[0758]

[0759] 9-(4-Bromobutylidene)heptadecane (8.84 g, 23.7 mmol), benzyl(chloro)triethylamine (540 mg, 2.4 mmol) and NaOAc (7.8 g, 94.7 mmol) were stirred in DMF (60 mL) at 70°C for 20 hr. The reaction was poured into ice / water and washed with Et 2 The combined organic matter was dried (MgSO 4 ), filtered and concentrated in vacuo. The residue was dissolved in MeOH and H 2 KOH (18.6 g, 332 mmol) in 2% CO was added and the reaction was stirred for 30 min. MeOH was removed in vacuo and the reaction was stirred under H 2 O and Et 2 The combined organics were dried (MgSO 4 ), filtered and concentrated in vacuo, and the crude material was purified by automated flash chromatography (0%-15% EtOAc / Hex) to give 5-octyltrideca-4-en-1-ol (4.5 g, 60.8%).

[0760] Step 4. Synthesis of 5-octyltridecane-1-ol

[0761]

[0762] 5-Octyltridecan-4-en-1-ol (4.469 g, 14.39 mmol) was hydrogenated over Pd-C catalysis in MeOH (50 mL) at RT for 15 hr. The reaction was filtered and concentrated in vacuo to give 5-octyltridecan-1-ol (3.5 g, 77.8%) which was used without further purification.

[0763] The following compounds were prepared using similar methods as described above

[0764]

[0765] Preparation Example 8. General Method for Synthesis of Branched Alkyl Alcohols (b) - Illustrated by the Synthesis of 3-Amyloctan-1-ol

[0766] Step 1. Synthesis of ethyl 3-pentyloct-2-enoate

[0767]

[0768] Phosphonoacetic acid triethyl ester (65.8g, 294mmol) is stirred in THF (220mL) at -10 ° C. 1M LiHMDS in THF (294mL, 294mmol) is added dropwise, and the reactant is stirred for 1hr at -10 ° C, and then stirred for 1hr at 0 ° C. 6-undecanone (25g, 147mmol) is added, and the reactant is stirred for 16hr at 45 ° C. The reactant is quenched with H2O, extracted with Et2O and washed with brine. Organic matter is dried (MgSO4), filtered and concentrated in vacuo to obtain 3-pentyl oct-2-enoic acid ethyl ester (43.5g), which is used in subsequent steps without further processing.

[0769] Step 2. Synthesis of ethyl 3-pentyloctanoate

[0770]

[0771] Ethyl 3-pentyloct-2-enoate (35 g, 147 mmol) was hydrogenated over Pd-C catalysis in MeOH (100 mL) at RT for 20 hr. The reaction was filtered and concentrated in vacuo to give ethyl 3-pentyloctanoate (33.3 g, 93.6%) which was used without further purification.

[0772] Step 3. Synthesis of 3-pentyloctan-1-ol

[0773]

[0774] LiAlH 4 (6.8 g, 179 mmol) was stirred in THF (500 mL) at 0°C for 30 min. Ethyl 3-pentyloctanoate (33.3 g, 138 mmol) in THF (500 mL) was added dropwise and the reaction was stirred at RT until completion. The reaction was cooled to 0°C and washed with Et 2 O (500 mL) and quenched with 1 M NaOH (16 mL). The reaction was stirred for 30 min and dried (MgSO 4 ), filtered through celite and concentrated in vacuo. The crude material was purified by automated flash chromatography (0%-30% EtOAc / Hex) to give 3-pentyloctan-1-ol (24.7 g, 89.7%).

[0775] The following compounds were prepared using similar procedures as described above:

[0776]

[0777] Preparation Example 9. Synthesis of (3,5-dihexylphenyl)methanol

[0778] Step 1. Synthesis of methyl 3,5-bis(hex-1-yn-1-yl)benzoate

[0779]

[0780] 3,5-dibromobenzoic acid methyl ester (7.4g, 25.0mmol), hexine (8.2g, 100.0mmol), dichlorobis [4- (diphenylphosphino) phenyl] palladium (1.4g, 2.0mmol), CuI (0.2g, 1.0mmol) and TEA (21.0mL, 150mmol) were stirred at 80 ° C for 48hr in benzene (100mL). The reactant was filtered through a silica pad and eluted with EtOAc. The organic matter was concentrated in vacuo, and the crude material was purified by automatic flash chromatography (0%-20% EtOAc / Hex) to obtain 3,5-bis (hex-1-yn-1-yl) methyl benzoate (7.0g, 94.4%).

[0781] Step 2. Synthesis of methyl 3,5-dihexylbenzoate

[0782]

[0783] Methyl 3,5-bis(hex-1-yn-1-yl)benzoate (7.0 g, 23.6 mmol) was hydrogenated over Pd-C catalysis in EtOH (100 mL) at RT for 18 hr. The reaction was filtered through celite and concentrated in vacuo to give methyl 3,5-dihexylbenzoate (6.3 g, 87.7%) which was used without further purification.

[0784] Step 3. Synthesis of (3,5-dihexylphenyl)methanol

[0785]

[0786] Methyl 3,5-dihexylbenzoate (6.3 g, 20.7 mmol) was stirred in anhydrous THF at 0 °C. LiAlH was added portionwise. 4 (1.2 g, 31.0 mmol) and the reaction was stirred for 1 hr and allowed to warm to RT. After completion, the reaction was treated with H 2 O and 1M NaOH, and extracted with EtOAc. The organic matter was dried (MgSO 4 ), filtered, concentrated in vacuo and purified by automated flash chromatography (10% EtOAc / Hex) to afford (3,5-dihexylphenyl)methanol (3.0 g, 52.4%).

[0787] Preparation Example 10. Synthesis of 2-fluoro-2-hexyldecanoic acid

[0788] Step 1. Synthesis of ethyl 2-hexyldecanoate

[0789]

[0790] Hexyldecanoic acid (3 g, 11.7 mmol) and H 2 SO 4 (catalytic amount) in EtOH (20 mL) and refluxed for 15 hr. The reaction was concentrated in vacuo and the residue was partitioned between hexanes and water. The organics were dried (MgSO 4 ), filtered, concentrated in vacuo and the residue purified by automated flash chromatography (0%-6% EtOAc / Hex) to give ethyl 2-hexyldecanoate (3.0 g, 90.7%).

[0791] Step 2. Synthesis of ethyl 2-fluoro-2-hexyldecanoate

[0792]

[0793] 2-Hexyldecanoic acid ethyl ester (1 g, 3.5 mmol) in THF was added dropwise to LDA solution (2.6 mL, 2M, 5.273 mmol) at -78 ° C and stirred for 0.5 hr. N-Fluorobenzenesulfonimide (1.7 g, 5.3 mmol) in THF (15 mL) was added dropwise and the reaction was stirred for 18 hr to warm it to RT. The reaction was diluted with EtOAc, washed with saturated NH4Cl aqueous solution, water and brine, dried (MgSO4), concentrated in vacuo and purified by automatic flash chromatography (0%-6% EtOAc / Hex). NMR showed 60% conversion. The reaction was repeated for a second time to obtain 2-fluoro-2-hexyldecanoic acid ethyl ester (770 mg, 72.4%).

[0794] Step 3. Synthesis of 2-fluoro-2-hexyldecanoic acid

[0795]

[0796] Ethyl 2-fluoro-2-hexyldecanoate (770 mg, 2.5 mmol) and LiOH (125 mg, 5.2 mmol) were dissolved in MeOH (10 mL) and H 2 O (2 mL) and stirred at RT for 15 hr. 6 M HCl (0.87 mL) was added and MeOH was removed in vacuo. The residue was dissolved in DCM, washed with brine, and dried (MgSO 4 ), filtered and concentrated in vacuo to afford 2-fluoro-2-hexyldecanoic acid (520 mg, 74.4%).

[0797] Preparation Example 11. Synthesis of amino alcohol THP ethers, illustrated by the synthesi...

Claims

1. A compound of formula (I): or a salt thereof, wherein: X is -CH2-, -O-, -O(C=O); or -C(=O)- Y is absent, -CH2-, -O-, -SO2- or -C(=O)-; R 1 It is C2-C 25 Hydrocarbon; R 2 is C1-C3 alkyl; and R 3 is C1-C3 alkyl; or R 2 and R 3 Together with the nitrogen to which they are attached they form an aziridino, azetidinino or pyrrolidino ring; m is 0, 1, 2, 3, 4, 5, or 6; n is 0-15; o is 0-15; L 1 does not exist, is -(C=O)-O-, -(C=O)N(H)N(R 4 )-、-(C=O)N(H)-N=C(R 4 )-、-(C=O)N(H)N(H)C(R 4 )(R 5 )-、-(C=O)-O-CH2-R z or -O(C=O)-R w -; L 2 does not exist, is -(C=O)-O-, -(C=O)N(H)N(R 4’ )-、-(C=O)N(H)-N=C(R 4’ )-、-(C=O)N(H)N(H)C(R 4’ )(R 5’ )-、-(C=O)-O-CH2-R z’ or -O(C=O)-R x - a is H or F; b is H or F; c is H or F; and d is H or F; or c and d together with the carbon to which they are attached form -C(=O)-; R 4 Is H or C2-C 25 Hydrocarbon; R 5 Is H or C2-C 25 Hydrocarbon; R 4’ Is H or C2-C 25 Hydrocarbon; R 5’ Is H or C2-C 25 Hydrocarbon; R 6 It is C2-C 25 Hydrocarbon; R 7 It is C2-C 25 Hydrocarbon; R w does not exist, is -C(F)H- or -C(F)2-; R x does not exist, is -C(F)H- or -C(F)2-; R z is 1, 2 or 3 independently selected from C2-C 10 a phenyl group substituted with a hydrocarbyl group; and R z’ is 1, 2 or 3 independently selected from C2-C 10 A phenyl group substituted with a hydrocarbyl group.

2. The compound or salt of claim 1, wherein X is -CH2-.

3. The compound or salt of claim 1, wherein X is -C(=O)-.

4. The compound or salt of claim 1, wherein X is -O-.

5. The compound or salt of any one of claims 1 to 4, wherein R 2 It's methyl.

6. The compound or salt of any one of claims 1 to 4, wherein R 2 It is ethyl.

7. The compound or salt of any one of claims 1 to 4, wherein R 2 It is propyl.

8. The compound or salt of any one of claims 1 to 7, wherein R 3 It's methyl.

9. The compound or salt of any one of claims 1 to 7, wherein R 3 It is ethyl.

10. The compound or salt of any one of claims 1 to 7, wherein R 3 It is propyl.

11. The compound or salt of any one of claims 1-10, wherein m is 1.

12. The compound or salt of any one of claims 1-10, wherein m is 2.

13. The compound or salt of any one of claims 1-10, wherein m is 3.

14. The compound of claim 1, wherein: Selected from the group consisting of (CH3)2NCH2CH2C(=O)-, (CH3)2NCH2CH2CH2C(=O)-, (CH3)2NCH2CH2CH2CH2C(=O)-, (CH3)2NCH2CH2CH2CH2C(=O)-, (CH3)2NCH2CH2-, (CH3)2NCH2CH2CH-, 5-pyrrolidin-1-ylpentanoyl and (CH3)2NCH2CH2CH2O-.

15. The compound or salt of any one of claims 1 to 14, wherein R 1 It is C5-C 25 Hydrocarbon.

16. The compound or salt of any one of claims 1 to 14, wherein R 1 It is C2-C 25 alkyl.

17. The compound or salt of any one of claims 1 to 14, wherein R 1 It is C5-C 25 alkyl.

18. The compound or salt of any one of claims 1 to 14, wherein R 1 It is C5-C 25 Alkenyl.

19. The compound or salt of any one of claims 1 to 14, wherein R 1 It is 1-nonyl or 1-decyl.

20. The compound or salt of any one of claims 1-19, wherein o is 2-15.

21. The compound or salt of any one of claims 1-19, wherein o is 10-15.

22. The compound or salt of any one of claims 1-19, wherein o is 2-10.

23. The compound or salt of any one of claims 1-19, wherein o is 2-5.

24. The compound or salt of any one of claims 1 to 23, wherein L 2 is -(C=O)-O-, -(C=O)N(H)N(R 4 )(R 5 )-、-(C=O)N(H)-N=C(R 4 )-、-(C=O)N(H)N(H)C(R 4 )(R 5 )- or -(C=O)-O-CH2-R z .

25. The compound or salt of any one of claims 1 to 23, wherein L 2 It is -(C=O)-O-.

26. The compound or salt of any one of claims 1 to 23, wherein L 2 is -(C=O)N(H)N(R 4 )(R 5 )-.

27. A compound or salt as described in any one of claims 1 to 23, wherein L 2 is -(C=O)-O-CH2-R z .

28. The compound or salt of any one of claims 1-27, wherein a is H.

29. The compound or salt of any one of claims 1-27, wherein a is F.

30. The compound or salt of any one of claims 1-29, wherein b is H.

31. The compound or salt of any one of claims 1-29, wherein b is F.

32. A compound or salt as described in any one of claims 1 to 31, wherein R 6 It is C2-C 25 Hydrocarbon.

33. A compound or salt as described in any one of claims 1 to 31, wherein R 6 It is C5-C 25 Hydrocarbon.

34. A compound or salt as described in any one of claims 1-31, wherein R 6 It is C2-C 25 alkyl.

35. A compound or salt as described in any one of claims 1-31, wherein R 6 It is C5-C 25 alkyl.

36. A compound or salt as described in any one of claims 1-31, wherein R 6 It is C5-C 25 Alkenyl.

37. The compound or salt of any one of claims 1 to 14, wherein: Selected from the group consisting of:

38. The compound or salt of any one of claims 1 to 14, wherein: Selected from the group consisting of:

39. The compound or salt of any one of claims 1 to 14, wherein: Selected from the group consisting of:

40. The compound or salt of any one of claims 1-39, wherein Y is -CH2-.

41. The compound or salt of any one of claims 1-39, wherein Y is -C(=O)-.

42. The compound or salt of any one of claims 1-39, wherein Y is -O-.

43. The compound or salt of any one of claims 1-42, wherein n is 2-15.

44. The compound or salt of any one of claims 1-42, wherein n is 10-15.

45. The compound or salt of any one of claims 1-42, wherein n is 2-10.

46. ​​The compound or salt of any one of claims 1-42, wherein n is 2-5.

47. A compound or salt as described in any one of claims 1-46, wherein L 1 does not exist; and L 2 is -(C=O)-O-, -(C=O)N(H)N(R 4 )(R 5 )-、-(C=O)N(H)-N=C(R 4 )-、-(C=O)N(H)N(H)C(R 4 )(R 5 )- or -(C=O)-O-CH2-R z .

48. A compound or salt as described in any one of claims 1-46, wherein L 1 is -(C=O)-O-, -(C=O)N(H)N(R 4 )(R 5 )-、-(C=O)N(H)-N=C(R 4 )-、-(C=O)N(H)N(H)C(R 4 )(R 5 )- or -(C=O)-O-CH2-R a ; and L 2 Does not exist.

49. A compound or salt as described in any one of claims 1-46, wherein L 1 is -(C=O)-O-, -(C=O)N(H)N(R 4 )(R 5 )-、-(C=O)N(H)-N=C(R 4 )-、-(C=O)N(H)N(H)C(R 4 )(R 5 )- or -(C=O)-O-CH2-R a .

50. A compound or salt as described in any one of claims 1-46, wherein L 1 It is -(C=O)-O.

51. A compound or salt as described in any one of claims 1-46, wherein L 1 is -(C=O)N(H)N(R 4 )(R 5 )-.

52. A compound or salt as described in any one of claims 1-46, wherein L 1 is -(C=O)-O-CH2-R z .

53. The compound or salt of any one of claims 1-52, wherein c is H.

54. The compound or salt of any one of claims 1-52, wherein c is F.

55. The compound or salt of any one of claims 1-54, wherein d is H.

56. The compound or salt of any one of claims 1-54, wherein d is F.

57. A compound or salt as described in any one of claims 1-56, wherein R 7 It is C2-C 25 Hydrocarbon.

58. A compound or salt as described in any one of claims 1-56, wherein R 7 It is C5-C 25 Hydrocarbon.

59. A compound or salt as described in any one of claims 1-56, wherein R 7 It is C2-C 25 alkyl.

60. A compound or salt as described in any one of claims 1-56, wherein R 7 It is C5-C 25 alkyl.

61. A compound or salt as described in any one of claims 1-56, wherein R 7 It is C5-C 25 Alkenyl.

62. The compound or salt of any one of claims 1-39, wherein: Selected from the group consisting of:

63. The compound or salt of any one of claims 1-39, wherein: Selected from the group consisting of:

64. The compound or salt of any one of claims 1-37, wherein: Selected from the group consisting of:

65. A compound or salt as described in any one of claims 1-46 and 53-61, wherein R 4 It is C2-C 25 Hydrocarbon.

66. A compound or salt as described in any one of claims 1-46 and 53-61, wherein R 4 It is C5-C 25 Hydrocarbon.

67. A compound or salt as described in any one of claims 1-46 and 53-61, wherein R 4 It is C2-C 25 alkyl.

68. A compound or salt as described in any one of claims 1-46 and 53-61, wherein R 4 It is C5-C 25 alkyl.

69. A compound or salt as described in any one of claims 1-46 and 53-61, wherein R 4 It is C5-C 25 Alkenyl.

70. A compound or salt as described in any one of claims 1-46 and 53-61, wherein R 5 It is C2-C 25 Hydrocarbon.

71. A compound or salt as described in any one of claims 1-46 and 53-61, wherein R 5 It is C5-C 25 Hydrocarbon.

72. A compound or salt as described in any one of claims 1-46 and 53-61, wherein R 5 It is C2-C 25 alkyl.

73. A compound or salt as described in any one of claims 1-46 and 53-61, wherein R 5 It is C5-C 25 alkyl.

74. A compound or salt as described in any one of claims 1-46 and 53-61, wherein R 5 It is C5-C 25 Alkenyl.

75. A compound or salt as described in any one of claims 1-23 and 28-36, wherein R 4’ It is C2-C 25 Hydrocarbon.

76. A compound or salt as described in any one of claims 1-23 and 28-36, wherein R 4’ It is C5-C 25 Hydrocarbon.

77. A compound or salt as described in any one of claims 1-23 and 28-36, wherein R 4’ It is C2-C 25 alkyl.

78. A compound or salt as described in any one of claims 1-23 and 28-36, wherein R 4’ It is C5-C 25 alkyl.

79. A compound or salt as described in any one of claims 1-23 and 28-36, wherein R 4’ It is C5-C 25 Alkenyl.

80. A compound or salt as described in any one of claims 1-23 and 28-36, wherein R 5’ It is C2-C 25 Hydrocarbon.

81. A compound or salt as described in any one of claims 1-23 and 28-36, wherein R 5’ It is C5-C 25 Hydrocarbon.

82. A compound or salt as described in any one of claims 1-23 and 28-36, wherein R 5’ It is C2-C 25 alkyl.

83. A compound or salt as described in any one of claims 1-23 and 28-36, wherein R 5’ It is C5-C 25 alkyl.

84. A compound or salt as described in any one of claims 1-23 and 28-36, wherein R 5’ It is C5-C 25 Alkenyl.

85. A compound or salt as described in any one of claims 1-46 and 53-61, wherein R z is 1 or 2 independently selected from C2-C 10 A phenyl group substituted with a hydrocarbyl group.

86. The compound or salt of claim 85, wherein each C2-C 10 The hydrocarbon groups are independently selected from C5-C 10 A group consisting of hydrocarbon groups.

87. The compound or salt of claim 85, wherein each C2-C 10 The hydrocarbon groups are independently selected from C2-C 10 Alkyl group.

88. The compound or salt of claim 85, wherein each C2-C 10 The hydrocarbon groups are independently selected from C5-C 10 Alkyl group.

89. The compound or salt of claim 85, wherein each C2-C 10 The hydrocarbon groups are independently selected from C5-C 10 A group consisting of alkenyl.

90. A compound or salt as described in any one of claims 1-23 and 28-36, wherein R z’ is 1 or 2 independently selected from C2-C 10 A phenyl group substituted with a hydrocarbyl group.

91. The compound or salt of claim 90, wherein each C2-C 10 The hydrocarbon groups are independently selected from C5-C 10 A group consisting of hydrocarbon groups.

92. The compound or salt of claim 90, wherein each C2-C 10 The hydrocarbon groups are independently selected from C2-C 10 Alkyl group.

93. The compound or salt of claim 90, wherein each C2-C 10 The hydrocarbon groups are independently selected from C5-C 10 Alkyl group.

94. The compound or salt of claim 90, wherein each C2-C 10 The hydrocarbon groups are independently selected from C5-C 10 A group consisting of alkenyl.

95. A compound selected from the group consisting of: or a salt thereof.

96. The compound or salt of claim 1, which is a compound: or a salt thereof.

97. The compound or salt of claim 1, which is a compound: or a salt thereof.

98. The compound or salt of claim 1, which is a compound: or a salt thereof.

99. The compound or salt of claim 1, which is a compound: or a salt thereof.

100. The compound or salt of claim 1, which is a compound: or a salt thereof.

101. The compound or salt of claim 1, which is a compound: or a salt thereof.

102. The compound or salt of claim 1, which is a compound: or a salt thereof.

103. The compound or salt of claim 1, which is a compound: or a salt thereof.

104. A nucleic acid-lipid particle comprising: (a) one or more nucleic acid molecules; (b) non-cationic lipids; (c) conjugating lipids; and (d) The compound or salt as described in any one of claims 1-103, wherein the one or more nucleic acid molecules are encapsulated within the lipid particle.

105. A nucleic acid-lipid particle as described in claim 104, wherein the compound or salt accounts for approximately 30 mol % to approximately 85 mol % of the total lipids present in the particle; the non-cationic lipid accounts for approximately 13 mol % to approximately 49.5 mol % of the total lipids present in the particle; and the conjugated lipid accounts for approximately 0.1 mol % to approximately 10 mol % of the total lipids present in the particle.

106. A nucleic acid-lipid particle as described in claim 104, wherein the compound or salt accounts for approximately 30 mol% to approximately 85 mol% of the total lipids present in the particle; the non-cationic lipid accounts for approximately 13 mol% to approximately 49.5 mol% of the total lipids present in the particle; and the conjugated lipid accounts for approximately 0.1 mol% to approximately 10 mol% of the total lipids present in the particle.

107. The nucleic acid-lipid particle of any one of claims 104-106, wherein the nucleic acid is selected from the group consisting of small interfering RNA (siRNA), Dicer-substrate dsRNA, small hairpin RNA (shRNA), asymmetric interfering RNA (aiRNA), microRNA (miRNA), mRNA, tRNA, rRNA, viral RNA (vRNA), self-amplifying RNA, and combinations thereof.

108. The nucleic acid-lipid particle of claim 107, wherein the nucleic acid is an mRNA molecule.

109. The nucleic acid-lipid particle of claim 107, wherein the nucleic acid comprises a double-stranded siRNA molecule.

110. The nucleic acid-lipid particle of claim 109, wherein the double-stranded siRNA molecule comprises at least one modified nucleotide.

111. The nucleic acid-lipid particle of claim 110, wherein the siRNA comprises at least one 2'-O-methyl (2'OMe) nucleotide.

112. The nucleic acid-lipid particle of any one of claims 104-111, wherein the non-cationic lipid comprises cholesterol or a derivative thereof.

113. A nucleic acid-lipid particle as described in claim 112, wherein the cholesterol or a derivative thereof constitutes about 31.5 mol% to about 42.5 mol% of the total lipid present in the particle.

114. The nucleic acid-lipid particle of any one of claims 104-111, wherein the non-cationic lipid comprises a phospholipid.

115. The nucleic acid-lipid particle of any one of claims 104-111, wherein the non-cationic lipid comprises a mixture of phospholipids and cholesterol or a derivative thereof.

116. The nucleic acid-lipid particle of claim 115, wherein the phospholipid comprises dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), or a mixture thereof.

117. A nucleic acid-lipid particle as described in claim 115, wherein the phospholipids account for about 4 mol% to about 10 mol% of the total lipids present in the particle, and the cholesterol accounts for about 30 mol% to about 40 mol% of the total lipids present in the particle.

118. A nucleic acid-lipid particle as described in claim 115, wherein the phospholipids account for about 10 mol% to about 30 mol% of the total lipids present in the particle, and the cholesterol accounts for about 10 mol% to about 30 mol% of the total lipids present in the particle.

119. The nucleic acid-lipid particle of any one of claims 104-118, wherein the conjugated lipid comprises a polyethylene glycol (PEG)-lipid conjugate.

120. The nucleic acid-lipid particle of claim 119, wherein the PEG-lipid conjugate comprises a PEG-diacylglycerol (PEG-DAG) conjugate, a PEG-dialkyloxypropyl (PEG-DAA) conjugate, or a mixture thereof.

121. The nucleic acid-lipid particle of claim 120, wherein the PEG-DAA conjugate comprises a PEG-dimyristyloxypropyl (PEG-DMA) conjugate, a PEG-distearyloxypropyl (PEG-DSA) conjugate, or a mixture thereof.

122. The nucleic acid-lipid particle of claim 120, wherein the PEG-DAA conjugate comprises a PEG-dimyristyloxypropyl (PEG-DMA) conjugate.

123. The nucleic acid-lipid particle of claim 119, wherein the polyethylene glycol (PEG)-lipid conjugate is a compound of the formula: ABC or a salt thereof, wherein: A is (C1-C6)alkyl, (C3-C8)cycloalkyl, (C3-C8)cycloalkyl(C1-C6)alkyl, (C1-C6)alkoxy, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkanoyl, (C1-C6)alkoxycarbonyl, (C1-C6)alkylthio or (C2-C6)alkanoyloxy, wherein any of (C1-C6)alkyl, (C3-C8)cycloalkyl, (C3-C8)cycloalkyl(C1-C6)alkyl, (C1-C6)alkoxy, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkanoyl, (C1-C6)alkoxycarbonyl, (C1-C6)alkylthio and (C2-C6)alkanoyloxy )alkanoyloxy is substituted with one or more anion precursor groups, and any (C1-C6)alkyl, (C3-C8)cycloalkyl, (C3-C8)cycloalkyl(C1-C6)alkyl, (C1-C6)alkoxy, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkanoyl, (C1-C6)alkoxycarbonyl, (C1-C6)alkylthio and (C2-C6)alkanoyloxy are optionally substituted with one or more groups independently selected from the group consisting of halo, hydroxy, (C1-C3)alkoxy, (C1-C6)alkanoyl, (C1-C3)alkoxycarbonyl, (C1-C3)alkylthio or (C2-C3)alkanoyloxy; B is a polyethylene glycol chain having a molecular weight of about 550 Daltons to about 10,000 Daltons; C is for -LR a L is selected from the group consisting of: direct bond, -C(O)O-, -C(O)NR b -、-NR b -、-C(O)-、-NR b C(O)O-、-NR b C(O)NR b -, -SS-, -O-, -(O)CCH2CH2C(O)-, and -NHC(O)CH2CH2C(O)NH-; R a Is a branched chain (C 10 -C 50 ) alkyl or branched (C 10 -C 50 ) alkenyl, wherein the branched chain (C 10 -C 50 ) alkyl or branched (C 10 -C 50 ) one or more carbon atoms of the alkenyl group have been replaced by -O-; and Each R b are independently H or (C1-C6) alkyl.

124. The nucleic acid-lipid particle of any one of claims 104-123, wherein the PEG has an average molecular weight of about 2,000 Daltons.

125. The nucleic acid-lipid particle of any one of claims 104-118, wherein the conjugated lipid comprises a PEG-lipid conjugate selected from: or a salt thereof.

126. The nucleic acid-lipid particle of any one of claims 93-107, wherein the conjugated lipid comprises a compound of the formula: Where n is 45-50.

127. The nucleic acid-lipid particle of any one of claims 104-126, wherein the conjugated lipid accounts for about 1 mol% to about 2 mol% of the total lipids present in the particle.

128. The nucleic acid-lipid particle of any one of claims 104-127, wherein the nucleic acid in the particle is substantially not degraded after incubation of the nucleic acid-lipid particle in serum at 37°C for 30 minutes.

129. nucleic acid-lipid particles as described in any one in claims 104-128, wherein the nucleic acid is completely encapsulated in the nucleic acid-lipid particle.

130. The nucleic acid-lipid particle of any one of claims 104-129, wherein the nucleic acid-lipid particle has a lipid:nucleic acid mass ratio of about 5 to about 15.

131. The nucleic acid-lipid particle of any one of claims 104-129, wherein the nucleic acid-lipid particle has a lipid:nucleic acid mass ratio of about 5 to about 30.

132. The nucleic acid-lipid particle of any one of claims 104-131, wherein the nucleic acid-lipid particle has a median diameter of about 40 nm to about 150 nm.

133. A nucleic acid-lipid particle as described in claim 104, wherein the compound or salt accounts for approximately 56.5 mol% to approximately 66.5 mol% of the total lipid present in the particle; the non-cationic lipid comprises cholesterol or a derivative thereof that accounts for approximately 31.5 mol% to approximately 42.5 mol% of the total lipid present in the particle; and the PEG-lipid conjugate accounts for approximately 1 mol% to approximately 2 mol% of the total lipid present in the particle.

134. A nucleic acid-lipid particle as described in claim 133, wherein the nucleic acid-lipid particle comprises about 61.5 mol% of the compound or salt, about 36.9% of cholesterol or a derivative thereof, and about 1.5 mol% of a PEG-lipid conjugate.

135. A nucleic acid-lipid particle as described in claim 104, wherein the compound or salt accounts for approximately 52 mol% to approximately 62 mol% of the total lipids present in the particle; the non-cationic lipid comprises a mixture of phospholipids and cholesterol or a derivative thereof that accounts for approximately 36 mol% to approximately 47 mol% of the total lipids present in the particle; and the PEG-lipid conjugate accounts for approximately 1 mol% to approximately 2 mol% of the total lipids present in the particle.

136. The nucleic acid-lipid particle of claim 135, wherein the nucleic acid-lipid particle comprises about 57.1 mol% of the compound or salt, about 7.1 mol% of the phospholipid, about 34.3 mol% of cholesterol or a derivative thereof, and about 1.4 mol% of a PEG-lipid conjugate.

137. The nucleic acid-lipid particle of claim 135, wherein the nucleic acid-lipid particle comprises about 57.1 mol% of a compound or salt, about 20 mol% of a phospholipid, about 20 mol% of cholesterol or a derivative thereof, and about 1.4 mol% of a PEG-lipid conjugate.

138. A nucleic acid-lipid particle as described in claim 104, wherein the compound or salt accounts for 50 mol% to 65 mol% of the total lipids present in the particle; the non-cationic lipid comprises a mixture of phospholipids and cholesterol or a derivative thereof, wherein the phospholipids account for 4 mol% to 10 mol% of the total lipids present in the particle, and the cholesterol or a derivative thereof accounts for 30 mol% to 40 mol% of the total lipids present in the particle; and the conjugated lipid accounts for 0.5 mol% to 2 mol% of the total lipids present in the particle.

139. A nucleic acid-lipid particle as described in claim 104, wherein the compound or salt accounts for 50 mol% to 65 mol% of the total lipids present in the particle; the non-cationic lipid comprises a mixture of phospholipids and cholesterol or a derivative thereof, wherein the phospholipids account for 3 mol% to 15 mol% of the total lipids present in the particle, and the cholesterol or a derivative thereof accounts for 30 mol% to 40 mol% of the total lipids present in the particle; and the conjugated lipid accounts for 0.5 mol% to 2 mol% of the total lipids present in the particle.

140. A nucleic acid-lipid particle as described in claim 104, wherein the compound or salt accounts for 50 mol% to 65 mol% of the total lipids present in the particle; the non-cationic lipid accounts for up to 49.5 mol% of the total lipids present in the particle; the cholesterol or its derivatives account for 30 mol% to 40 mol% of the total lipids present in the particle; and the conjugated lipid accounts for 0.5 mol% to 2 mol% of the total lipids present in the particle.

141. A nucleic acid-lipid particle as described in claim 104, wherein the compound or salt accounts for 50 mol% to 85 mol% of the total lipids present in the particle; the non-cationic lipid accounts for 13 mol% to 49.5 mol% of the total lipids present in the particle; and the conjugated lipid accounts for 0.5 mol% to 2 mol% of the total lipids present in the particle.

142. A nucleic acid-lipid particle as described in claim 104, wherein the compound or salt accounts for approximately 30 mol % to approximately 50 mol % of the total lipids present in the particle; the non-cationic lipid comprises a mixture of phospholipids and cholesterol or a derivative thereof that accounts for approximately 47 mol % to approximately 69 mol % of the total lipids present in the particle; and the PEG-lipid conjugate accounts for approximately 1 mol % to approximately 3 mol % of the total lipids present in the particle.

143. The nucleic acid-lipid particle of claim 104, wherein the non-cationic lipid comprises a mixture of cholesterol and DSPC; the conjugated lipid is: where n is chosen so that the resulting polymer chain has a molecular weight of about 2000 Daltons wherein the conjugated lipid accounts for about 2 mol% of the total lipids present in the particle; DSPC accounts for about 10 mol% of the total lipids present in the particle; cholesterol accounts for about 48 mol% of the total lipids present in the particle; and the compound or salt accounts for about 40 mol% of the total lipids present in the particle.

144. The nucleic acid-lipid particle of claim 104, wherein the non-cationic lipid comprises a mixture of cholesterol and DSPC; the conjugated lipid is: wherein n is selected so that the resulting polymer chain has a molecular weight of about 2000 Daltons; wherein the conjugated lipid accounts for about 2 mol% of the total lipids present in the particle; DSPC accounts for about 10 mol% of the total lipids present in the particle; cholesterol accounts for about 48 mol% of the total lipids present in the particle; and the compound or salt accounts for about 40 mol% of the total lipids present in the particle.

145. The nucleic acid-lipid particle of claim 104, wherein the non-cationic lipid comprises a mixture of cholesterol and DSPC; the conjugated lipid is: wherein n is selected so that the resulting polymer chain has a molecular weight of about 2000; wherein the conjugated lipid accounts for about 1.6 mol% of the total lipids present in the particle; DSPC accounts for about 10.9 mol% of the total lipids present in the particle; cholesterol accounts for about 32.8 mol% of the total lipids present in the particle; and the compound or salt accounts for about 54.9 mol% of the total lipids present in the particle.

146. The nucleic acid-lipid particle of any one of claims 142-145, wherein the lipid to nucleic acid ratio is about 24.

147. The nucleic acid-lipid particle of any one of claims 104-146, comprising two or more compounds or salts of any one of claims 1-103.

148. A pharmaceutical composition comprising a nucleic acid-lipid particle as described in any one of claims 104-147 and a pharmaceutically acceptable carrier.

149. A method for introducing a nucleic acid into a cell, the method comprising: The cell is contacted with the nucleic acid-lipid particle of any one of claims 104-147 or the composition of claim 148.

150. The method of claim 149, wherein the cell is in a mammal.

151. A method for delivering a nucleic acid in vivo, the method comprising: The nucleic acid-lipid particle of any one of claims 104-147 or the composition of claim 148 is administered to a mammalian subject.

152. The method of claim 151, wherein the administration is selected from the group consisting of oral, intranasal, intravenous, intraperitoneal, intramuscular, intraarticular, intralesional, intratracheal, subcutaneous, and intradermal.

153. A nucleic acid-lipid particle as described in any one of claims 104-147 or a composition as described in claim 148, for delivering a nucleic acid in vivo to a mammal.

154. Use of a nucleic acid-lipid particle as described in any one of claims 104-147 or a composition as described in claim 148 for the preparation of a medicament for delivering a nucleic acid in vivo to a mammal.

155. A method for treating a disease or condition in a mammalian subject in need thereof, the method comprising: A therapeutically effective amount of the nucleic acid-lipid particle of any one of claims 104-147 or the composition of claim 148 is administered to the mammalian subject.

156. The method of claim 155, wherein the disease or condition is selected from the group consisting of a viral infection, a liver disease or condition, and cancer.

157. A nucleic acid-lipid particle as described in any one of claims 104-147 or a composition as described in claim 148 for use in treating a mammalian disease or disorder.

158. Use of the nucleic acid-lipid particle of any one of claims 104-147 or the composition of claim 148 for the preparation of a medicament for treating a disease or condition in a mammal.

Citation Information

Patent Citations

  • RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (SINA)

    CA2456444A1

  • Synthetic, catalytic oligonucleotides

    EP0519463A1

  • Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)

    GB2397818B

  • Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers

    US20020072121A1

  • Lipid-based formulations

    US20030077829A1